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Abstract 
Pathological left ventricular hypertrophy is a maladaptive cardiomyocyte growth response to 
various cardiovascular conditions such as hypertension, and is a major risk factor for heart 
failure and stroke. The majority of drugs used to treat cardiovascular diseases target G protein 
coupled receptors (GPCRs), which are regulated by regulator of G protein signalling (RGS) 
proteins. RGS2 is a GTPase activating protein which limits Gq- and Gs-mediated signalling, 
which are known to play major roles in the development of pathological cardiac hypertrophy. 
In addition to its G protein effects, we have previously shown that RGS2 can also inhibit 
protein synthesis and cultured cardiomyocyte growth via a region in its RGS domain, RGS2eb, 
which inhibits the rate-limiting eIF2B/eIF2 step of protein synthesis initiation. Thus, we 
hypothesized that the in vivo expression of RGS2eb could limit the development of 
experimentally induced hypertrophy. Herein, we demonstrate that the in vivo cardiomyocyte 
specific overexpression of RGS2eb prevents the development of cardiac hypertrophy in a 
transverse aortic constriction (TAC) model of experimental pressure overload, as well as 
functional loss and the expression of “fetal” genes associated with hypertrophy and heart 
failure. Although we further hypothesized that the expression of RGS2eb in Rgs2-/- mice (which 
are highly sensitive to hypertrophy and heart failure following pressure overload) could 
compensate for the loss of endogenous RGS2, we were limited in our characterizations by poor 
survival rates in Rgs2-/- animals following TAC surgery.  
Cardiovascular dysfunction is also known to be directly influenced by obesity and weight gain, 
which reflects the importance of understanding the mechanisms behind metabolic 
dysregulation. We have previously demonstrated that Rgs2-/- mice exhibit a lean phenotype on 
a normal chow diet, but still gain weight on a high fat diet. We thus sought to further 
characterize the metabolic role of RGS2 via Comprehensive Lab Animal Monitoring System 
(CLAMS) metabolic cages and gene expression analysis of skeletal rather than adipose tissue. 
Here we report that loss of RGS2 leads to greater use of carbohydrates and significant increases 
in basal metabolism, as well as increases in associated metabolism-related genes. Altogether, 
these studies provide new insights into the role of RGS2 in cardiovascular health and 
metabolism. 
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1 INTRODUCTION 
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 Regulator of G protein signalling (RGS) proteins 
Agonist binding of G protein coupled receptors (GPCRs) promotes G protein activation, which 
is achieved by catalyzing GDP–GTP exchange on the Gα subunit; a conformational change in 
the GTP–bound α subunit is thought to lead to the dissociation of Gα from the stable G-βγ-
dimer, thus enabling the regulation of downstream effectors. These signalling events are 
terminated as a consequence of the intrinsic GTPase activity of the Gα subunit, which 
hydrolyzes GTP to GDP, resulting in a return to the inactive form of the G protein heterotrimer. 
The intrinsic GTPase activity of Gα subunits is generally insufficient to explain the observed 
physiological rates of G protein inactivation (Tang and Insel, 2004), and has been found to be 
accelerated by GTPase–activating proteins (GAPs) such as regulator of G–protein signalling 
(RGS) proteins.  
RGS proteins are a family of GAPs that bind to G–proteins and inactivate them by increasing 
the intrinsic rate of GTP hydrolysis. They thus function to limit the intensity and duration of 
GPCR-initiated signalling, and this is mainly accomplished via a conserved, ~120 amino acid 
RGS domain that is responsible for their GAP activity (Popov et al., 1997; Ross and Wilkie, 
2000). Most RGS proteins act as GAPs towards Gαi –mediated signalling and can be classified 
into four subfamilies (R4, RZ, R7, and R12) (Berman, Kozasa and Gilman, 1996; Abramow-
Newerly et al., 2006; Jayaraman et al., 2009). There are currently no RGS proteins known to 
inhibit Gαs
 activity, although RGS2 has been shown to inhibit Gαs pathways in a GAP-
independent manner (Salim et al., 2003; Roy, Baragli, et al., 2006). The GAP activity of RGS 
proteins is sensitive to a variety of factors such as cations and phospholipids (Wang et al., 
1997; Tu, Woodson and Ross, 2001; Cladman and Chidiac, 2002; Ishii, Inanobe and Kurachi, 
2002); post-translational modifications can also influence RGS intracellular localization as 
well as interactions with G proteins and other binding partners (Chidiac and Roy, 2003). 
Although the RGS domain is necessary and sufficient to confer GAP activity (Popov et al., 
1997), other domains can also determine cellular localization, increase substrate specificity, 
and provide additional activities (Snow et al., 1998; Traver et al., 2004; Wang et al., 2005).  
 3 
 
 Regulator of G protein signalling 2 (RGS2) 
RGS2 is part of the B/R4 subfamily of RGS proteins (RGS1-5, RGS8, RGS13, RGS16, 
RGS18, RGS21) which are relatively small and simple in structure (~20-30 kDa), and contain 
a conserved RGS domain flanked by short N- and C-terminal domains (Riddle et al., 2005). 
While almost all RGS proteins function as GAPs on Gαi/o signalling, RGS2 is unique; it 
demonstrates a low affinity for Gαi/o, and instead selectively inhibits Gαq and Gαs–mediated 
signalling via GAP–dependent and GAP–independent mechanisms (Heximer et al., 1997, 
1999; Bernstein et al., 2004; Hague et al., 2005; Roy, Baragli, et al., 2006). The Gαq selectivity 
of RGS2 is largely due to three Gαq amino acid residues (Cys
106, Asn184, and Glu191) which 
appear to reduce RGS2 affinity for Gαi by steric hindrance, whereas inhibition of Gαs signalling 
is due at least in part to direct interactions of RGS2 with adenylate cyclases I, II, and VI via its 
N-terminal domain. (Salim et al., 2003; Roy, Baragli, et al., 2006). In addition, the N-terminal 
domain of RGS2 can bind other proteins such as spinophilin, muscarinic receptors, α-
adrenergic receptors, TRPV6 calcium channels, and tubulin (Bernstein et al., 2004; Hague et 
al., 2005; Wang et al., 2005; Heo et al., 2006; Schoeber et al., 2006); we have also 
demonstrated that RGS2 can inhibit protein synthesis in a GAP-independent manner, which 
will be addressed in detail further below (Nguyen et al., 2009; Chidiac et al., 2014). 
1.2.1  Expression and regulation of RGS2 
RGS2 is found ubiquitously, with its mRNA expressed in organs such as the heart, brain, lungs, 
and kidneys, as well as in cell types including pre-adipocytes, vascular smooth muscle cells, 
osteoblasts, and chondrocytes (Miles et al., 2000; Huang et al., 2003; Larminie et al., 2004). 
Various signalling pathways and stimuli can induce Rgs2 gene transcription. In human 
neuroblastoma cells, carbachol stimulation of muscarinic receptors, which are coupled to the 
phosphoinositide signal transduction system, results in rapid and lasting increases in Rgs2 
mRNA levels (Song, De Sarno and Jope, 1999). Gq agonists such as angiotensin II and 
phenylephrine, as well as Gs agonists which increase cAMP levels or intracellular Ca
2+, have 
also been shown to upregulate Rgs2 gene expression in multiple cell types including vascular 
smooth muscle cells, neonatal cardiomyocytes, and HEK293 cells lines (Grant et al., 2000; 
Zou et al., 2006). In addition, conserved cAMP response bindings elements in the RGS2 
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promoter are critical for cAMP-response element binding protein (CREB) binding and RGS2 
promoter activation; three single nucleotide polymorphisms (SNPs) have been identified in the 
human RGS2 promoter CREB binding site in hypertensive patients, with the corresponding 
point mutations reducing the RGS2 inhibition of forskolin-stimulated adenylyl cyclase activity 
(Nunn et al., 2010; Xie et al., 2011; Nguyen et al., 2012).  
Endogenous RGS2 protein is rapidly degraded via proteasomal mechanisms (Bodenstein, 
Sunahara and Neubig, 2007; Osei-Owusu et al., 2007). Polymorphisms which enhance RGS2 
degradation have been associated with hypertension and cardiovascular dysfunction, and 
suggest that stabilizing RGS2 protein expression may result in beneficial effects (Bodenstein, 
Sunahara and Neubig, 2007; Gu, Tirgari and Heximer, 2008; Hahntow et al., 2009; Sjogren et 
al., 2012). Indeed, more than 30 RGS2 gene polymorphisms have been identified in human 
hypertensive patients (Yang et al., 2005; Riddle et al., 2006; Semplicini et al., 2006; Zhao et 
al., 2008); conversely, hypotensive patients with Bartter/Gitelman syndrome have increased 
RGS2 expression (Calò et al., 2004). In addition, RGS2 deficiency or dysfunction has been 
linked to anxiety disorders and airway hyper-responsiveness (Xie et al., 2012; Hettema et al., 
2013), further highlighting the importance of RGS2 regulation. 
1.2.2 RGS2eb regulates mRNA translation 
1.2.2.1 Regulation of protein synthesis during translation initiation 
The rate of global protein synthesis is controlled primarily at the initiation level, and is divided 
into multiple stages: (1) GTP-bound eukaryotic initiation factor 2 (eIF2) recognizes and binds 
initiator tRNA (Met-tRNAMeti), forming the ternary complex eIF2-GTP-Met-tRNAMeti, 
followed by binding of the complex to the 40S ribosomal subunit; (2) In cap-dependent 
initiation, the cap structure at the 5’end of mRNA is recognized and bound by eIF4F, which 
guides the activated 40S subunit to the 5’ end of the mRNA; (3) mRNA-bound 40S travels 
along the 5’–untranslated end of the mRNA, scanning until it reaches an AUG start codon; (4) 
Upon start codon detection, the 60S subunit binds to the 40S subunit, initiation factors are 
released, and the Met-tRNAMeti becomes positioned in the ribosomal P site in preparation for 
the elongation phase (Jackson, Hellen and Pestova, 2010) .  
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1.2.2.2 Rate limiting step of translation initiation: eIF2 and eIF2B 
Of particular importance in the regulation of initiation is the heterotrimeric initiation factor 
eIF2 which, when bound to GTP, is active and recruits Met–tRNAMeti to the ribosomal 
initiation complex. eIF2 is inactivated by the hydrolysis of GTP; in order for reactivation to 
occur, GDP must first dissociate. This intrinsically slow process is sped up by the 
heteropentameric protein eIF2B (α – ε) , which acts as a guanine nucleotide exchange factor 
(GEF) by binding to eIF2, and catalyzing GDP/GTP exchange (Abbott and Proud, 2004). Thus, 
the rate limiting step of initiation is ultimately eIF2B-facilitated GDP/GTP exchange on eIF2 
(Rolfe et al., 2005; Singh et al., 2006; Elsby et al., 2011). This makes the modulation of eIF2B 
activity an important aspect in the regulation of global protein synthesis. Stimuli that promote 
cell growth may do so by causing the dephosphorylation and consequent activation of eIF2B 
(Wek, Jiang and Anthony, 2006; Chidiac et al., 2014). Conversely, phosphorylation of eIF2B, 
as well as eIF2, inhibits their activity and results in the attenuation of cell growth (Hardt et al., 
2004).  
1.2.2.3 RGS2eb binds to eIF2B and inhibits protein translation 
While the G-protein dependent effects of RGS2 are well established, studies have also shown 
that RGS2 can bind and regulate other targets (Wang et al., 2005; Heo et al., 2006; Schoeber 
et al., 2006; Zhang and Mende, 2011). Our lab has previously discovered a novel binding 
partner for RGS2. We have shown that RGS2 can bind to the ε subunit of eIF2B, resulting in 
the inhibition of mRNA translation (Nguyen et al., 2009). By binding to eIF2Bε, RGS2 inhibits 
its ability to facilitate GDP dissociation on eIF2, which ultimately leads to the attenuation of 
de novo protein synthesis. This novel, G-protein independent property of RGS2 has been 
mapped to a 37 amino acid domain (residues 79-115) that is homologous to a region in the β 
subunit of eIF2 that binds to eIF2Bε, suggesting that RGS2 may inhibit initiation by competing 
or otherwise interfering with binding between eIF2 and eIF2B.  
We have shown that the eIF2Bε binding domain, RGS2eb, to be both necessary and sufficient 
for the inhibition of protein synthesis by RGS2; a corresponding 37-oligomer peptide based on 
this region also dose-dependently decreased in vitro mRNA translation (Nguyen et al., 2009). 
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In addition, the cellular expression via adenoviral infection of RGS2eb or full-length RGS2 
decreased levels of protein synthesis to a comparable extent (Nguyen et al., 2009). 
Furthermore, the rate of protein synthesis was increased in cells from RGS2 knockout animals, 
which suggests that the effect of RGS2 on protein synthesis is physiologically relevant 
(Nguyen et al., 2009). Thus, RGS2, and more specifically its eIF2Bε binding domain, appears 
to be an important regulator of mRNA translation.  
This novel mechanism of eIF2B inhibition adds to a group of studies which demonstrate that 
inhibition of eIF2B leads to decreased protein synthesis. Glycogen synthase kinase 3 (GSK3) 
can directly phosphorylate eIF2Bε at serine 540 in intact cells, which inhibits eIF2B GEF 
activity by up to 80% (Welsh et al., 1998). It has also been shown that the effects of eIF2B on 
eIF2 can be decreased by the binding of eIF2 to eIF5. The primary function of eIF5 is to 
promote GTP hydrolysis by eIF2; when present at elevated levels, eIF5 may act to sequester 
eIF2 from eIF2B, thereby impeding protein synthesis (Singh et al., 2006). Other groups have 
successfully used eIF2Bε siRNA (Deng et al., 2008) in vitro, as well as adeno-associated 
viruses (AAVs) in vivo to specifically inhibit eIF2Bε (Guo et al., 2016; Merentie et al., 2016). 
However, cardiac specific overexpression of full-length RGS2 (which contains the RGS2eb 
domain) does not appear to confer protective effects against hypertrophy in a pressure overload 
model (Park-Windhol et al., 2012). As previously mentioned, RGS2 possesses multiple 
properties not known to be shared by either RGS4 or RGS5, although the latter two are also 
able to inhibit cardiac hypertrophy when overexpressed (Heximer et al., 1999; Chidiac and 
Roy, 2003; Roy, Nunn, et al., 2006; Tokudome et al., 2008; Endale et al., 2010; Li et al., 2010; 
Sethakorn, Yau and Dulin, 2010; Chidiac et al., 2014). Since our studies suggest that the 
RGS2eb region specifically, and exclusively, inhibits eIF2/eIF2B interactions (and thus protein 
synthesis) (Nguyen et al., 2009), it is possible that the other properties of RGS2 may have 
confounded or attributed to the limited cardioprotection that was observed by groups 
expressing full-length RGS2. Thus in the context of cardiovascular health, the protein synthesis 
inhibitory effects of RGS2eb could be a major contributor to the reported beneficial effects of 
RGS2.  
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 Signalling pathways of cardiac hypertrophy 
1.3.1 Physiological hypertrophy is regulated by PI3K-Akt signalling 
Physiological and pathological hypertrophies differ not only in terms of phenotype, but can be 
distinguished by the different signalling cascades that drive them. Exercise or 
developmentally-induced growth is primarily mediated by growth hormones, and a critical 
pathway for physiological hypertrophy is the phosphoinositide 3-kinase (PI3K)–Akt pathway 
(Hunter and Chien, 1999; McMullen and Jennings, 2007). When IGF-1, insulin, and other 
growth factors bind to their membrane tyrosine receptor kinases, the PI3K isoform p110α is 
activated, and phosphorylates membrane phosphatidylinositols at the 3' position of the inositol 
ring (Dorn and Force, 2005). This phosphorylation results in the recruitment of the protein 
kinase Akt (also known as PKB) and its activator 3-phosphoinositide-dependent protein 
kinase-1 (PDK1). Activation of Akt by PDK1 leads to the activation of mammalian target of 
rapamycin (mTOR), which is a central regulator of protein synthesis via its ability to activate 
translational machinery and ribosome biogenesis (Dorn and Force, 2005). In addition, Akt can 
phosphorylate and inhibit the activity of glycogen synthase kinase-3 (GSK-3), a constitutively 
active negative regulator of cardiac hypertrophy (Haq et al., 2000; Hardt and Sadoshima, 2004; 
Kerkelä, Woulfe and Force, 2007). 
Several studies have demonstrated the importance of PI3K-p110α/PDK1/Akt signalling for 
adaptive cardiac hypertrophy. Transgenic mice constitutively overexpressing the p110α 
isoform of PI3K exhibited exercise-induced hypertrophy that did not transition into 
pathological growth (Shioi et al., 2000). Furthermore, cardiac expression of a mutant 
dominant-negative p110α prevented exercise-induced growth, but maladaptive hypertrophy 
still occurred in response to pressure overload (McMullen et al., 2003). Together, these studies 
demonstrate the critical role that PI3K-p110α/PDK1/Akt signalling plays in the regulation of 
physiological hypertrophy.  
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1.3.2 Pathological cardiac hypertrophy is regulated by GPCR 
signalling 
While adaptive hypertrophy is mediated by receptor tyrosine signalling, the critical pathways 
for maladaptive growth are initiated by G-protein coupled receptors (Dorn and Force, 2005; 
Heineke and Molkentin, 2006; Hendriks-Balk et al., 2008). GPCRs are seven transmembrane 
domain proteins involved in signal transmission. With more than 800 members, they represent 
the largest and most diverse family of cell surface receptors existing in the mammalian genome 
(Oldham and Hamm, 2008); cardiovascular cells alone possess greater than 100 different 
GPCRs (Tang and Insel, 2004). GPCRs play a critical role in linking messages from 
extracellular ligands to signalling pathways within the cell. With a wide variety of activating 
ligands and with their localization at the cell membrane, GPCRs represent the largest class of 
drug targets – more than one-third of current drugs on the market act by binding to GPCRs 
(Ma and Zemmel, 2002; Wise, Gearing and Rees, 2002; Dror et al., 2011).  
Isoforms of the Gα subunit result in four heterotrimeric G protein families: Gαs, Gαi/o, Gαq/11, 
and Gα12. While both Gq/11 and Gs signalling can result in cardiomyocyte growth, Gq in 
particular has been widely shown to play a crucial role in the development of pathological 
hypertrophy (D’Angelo et al., 1997; Mende et al., 1998; Bernardo et al., 2010). 
1.3.3 Prolonged Gαq/11 signalling leads to maladaptive cardiac 
hypertrophy 
Heterotrimeric Gq and the functionally similar G11 transduce signals from hypertrophic 
receptors for angiotensin, endothelin, norepinephrine, and other neurohormones (Rockman, 
Koch and Lefkowitz, 2002). When activated, the Gαq/11 subunit recruits phospholipase C beta 
(PLCβ) to the cell membrane, where it hydrolyzes phosphatidylinositol 4,5-bisphosphate 
(PIP2), resulting in the release of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). 
IP3 can then bind to receptors in the sarcoplasmic reticulum (SR), causing calcium release into 
the cytosol. At this point, two pathways can contribute to a hypertrophic response. Calcium 
release along with DAG can activate protein kinase C (PKC), which leads to the subsequent 
inhibition of GSK-3. It can also affect MAP kinase (MAPK) signalling through proteins such 
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as ERK1/2, JNK and p38 (Frey and Olson, 2003). Alternatively, Ca2+ release can cause the 
messenger protein calmodulin to activate calcineurin, which dephosphorylates the 
transcription factor NFAT. Subsequently, NFAT can translocate to the nucleus, and activate 
the transcription of hypertrophic response genes (Dorn and Force, 2005). 
The importance of Gαq/11 signalling in the maladaptive hypertrophic response has been 
demonstrated in several studies. Transgenic mice with cardiac-specific transgenic 
overexpression of Gαq/11 –linked receptors demonstrate severe cardiac hypertrophy and 
dysfunction, upregulation of the “fetal” gene response, and premature death (D’Angelo et al., 
1997; Mende et al., 1998). Conversely, mice overexpressing a dominant-negative Gαq/11 
peptide or which lacked Gαq/11 were resistant to hypertrophy following pressure overload, but 
still exhibited exercise-induced physiological cardiac growth (Akhter et al., 1997; 
Wettschureck et al., 2001). Altogether, these studies indicate that Gq/11 signalling is sufficient 
for pathophysiological hypertrophy to occur. 
In addition to PLCβ-mediated hypertrophy, Gαq/11 signalling can also act through the PI3K-
Akt pathway that is normally associated with physiological growth. Gαq/11 stimulated PI3K 
differs from physiological PI3K in that the activated isoform is changed from p110γ to p110α. 
However, since both types of PI3K can go on to activate Akt and its downstream mTOR and 
GSK-3 pathways, it is not well understood how these events can result in different forms of 
hypertrophy (Dorn and Force, 2005). 
1.3.4 Gαs signalling mediates β-adrenergic induced hypertrophy 
Although Gαq/11 signalling is the major mediator of maladaptive hypertrophy, Gαs also plays a 
significant role in cardiomyocyte growth. In the heart, Gαs proteins are mainly coupled to β1-
adrenergic receptors. Upon agonist binding (e.g. isoproterenol), the Gα subunit activates 
adenylyl cyclase (AC), which in turn catalyzes the conversion of ATP into the second 
messenger cAMP (Dorn and Force, 2005). Increased concentrations of cAMP can then activate 
protein kinase A (PKA) which, among other functions, inhibits GSK-3 and causes an increase 
in protein synthesis. Overexpression of β1-receptors in the hearts of transgenic mice has been 
shown to initially increase contractile function and responsiveness to isoproterenol, which can 
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initially be seen as beneficial during early heart failure (Bisognano et al., 2000; Engelhardt et 
al., 2002). However, chronic stimulation of these receptors results in progressive deterioration 
of cardiac function, as well as increased hypertrophy and fibrosis (Bisognano et al., 2000; 
Engelhardt et al., 2002; Bernardo et al., 2010). Thus in addition to Gq signalling, Gs –mediated 
cell growth and heart function also contributes to the maladaptive hypertrophic response. 
 
 Regulation of protein synthesis in cardiac hypertrophy 
1.4.1 Overview of protein synthesis 
In order for either adaptive or maladaptive cardiac hypertrophy to occur, individual 
cardiomyocytes must increase in size, and such growth requires increased global protein 
synthesis. Thus, regardless of the initial stimuli and receptors involved, hypertrophic signals 
will ultimately result in increased mRNA translation/protein synthesis. 
Protein synthesis consists of three main stages: initiation, elongation, and termination. During 
eukaryotic initiation, an initiator methionyl tRNA forms a complex with a 40S ribosomal 
subunit, and is then positioned at the start codon of an mRNA molecule (Jackson, Hellen and 
Pestova, 2010). Binding of the 60S ribosomal subunit allows for elongation to occur, during 
which amino acids are sequentially added to a growing polypeptide chain via specific tRNA 
molecules. When a stop codon is reached, protein synthesis is terminated by the release of the 
newly formed peptide chain and separation of the ribosomal-mRNA complex (Proud, 2007). 
1.4.2 Regulation of eIF2Bε 
As previously mentioned, regeneration of GTP-bound eIF2 requires eIF2B, and specifically 
the ε subunit, which contains the catalytic domain towards its C-terminus (Welsh and Proud, 
1993; Wang et al., 2001; Gomez, Mohammad and Pavitt, 2002). eIF2B can be activated by 
multiple stimuli that increase mRNA translation, including insulin and growth factors (Welsh 
and Proud, 1992; Welsh et al., 1996; Kleijn et al., 1998). Overexpression of eIF2Bε has also 
been shown to enhance growth in neonatal cardiomyocytes (Hardt et al., 2004). The 
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importance of eIF2B regulation can be seen by the convergence of hypertrophic signals on 
constitutively active glycogen synthase kinase 3. GSK-3, and more specifically its β isoform 
(GSK-3β), has been shown to be the predominant kinase for mediating eIF2B phosphorylation 
(Hardt and Sadoshima, 2002; Hardt et al., 2004). Under resting conditions, GSK-3β 
phosphorylates the catalytic ε subunit of eIF2B at a highly conserved serine (Ser540), resulting 
in the inhibition of eIF2B activity (Hardt et al., 2004). In addition to Ser540, the epsilon subunit 
of eIF2B has several other regulatory phosphorylation sites (Wang et al., 2001; Proud, 2007), 
which suggests that its regulation, and consequently that of eIF2, is critical in the control of 
global protein synthesis. 
Hypertrophic signals can promote the phosphorylation and deactivation of GSK-3β. As 
previously discussed, several pathways in both adaptive (e.g. IGF1-PI3K-Akt) and 
maladaptive cardiac hypertrophy (e.g. Gq and Gs-mediated) can result in the inhibition of GSK-
3β. Studies using β-receptor agonists have shown that inhibition of GSK-3β results in greater 
eIF2B activity and marked increases in cell size and protein synthesis; conversely, 
overexpression of GSK-3β decreases levels of eIF2B activity (Hardt et al., 2004). In addition, 
GSK-3β has been found to block hypertrophy in response to the Gq-agonists endothelin and 
phenylephrine (Dorn and Force, 2005). Together, these studies not only suggest that GSK-3β 
is the predominant kinase in eIF2Bε regulation, but demonstrate that regardless of the initial 
stimuli, eIF2Bε is required for hypertrophy to occur. Thus, targeting eIF2B for inhibition could 
prevent or decrease the levels of protein synthesis associated with pathological cardiac 
hypertrophy.  
 
 RGS proteins in the heart 
Several RGS proteins are expressed in mammalian hearts and have been detected in both 
cardiomyocytes and fibroblasts (Kardestuncer et al., 1998; Doupnik, Xu and Shinaman, 2001; 
Riddle et al., 2005; Zhang and Mende, 2011). In failing human hearts, variable expression 
results have been obtained, although the expression profiles of RGS2, RGS3, and RGS4 are 
noticeably altered (Riddle et al., 2005). Some groups have found RGS4 mRNA to be increased 
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but not RGS2 or RGS3 (Mittmann et al., 2002), whereas others have shown an apparent 
upregulation of RGS3 and RGS4 mRNA (Owen et al., 2001); other groups have identified 
decreases in RGS2 protein levels (Takeishi et al., 2000). Overall, it appears that RGS2 is 
normally highly expressed in the ventricles, whereas RGS4, RGS5, and RGS10 are mainly 
localized to the atria (Doupnik, Xu and Shinaman, 2001; Mittmann et al., 2002; Larminie et 
al., 2004; Gu et al., 2009; Miao et al., 2016), suggesting that targeting RGS2 is physiologically 
relevant. 
Animal overexpression and knockout models have demonstrated the cardiovascular roles of 
various RGS proteins. Gene expression studies have found RGS2, RGS3, and RGS5 to be the 
most highly expressed RGS proteins in the myocardium, (Larminie et al., 2004), and RGS4 
and RGS6 to be concentrated in the sinoatrial node (Grillet et al., 2005; Cifelli et al., 2008, 
Yang et al., 2010). A cardiac mouse model with transgenic overexpression of RGS4 transiently 
decreased cardiac hypertrophy and heart failure in Gαq– overexpressing mouse hearts (Rogers 
et al., 2001), although it should be noted that endogenous levels of RGS4 are virtually absent 
in the ventricular myocardium (Grillet et al., 2005; Cifelli et al., 2008). An overexpression 
model of RGS5 was protected against pressure overload-induced experimental cardiac 
hypertrophy and fibrosis, whereas marked cardiac hypertrophy, fibrosis, and dysfunction 
occurred in RGS5 knockout mice (Li et al., 2010). Recently, RGS10 was found to be 
downregulated in failing mouse hearts; similarly to RGS5, cardiac-specific overexpression led 
to decreased cardiac hypertrophy and fibrosis following experimentally induce pressure 
overload (Miao et al., 2016).  
RGS proteins also play an essential role in regulating heart rate. Knock-in mice expressing a 
RGS–resistant form of Gαi2 displayed enhanced carbachol–induced bradycardia (Fu et al., 
2006, 2007). RGS4 and RGS6 knockout models also suggest key roles in regulating 
parasympathetic heart rate control, as their loss resulted in severe bradycardia in response to 
in vivo parasympathetic stimulation (Cifelli et al., 2008; Posokhova et al., 2010; Yang et al., 
2010). RGS2 in particular has been shown to play a significant role in cardiovascular function. 
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1.5.1 Cardioprotective role of RGS2  
Because of the critical roles that Gαq and Gαs signalling play in the induction of pathological 
hypertrophy, the inhibitory effects of RGS2 on these signals makes it a potential target in the 
study of cardiovascular disease (Heineke and Molkentin, 2006; Hendriks-Balk et al., 2008). In 
addition to the heart, RGS2 is expressed in the brain, vasculature and kidneys (Kehrl and 
Sinnarajah, 2002) . Along with RGS1, 4, and 5, RGS2 is detectable at both the mRNA or 
protein level in endothelial or vascular smooth muscles cells of the arterial system (Bondjers 
et al., 2003; Heximer et al., 2003; Wang et al., 2008; Timofeeva et al., 2009). Rgs2-/- mice 
have been reported to exhibit elevated blood pressures (Heximer et al., 2003), and Gq -
mediated smooth muscle contraction is enhanced in several regions of the vasculature (e.g. 
mesenteric and renal arteries) (Hercule et al., 2007; Osei-Owusu et al., 2007; Osei-Owusu and 
Blumer, 2015). Interestingly, although global deletion of RGS2 has been observed to induce 
hypertension, vascular smooth muscle or endothelium-specific deletion of RGS2 does not 
appear to increase blood pressure (Osei-Owusu et al., 2012). However, transplanting Rgs2-/- 
kidneys into wild type recipient mice is sufficient to induce hypertension, with the reverse 
transplantation (i.e. WT kidneys transplanted in Rgs2-/- mice) “rescuing” Rgs2-/- animals from 
an observed hypertensive phenotype (Gurley et al., 2010), suggesting that renal RGS2 is 
important in maintaining normal levels of blood pressure.  
RGS2 appears to be necessary for the antihypertrophic and vasodilatory effects of cGMP and 
nitric oxide (Sun et al., 2005; Takimoto et al., 2009). Studies in cultured cardiomyocytes have 
shown that hypertrophy caused by prolonged Gαq–coupled receptor stimulation, such as that 
induced by phenylephrine (PE), can be blocked by the overexpression of RGS2 (Hao et al., 
2006; Zou et al., 2006). Moreover, RGS2 negatively regulates angiotensin II-induced 
signalling in cardiac fibroblasts (Zhang et al., 2011). RNAi–mediated knockdown of RGS2 
also leads to increased endothelin and phenylephrine–induced cardiomyocyte hypertrophy 
(Zhang et al., 2006, Nunn et al., 2010, Zou et al., 2006). A similar effect has been seen against 
Gαs mediated cardiomyocyte hypertrophy induced by isoproterenol (ISO) (Nunn et al., 2010).  
The cardiovascular role of RGS2 has been further demonstrated in knockout animal studies. 
Under normal conditions, the absence of RGS2 appears to have minimal effects on cardiac 
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function, although studies have shown Rgs2-/- or Rgs2+/- mice to be hypertensive (Heximer et 
al., 2003; Tang et al., 2003). However, experimentally induced pressure overload causes 
marked hypertrophy, heart failure, and death, as well as increased expression of cardiac fetal 
genes in RGS2 knockout mice (Takimoto et al., 2009). In addition, Rgs2-/- mice have been 
shown to have increased susceptibility to atrial fibrillation (AF) via enhanced M3 muscarinic 
receptor activity, which is known to be involved in vagally induced atrial fibrillation (Tuomi, 
Chidiac and Jones, 2010; Jones, Tuomi and Chidiac, 2012). 
Endogenous RGS2 protein is rapidly degraded via proteasomal mechanisms (Bodenstein, 
Sunahara and Neubig, 2007), and low RGS2 protein levels have been associated with 
cardiovascular dysfunction and hypertension in human patients (Heximer et al., 2003; Tsang 
et al., 2010); RGS2 is also selectively downregulated in pressure overload mouse models of 
cardiac hypertrophy and heart failure (Zhang et al., 2006), notwithstanding its acute 
upregulation in cardiomyocytes in response to hypertrophy-inducing Gq and Gs-coupled 
receptor stimulating agonists (Zou et al., 2006; Nunn et al., 2010) These observations suggest 
that overexpressing, or stabilizing RGS2 protein expression may result in cardioprotective 
effects. Digoxin and other cardiotonic steroids, which are used to treat atrial fibrillation and 
heart failure (Gheorghiade, Adams and Colucci, 2004), have been shown to act as selective 
stabilizers of RGS2 in vitro (Sjogren et al., 2012). Digoxin has also been shown to be 
cardioprotective in a drug–induced model of cardiac hypertrophy and injury, an effect which 
was lost in similarly treated RGS2 knockout mice (Sjögren et al., 2016).  
Surprisingly, cardiac specific overexpression of full-length RGS2 does not appear to offer 
substantial cardioprotection against either hypertrophy or dysfunction in a pressure overload 
mouse model (Park-Windhol et al., 2012). RGS2 possesses multiple properties not known to 
be shared by either RGS4 or RGS5 (Chidiac et al., 2014), including low affinity for Gαi/o 
(Heximer et al., 1999), ability to inhibit Gs-stimulated adenylyl cyclase signalling (Roy, 
Baragli, et al., 2006), nuclear localization (Chidiac and Roy, 2003), and the apparent ability to 
promote apoptosis (Endale et al., 2010). In addition, although RGS2 is selectively upregulated 
in cultured cardiomyocytes following Gαq or Gαs stimulation (Hao et al., 2006; Zou et al., 2006; 
Nunn et al., 2010), it is progressively downregulated in in vivo models of hypertrophy and 
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heart failure (Zhang et al., 2006). Since complete ablation of RGS2 signalling is 
unambiguously detrimental (Takimoto et al., 2009), it follows that optimal RGS2 levels under 
pathological conditions may be lower than those needed under basal conditions.  
Our lab has also shown that expression of either full-length RGS2 or RGS2eb can both block 
increases in cardiomyocyte size induced by phenylephrine (PE) or isoproterenol (ISO) (Zou et 
al., 2006; Chidiac et al., 2014). In addition, the reactivation of “fetal” genes such as ANP and 
β-MHC, which are indicators of pathological hypertrophic growth, were suppressed in 
cardiomyocytes expressing RGS2eb (Chidiac et al., 2014). An important distinction between 
full length RGS2 and RGS2eb is that while the latter prevents hypertrophy, it does not have 
GAP activity for Gαq, and also seems to have no inhibitory effect on ISO-induced Gαs signalling 
(Nguyen et al., 2009; Chidiac et al., 2014). This indicates that in addition to the established 
role of the RGS2 GAP domain as an inhibitor of G-protein and GPCR signalling, the RGS2eb 
region further regulates G-protein induced hypertrophy through its binding to eIF2Bε, which 
leads to the direct, G-protein independent inhibition of protein synthesis. 
 
 Clinical aspects of pathological left ventricular hypertrophy 
(LVH) 
1.6.1 General characteristics cardiac hypertrophy 
During fetal development, mammalian cardiomyocytes rapidly proliferate; this growth ceases 
during the perinatal period, and the heart is thus generally regarded as a post-mitotic organ, 
with further increases in heart mass thought to be mainly achieved through increases in cell 
size, i.e. hypertrophy (Ahuja, Sdek and MacLellan, 2007; Shimizu and Minamino, 2016). In 
the adult heart, various intrinsic and extrinsic stimuli can increase biomechanical stress and 
lead to a thickening of ventricular heart walls. Depending on the stimuli, either physiological 
or pathological hypertrophy can occur (Fig. 1.1). Physiological cardiac hypertrophy mainly 
develops in response to growth of the body (e.g. childhood growth) or chronic exercise 
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training, whereas pathological cardiac hypertrophy occurs in a disease setting (Levy et al., 
1990).  
Physiological and pathological hypertrophy can be further subclassified as either concentric or 
eccentric hypertrophy (McMullen and Jennings, 2007). During concentric hypertrophy, which 
is induced by pressure overload on the heart, sarcomeres in cardiomyocytes are added in 
parallel, leading to an increase in myocyte cell width and a subsequent increase in heart wall 
thickness; this results in hearts with thick walls and relatively small ventricular cavities 
(Grossman, Jones and McLaurin, 1975; Bernardo et al., 2010). In a physiological context, 
concentric hypertrophy develops following isometric or static exercise such as weight lifting, 
which involves developing muscular tension against resistance with little movement (Pluim et 
al., 2000; McMullen and Jennings, 2007). Pathological stimuli such as hypertension or aortic 
stenosis similarly cause pressure overload on the heart and the development of concentric 
hypertrophy (Frey and Olson, 2003). In contrast, eccentric hypertrophy results in sarcomeres 
being added in series to increase myocyte cell length, leading to relatively thinner walls and 
larger ventricular cavities (Bernardo et al., 2010). Isotonic exercise, such as running and 
swimming, involves the movement of large muscle groups; vasodilation of the skeletal 
vasculature produces eccentric hypertrophy due to increased venous return to the heart, which 
results in volume overload (Zak, 1984; McMullen and Jennings, 2007). Pathological stimuli 
such as aortic regurgitation and arteriovenous fistulas can increase diastolic wall stress, and 
also result in eccentric hypertrophy (Grossman, Jones and McLaurin, 1975; Pluim et al., 2000). 
While both physiological and pathological hypertrophies are characterized by an increase in 
cardiomyocyte size due to increased global protein synthesis, the two conditions differ in 
multiple aspects. In physiological hypertrophy, cardiomyocytes increase in size but display a 
normal phenotype, and this is associated with normal cardiac function (Shimizu and 
Minamino, 2016). Fatty acid oxidation is the main metabolic pathway for ATP production, 
with the heart capable of switching to glucose and lactate metabolism depending on workload 
(van der Vusse et al., 1992). In contrast, pathological hypertrophy results in a switch to 
increased glucose metabolism and structural changes such as increased fibrosis, as well as 
functional abnormalities (Conrad et al., 1995; Bernardo et al., 2010). Pathological hypertrophy  
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Figure 1.1. Characteristics of physiological and pathological hypertrophy. 
 18 
 
is also characterized by a return to the “fetal” gene program, which includes increased 
expression of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and α-skeletal 
actin, as well as alterations in the cardiac contractile proteins α-and β-myosin heavy chain 
(Hannan et al., 2003; Bernardo et al., 2010; Taegtmeyer, Sen and Vela, 2010; Kuwahara, 
Nishikimi and Nakao, 2012). Maladaptive hypertrophy can drastically affect cardiovascular 
health. Aside from age, left ventricular hypertrophy is the most potent predictor of poor 
cardiovascular outcomes in hypertensive patients, and is an independent risk factor for sudden 
death, stroke, coronary heart disease, and heart failure (Levy et al., 1990; Cipriano et al., 2001; 
Gardin et al., 2001; Verdecchia, Carini, et al., 2001; Verdecchia, Porcellati, et al., 2001; 
Gradman and Alfayoumi, 2006). With cardiovascular disease as the leading cause of mortality 
in many nations (Schou et al., 2013), identifying regulators of pathological hypertrophy is of 
great interest and importance. 
1.6.2 General overview of LVH in patient populations 
Since the left ventricle is responsible for pumping oxygenated blood throughout the body, the 
majority of ventricular hypertrophy in a disease setting develops in the left myocardium. Most 
LVH develops in early response to chronic hypertension; patients with transient elevations in 
blood pressure, such as during mental stress or exercise, are also prone to hypertrophy (Daniels, 
Meyer and Loggie, 1990; Schnall et al., 1990). Although hypertension is the leading cause of 
LVH, factors other than blood pressure can also be important in the development of 
hypertrophy, including angiotensin II and catecholamine levels, body mass or obesity, genetic 
background, age of onset of high blood pressure, and insulin sensitivity (Simpson, 1983; Levy 
et al., 1988; Sasson et al., 1993; Schunkert et al., 1994; Ichikawa et al., 1996; Re, 2003). In 
addition, genetics may play a role in the development of LVH; mutations in genes encoding 
sarcomeric proteins have been shown to directly correlate with hypertrophic cardiomyopathy 
(Maron, 2002), and some patients with mild hypertension appear genetically predisposed to 
LVH development (Liebson et al., 1993; Martinez et al., 2003).  
The test of choice for accurate estimation of patient LV heart mass comes from 2D 
echocardiography (Lorell and Carabello, 2000); although cardiac MRI is the gold standard test 
for LVH due to its accuracy and reproducibility, it is cost prohibitive for regular clinical use 
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(Bottini et al., 1995; Bauml and Underwood, 2010). In hypertensive patients, LVH usually 
presents as an increase in wall thickness, which may are may not be accompanied by an 
increase in the size of the LV cavity (Douglas and Kaplan, 2017). Interestingly, patients 
without an increase in absolute LV mass but with an increase in their wall thickness–to–cavity 
diameter ratio (concentric remodelling) have the same adverse risk for cardiovascular disease 
and death as patients who develop concentric hypertrophy (increase in both mass and wall 
thickness–to–cavity diameter ratio) (van Hoeven and Factor, 1990; Jain et al., 1996). While 
hypertension induces pressure overload on the heart, concurrent volume overload due to 
coronary artery disease or valvular conditions can further increase LVH and reduce cardiac 
function (Zabalgoitia et al., 2001).  
1.6.3 LVH increases cardiovascular risk 
Diagnosed left ventricular hypertrophy comes with an increased risk of multiple cardiac events 
including angina and myocardial infarction (MI), arrhythmias, stroke, heart failure, and death 
(Levy et al. 1990; Koren et al. 1991; Verdecchia, Porcellati, et al. 2001; Haider et al. 1998; 
Drazner et al. 2004; D Levy et al. 1989). Increases in cardiovascular risk have been found to 
be directly related to the degree of increase in LV mass; this effect is also independent from 
that of blood pressure (Levy et al. 1990; Koren et al. 1991). In a study of ~1000 patients over 
50 years of age with primary hypertension and no previous cardiovascular events, LVH was 
associated with a 40% increased risk for a major cardiovascular event (e.g. MI, severe heart 
failure, severe kidney failure) even after adjustment for other risk factors (Verdecchia, Carini, 
et al., 2001). In the Framingham Heart Study, which originally followed more than 5000 men 
and women between the ages of 30 and 62 who had not yet developed overt symptoms of 
cardiovascular disease, a subset population of ~3000 individuals over the age of 44 were found 
to have a 22% prevalence of LVH; even after adjusting for other risk factors, these patients 
were found to be twice as likely to suffer from sudden death (Haider et al., 1998).  
LVH can cause electrophysiological alterations such as altered repolarization of the heart, non-
uniform action potential prolongation, and early afterpotentials; this can lead to an increased 
risk of atrial fibrillation, ventricular tachycardia, arrhythmias, and even sudden death (Gardin 
et al., 2001; Okin et al., 2006; Sarganas et al., 2014). Increases in cardiac risk associated with 
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LVH may also arise in part due to myocardial ischemia, which can be induced by multiple 
factors (Douglas and Kaplan, 2017). Enlarged cardiomyocytes, and thus increased muscle 
mass, can limit the ability of coronary arteries to properly dilate in response to vasodilatory 
stress (e.g. during exercise) or decreased perfusion (e.g. during an arrhythmic event); 
endocardial capillaries may also be directly compressed (Beache et al., 2001). These factors 
can result in adverse clinical implications as well as decreases in coronary flow reserve (the 
ratio between resting and maximal coronary artery blood flow), an important indicator of 
cardiovascular risk (Douglas and Kaplan, 2017). In patients with LVH, coronary occlusion 
events are associated with greater degrees of myocardial infarction and increased mortality 
rates (Carluccio et al., 2000). In cases of sudden cardiac death, patients with LVH and 
hypertension tend to have less extensive coronary artery disease than normotensive cases of 
sudden death, suggesting that hypertrophied myocardium may be more susceptible to the 
effects of ischemia (Burke et al., 1996). Progressive LVH results in deleterious ventricular 
remodelling as well as depressed systolic and diastolic ventricular functions (Norton et al., 
2002). If improperly treated, LVH may ultimately lead to the development of irreversible heart 
failure, and is one of the greatest independent risk factors for this condition (Cipriano et al., 
2001).  
1.6.4 Non-pharmacological interventions 
Strategies to manage hypertension and co-morbidities such as obesity can contribute to 
lowering LV mass by reducing pressure overload on the heart. A high prevalence of 
hypertension in obese patients (>60%) accounts for more than 60% of incident hypertension 
(a systolic/diastolic blood pressure greater than 140/90 mmHg) in women and almost 80% of 
incident hypertension in men. Regression of LVH in patients with primary hypertension has 
been shown to occur with weight loss and exercise. Sympathetic signalling mechanisms play 
a well-established role in the development of hypertrophy, and weight loss in obese patients 
has been reported to reduce indices of sympathetic activity (e.g. plasma and urinary 
norepinephrine excretion, resting heart rate) (Ostman-Smith, 1981; Reisin et al., 1983; Sen, 
1983). Weight reduction also decreases plasma aldosterone levels and renin activity, 
components of the renin-angiotensin II system which have been implicated in the development 
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of hypertension and LVH (Iwai, Shimoike and Kinoshita, 1995; Lambert et al., 2014; Seravalle 
et al., 2014). In patients with hypertension and measurable LVH, calorie restriction-induced 
weight loss alone can decrease left ventricular mass by up to 20% (MacMahon, Wilcken and 
Macdonald, 1986). Thus, managing patient weight through diet and exercise can help limit the 
development of LVH. In addition to weight loss, sodium restriction can inhibit LVH 
progression. Obese patients often have hyperinsulinemia (excess levels of circulating insulin) 
leading to increased sodium reabsorption through the renal tubules, which can exacerbate 
already elevated blood pressures (Jula and Karanko, 1994; Kim et al., 2015). Recommended 
daily amounts of sodium range between 1000 – 1500 mg; average Canadians consume around 
~3400mg of sodium daily, with many eating well in excess of 5000 mg per day (Government 
of Canada, 2013). Dietary sodium restriction (<1600 mg/day) has been shown to reduce LVH 
through decreases to blood pressure and body fluid retention in patients with moderate primary 
hypertension and above average LV mass (Jula and Karanko, 1994). However, although diet 
and weight loss may markedly benefit patients, clinical studies have demonstrated that such 
lifestyle modifications are difficult to maintain in the long term (Whelton et al., 1992; Stamler, 
1997; Hedayati, Elsayed and Reilly, 2011). Thus, pharmacological intervention is often 
required to moderate the progression of LVH and associated hypertension.  
1.6.5 Pharmacological treatments 
Regression of LVH has been shown with multiple drugs including angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), some calcium channel 
blockers (e.g. verapamil, amlodipine, and diltiazem), renin inhibitors (e.g. aliskiren), and some 
sympatholytic agents (e.g. alpha–blockers and methyldopa) (Franz, Tönnesmann and Müller, 
1998; Okin et al., 2006; Cuspidi, Negri and Zanchetti, 2008; Os et al., 2008; Solomon et al., 
2009). Direct vasodilators appear to be largely ineffective in regards to LVH regression, which 
may be due to reflex stimulation of angiotensin II and norepinephrine release (both of which 
can directly promote the development of LVH) (Klingbeil et al., 2003). Although ARBs, 
calcium channel blockers, and ACE inhibitors produce significantly more LVH regression than 
diuretics and beta blockers, there is currently no evidence that a more rapid regression of LVH 
is associated with improved long-term health outcomes (Kaplan and Douglas, 2017).  
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ARBs have been demonstrated to be the most efficacious class of drugs for reducing LV mass 
(11% reduction in LV mass), followed by calcium channel blockers (11%), ACE inhibitors 
(10%), diuretics (8%), and beta-blockers (6%) (Klingbeil et al., 2003; Bauml and Underwood, 
2010). An important component in LVH development is myocardial fibrosis, which 
compromises cardiac function via initial diastolic dysfunction followed by progressive systolic 
dysfunction (Weber et al., 1990); angiotensin II has been shown to induce the development of 
fibrosis in the myocardium of hypertensive patients (González et al., 2002), and may be an 
additional mechanism of action by which ACE inhibitors and ARBs exhibit their beneficial 
effects in cardiac hypertrophy. As such, ACE inhibitors and ARBs are recommended as first-
line treatments for LVH, unless contraindicated in the individual patient (Bauml and 
Underwood, 2010). 
 
 Altered RGS2 expression in humans is associated with 
cardiovascular dysfunction 
Various studies have suggested a potential role of RGS2 dysfunction in human hypertension. 
Human skin fibroblasts and peripheral blood mononuclear cells from hypertensive patients 
display decreased RGS2 mRNA expression, increased Ang II-induced MAPK/ERK 
phosphorylation, and elevated Ca2+ release from internal stores (Semplicini et al., 2006). 
Multiple Rgs2 SNPs have been identified in genetic groups from China (Zhao et al., 2008; 
Zhang et al., 2010), Japan (Yang et al., 2005), the Netherlands (Riddle et al., 2006), and the 
United States (Hettema et al., 2013). Destabilizing N-terminal mutations appear to increase 
RGS2 susceptibility to arginylation/ubiquitination and subsequent proteasomal degradation 
(Bodenstein, Sunahara and Neubig, 2007), while other SNPs can affect RGS2 localization and 
impair GAP activity (Gu, Tirgari and Heximer, 2008). In contrast, RGS2 overexpression has 
been found in patients with Bartter/Gitelman syndrome, a kidney disorder caused by loss of 
function mutations of the thiazide-sensitive sodium-chloride symport that is characterized in 
part by hypotension and an increased risk for ventricular arrhythmia (Deschenes, Feldmann 
and Doucet, 2002; Foglia et al., 2004; Knoers and Levtchenko, 2008). The dysfunction of 
RGS2 in patients suggests that its study in relation to hypertension and hypertrophy may be 
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clinically relevant, and that stabilizing its expression or function may increase or decrease 
blood pressure; indeed, stabilizing RGS2 expression appears to be beneficial in in vitro and in 
animal models of cardiac hypertrophy (Sjögren, Blazer and Neubig, 2010; Sjogren et al., 2012; 
Sjögren et al., 2016), and suggests that RGS2 could be a potential target for drug discovery in 
cardiovascular disease.  
 
 Animal models of cardiac hypertrophy 
1.8.1 Transverse aortic constriction 
Transverse aortic constriction (TAC) in murine animals is a well-established technique of 
experimental pressure overload on the heart to induce cardiac hypertrophy and dysfunction, 
and has been used in multiple studies to examine the role of RGS2 in cardiovascular health 
(Wang et al., 2008; Takimoto et al., 2009; Takimoto, 2011; Park-Windhol et al., 2012) Briefly, 
following anaesthesia and intubation, the chest cavity is entered via the second intercostal 
space through a small incision, and aortic constriction is performed by tying sutures against a 
needle to yield a narrowing of the aorta once the needle is removed (Rockman et al., 1991). 
Since its initial development (Rockman et al., 1991), TAC has been extensively used as a 
model of human cardiovascular disease and for the study of signalling processes involved in 
hypertrophic responses and heart failure. In comparison to other experimental models of heart 
failure, such as coronary artery ligation (which results in complete occlusion of the vessel), 
TAC provides a more gradual model of cardiac hypertrophy development (deAlmeida, van 
Oort and Wehrens, 2010), which can be modified by both the duration (Mohammed et al., 
2012) and severity of the constriction (i.e. the gauge of the needle); TAC initially induces 
compensatory cardiac hypertrophy, which can often present as temporarily enhanced cardiac 
contractile function. Over time, chronic pressure overload leads to maladaptive cardiac 
hypertrophy and fibrosis, which can ultimately devolve into heart failure and cardiac dilation 
(Patten and Hall-Porter, 2009).  
A major advantage of TAC is the ability to measure the pressure gradient that is created across 
the aortic stricture (Patten and Hall-Porter, 2009); since the constriction is performed on the 
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aorta between the left and right carotid arteries, arterial pressures (as measured by conductance 
catheters) should be measurably higher in the right carotid artery, thus validating the success 
of TAC surgery. The utility of this model can be seen from the promising and novel 
therapeutics targets that have been identified through its use (Braz et al., 2004; Wilkins et al., 
2004; Takimoto et al., 2005; Jeong et al., 2006) 
1.8.2 Osmotic pump infusion 
Although the TAC method is a highly reproducible (Rockman et al., 1991) and useful model 
of cardiac hypertrophy and heart failure, the acute onset of severe hypertension via aortic 
stricture may lack direct clinical relevance (Patten and Hall-Porter, 2009). Multiple studies 
have used continuous drug infusion to induce systemic hypertension (and thus hypertrophy) 
via angiotensin II (Bueno et al., 2002; Freund et al., 2005; Kee et al., 2006), which is arguably 
a more clinically relevant model in light of the major role of the renin-angiotensin system 
(RAS) in the development of human hypertension and cardiac hypertrophy (Weber and Brilla, 
1991; Dostal and Baker, 1999). Other groups have chronically infused isoproterenol to 
stimulate β-adrenergic signalling, and often do so in conjunction with angiotensin and/or TAC 
models (Soonpaa and Field, 1994; Kudej et al., 1997; Saadane, Alpert and Chalifour, 1999; 
De Windt et al., 2001; Bueno et al., 2002; Freund et al., 2005). 
Following the initial development of an osmotic pump concept (Rose and Nelson, 1995), 
simplified mini-osmotic pumps have been designed which can systemically deliver sustained 
doses of desired drugs in a relatively non-invasive manner. Briefly, osmotic pumps operate via 
an osmotic pressure difference between a salt sleeve that surrounds a flexible and impermeable 
reservoir (containing a desired drug/solution) and the environment in which the pump is 
implanted (e.g. subcutaneous or intraperitoneal) (Alzet, 2017). The high osmolality of the salt 
sleeve draws water through a semipermeable membrane into the pump, leading to compression 
of the drug-containing reservoir; the drug/solution is thus displaced out of the pump (through 
a flow moderator) at a controlled rate which is predetermined by the water permeability of the 
pump’s outer membrane (Theeuwes and Yum, 1976).  
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 Cardiovascular health and obesity 
Cardiovascular dysfunction is known to be directly influenced by obesity and weight gain, 
which are major risk factors for cardiovascular diseases such as coronary heart disease, atrial 
fibrillation, hypertension, venous thromboembolisms, and congestive heart failure (Klein et 
al., 2004; Poirier et al., 2006; Tedrow et al., 2010; Wattanakit et al., 2012). In 2011 to 2012, 
only 65% of children and 31% of adults in the United States met body mass indexes (kg/m2) 
which correlated with ideal cardiovascular health (Lloyd-Jones et al., 2010). Conversely, 32% 
of US children and 69% of adults are currently estimated to be overweight or obese 
(Mozaffarian et al., 2016). The health and economic costs of obesity and its related co-
morbidities, such as cardiovascular diseases, are substantial. In 2008, the estimated medical 
cost of obesity was $147 billion; costs related to the current prevalence of obesity and weight 
gain in children and adolescents is projected to be $254 billion ($46 billion in direct medical 
costs, and $208 billion in lost productivity due to morbidities and mortality) (Finkelstein et al., 
2009; Lightwood et al., 2009). Although addressing obesity requires a multifactorial response 
involving clinical, biomedical, and socio-economic approaches, we will focus on examining 
the physiological mechanisms underlying weight regulation and metabolism, which may 
provide beneficial insights into treatments and novel drug targets.  
 
  Regulation of energy balance by GPCRs 
Multiple GPCRs have been shown to be involved in energy metabolism. Adiposity is 
determined by energy intake (e.g. food intake) versus energy expenditure (e.g. physical 
activity, adaptive thermogenesis, basal metabolism), and possible sources of energy imbalance 
in cases of obesity or conversely, loss of body weight, could come from dysfunctions in food 
intake/nutrient absorption, lipid storage, metabolic rate, physical activity, or CNS-related 
changes. 
Several studies have demonstrated the involvement of a vast range of GPCR signalling in 
appetite and satiation. Brain cannabinoid receptors play a physiological role in the control of 
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appetite and body weight, and cannabinoid CB1 receptor antagonists reduce appetite and 
decrease body weights in non-obese Wistar rats (Colombo et al., 1998). Patients with eating 
disorders exhibit several clinical features and biologic findings indicative of serotonin (5-
hydroxytryptamine/5-HT) dysregulation (Brewerton, 1995), and ghrelin infusion has been 
shown to enhance appetite and increase food intake in humans (Wren et al., 2001). 
Furthermore, histamine, which acts as a central neurotransmitter, acts as an appetite 
suppressant via stimulation of histamine H1 receptors, thereby mediating the inhibitory effects 
of leptin on appetite (Jørgensen et al., 2007). In addition, amylin, a peptide secreted from the 
pancreas following a meal or in response to oral glucose ingestion, acts as a satiation factor, 
and has been found to be overexpressed in genetically obese animals due to receptor 
insensitivity (Morley et al., 1995). Oxyntomodulin (OXM) is another peptide released from 
the gut following food intake and binds to both glucagon-like peptide-1 receptor (GLP1R) and 
the glucagon receptor; both systemic and brain-specific injection of (OXM) in rats reduces 
food intake and weight gain (Cohen et al., 2003). Interestingly, some orphan GPCRs, including 
GPR61 and GPR82, appear to be involved in regulating food intake; loss of GRP61 and GPR82 
in mice resulted in hyperphagia and lower food intake, respectively (Engel et al., 2011; Nambu 
et al., 2011).  
Gastrointestinal (GI) motility, digestion, and nutrient sensing also involve GPCRs. Taste 
receptors belong to the T1R and T2R families of GPCRs; ligand (amino acid) binding triggers 
signal transduction and neurotransmitter release, and taste receptors can also be found in 
certain regions of the gut to regulate gastric inhibitory polypeptide (GIP) and GLP-1 stimulated 
insulin secretion (Chaudhari and Roper, 2010; Efeyan, Comb and Sabatini, 2015). The 
neuropeptide cholecystokinin (CCK) can slow gastric emptying (via induction of acetylcholine 
release from the GI tract) (Paton et al., 1971), and additionally acts as an appetite suppressant 
(Crawley and Corwin, 1994). In addition, endogenous opioids of three known classes have 
been found throughout the gastrointestinal tract (Kromer, 1988), and exogenous opioids are 
well known to depress GI motility (Schaumann, 1955); localization of peptide YY (PYY), a 
ligand for neuropeptide Y receptors, also decreases intestinal blood flow and motility 
(Lundberg et al., 1982). Overall, this non-exhaustive list of GPCRs and their related signalling 
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pathways demonstrates the fundamental role of these receptors in mediating energy 
metabolism.  
 
  Altered G protein signalling in lean and obese phenotypes 
Alterations in G protein signalling can lead to both lean and obese phenotypes. Loss of 
melanocortin 4 signalling results in severe obesity that is associated with hyperphagia, 
hyperinsulinemia, and hyperglycemia (Huszar et al., 1997); a triple knockout of β1/2/3-
adrenergic receptors in mice led to weight gain on a standard chow diet, and the development 
of massive high fat diet induced obesity, which was attributed to a failure to initiate diet-
induced thermogenesis (Bachman et al., 2002). Conversely, mice without Gβ5, a G protein β 
subunit that dimerizes with RGS proteins of the R7 family instead of Gγ, displayed a lean 
phenotype, were resistant to a high-fat diet, and demonstrated increased thermogenesis (Wang 
et al., 2011). Mice lacking the M3 muscarinic acetylcholine receptor are lean and hypophagic, 
indicating M3 receptor-mediated facilitation of food intake (Yamada et al., 2001). Moreover, 
loss of the neuropeptide melanin-concentrating hormone (MCH), which normally promotes 
feeding, led to reduced body weight due to hypophagia (Shimada et al., 1998). In addition, 
full-body RGS4 (Grillet et al., 2005) and RGS5 (Cho et al., 2008) knockout mice weight 
significantly less than WT counterparts, although lack of RGS5 has also been reported to 
exacerbate obesity, inflammation, hepatic steatosis, and insulin resistance (Deng et al., 2012). 
Rgs2-/- mice are also lean and display a hyperphagic phenotype, which will be subsequently 
discussed in detail.  
 
  Skeletal tissue is a major site of energy metabolism via 
thyroid hormone (TH) regulation       
Thyroid hormone (TH) signalling is critical for numerous biological functions including 
development and growth, energy expenditure, and thermogenesis. TH primarily acts through 
nuclear-receptor mediated stimulation or inhibition of gene transcription (Yen, 2001; Mebis et 
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al., 2009). This activity is mainly mediated by the alpha isoform of the thyroid hormone 
receptor in skeletal muscle. Thyroid hormone receptors in the unliganded state are usually 
bound to TH-responsive elements in various genes along with other proteins, leading to active 
repression of gene transcription (Yen, 2001); upon ligand binding, repression of the target gene 
is lifted and transcription is stimulated by co-activator recruitment to the complex (Brent, 
2012). In skeletal tissue, proteins which are transcriptionally regulated by TH include 
SERCA1A (Simonides et al., 1996), SERCA2A (Hartong et al., 1994), GLUT-4 (glucose 
transporter) (Zorzano, Palacin and Guma, 2005) , UCP3 (muscle-specific) (Solanes et al., 
2005), malic enzyme (ME1) (Desvergne, Petty and Nikodem, 1991), and glycerol – 3-
phosphate dehydrogenase (Dümmler, Müller and Seitz, 1996). In addition to modifying the 
glycolytic and oxidative capacities of skeletal tissue, TH affects mitochondrial capacity via 
transcription of the gene for PGC1α, a regulator of mitochondrial biogenesis (Weitzel, Iwen 
and Seitz, 2003).  
Resting metabolic rates in almost all tissues depend on thyroid hormone availability. TH has 
been shown to increases the rates of muscle contraction and relaxation, which is related to 
changes in the expression of proteins involved in intracellular Ca2+ flux (e.g. SERCA isoforms) 
(Salvatore et al., 2013). By promoting a shift from slow type I fibre phenotypes to the faster 
type II skeletal fibres, TH induces the increased expression of myosin and SERCA, leading to 
greater energy turnover and the generation of heat during activity (Thomas, Auwerx and 
Schoonjans, 2008). In skeletal muscle, TH signalling can alter the metabolic rate by uncoupling 
ATP synthesis in the mitochondria or by decreasing metabolic efficiency; a potential 
mechanism through which energy is “wasted” in the form of heat dissipation includes 
decreasing ATP synthesis efficiency via proton leak through skeletal tissue specific 
mitochondrial uncoupling protein 3 (UCP3) (de Lange et al., 2001). Since skeletal tissue 
comprises approximately 40-50% of total body mass, it is the largest single contributor to the 
metabolic resting state of an organism, as well as towards heat generation (Thomas, Auwerx 
and Schoonjans, 2008). 
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  TH regulation of metabolism and glucose homeostasis 
requires deiodinase type 2 (DIO2) for T4-T3 conversion 
In order for thyroid hormone to regulate various metabolic processes, it must be converted 
from its inactive prohormone form T4/thyroxine (3,5,3',5'-tetraiodothyronine) to the active 
thyroid hormone/T3 (3,5,3'-triiodothyronine, T3). Thyroid hormone signalling in individual 
tissues can change even as serum T4 concentrations remain normal due to local activation or 
inactivation of thyroid hormone, the underlying mechanism of which is deiodination by the 
intracellular iodothyronine deiodinases type I, II, and III (DIO1, DIO2, and DIO3) (St. 
Germain and Galton, 1997; Bianco et al., 2002). DIO1, 2, and 3 regulate thyroid hormone 
activity via removal of iodine moieties from T4 (2); DIO2 converts T4 to T3, whereas DIO3 
inactivates T3 (DIO1 function remains to be clarified) (Wondisford, 2003; Bianco and Kim, 
2006). Thus, the deiodinases, and specifically DIO2, are critical determinants of intercellular 
T3 levels.  
Glucose uptake into mammalian cells is mediated via the tissue specific transport proteins 
GLUT1-4, a process which is often a rate-limiting step in tissue glucose metabolism (Torrance 
et al., 1997). In skeletal muscle, insulin-sensitive GLUT-4 (or SLC2A4) is the main isoform 
expressed, and functions to rapidly remove circulating glucose from the blood following a 
meal; indeed, skeletal muscle accounts for more than 85% of whole body insulin-stimulated 
glucose uptake (Torrance et al., 1997). As previously mentioned, GLUT-4 protein and mRNA 
expression are regulated by TH (specifically T3); in conjunction, GLUT-4 translocation to the 
cell surface is an insulin-dependent event, and normal muscle responsiveness to insulin has 
been shown to require the DIO2-mediated conversion of T4 to T3 (Mills et al., 1987; Zorzano, 
Palacin and Guma, 2005; Grozovsky et al., 2009). The importance of DIO2 regulation of T3 
production and insulin action can be seen through in vitro and animal models. Cultured 
myotubes lacking DIO2 have decreased phosphorylated Akt (a downstream effector of insulin) 
(Grozovsky et al., 2009), and mice with targeted deletion of Dio2 are insulin resistant and 
susceptible to diet-induced obesity (Marsili et al., 2011). 
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  Role for RGS2 in metabolic pathways 
Human polymorphisms that result in the over- or under-expression of RGS2 point to the 
clinical relevance of RGS2 in the context of metabolism. A common polymorphism in the 3’ 
untranslated region of RGS2 has been shown to decrease RGS2 expression, and is considered 
to be a genetic marker that can predict male predisposition to weight gain and obesity (Sartori 
et al., 2008). Conversely, a C to G substitution in the RGS2 promoter region has been shown 
to increase RGS2 expression in adipocytes and is associated with the metabolic syndrome 
(Freson et al., 2007). RGS2 has been shown to have various effects on energy storage and 
usage; in vitro studies have demonstrated the role of RGS2 in mediating GLUT-4 (insulin-
responsive glucose transporter) translocation in adipocytes (Imamura et al., 1999), as well as 
GIP (glucose-dependent insulinotropic polypetide)-induced insulin release from pancreatic β 
cells (Tseng and Zhang, 1998). Thus, RGS2 may be involved in glucose entrance in adipocytes. 
RGS2 may also regulate metabolism via inhibitory effects on thyroid stimulating hormone 
receptor (TSHR)-induced Gq signal transduction; the TSHR ligand TSH is a pituitary hormone 
which stimulates the thyroid gland to produce T4 (Eszlinger et al., 2004). RGS2 also appears 
to promote the differentiation of adipocytes and expression of adipogenic markers, and is 
transiently and rapidly upregulated in differentiating mouse preadipocyte cells (Imagawa, 
Tsuchiya and Nishihara, 1999; Nishizuka et al., 2001). Other energy-dependent processes 
affected by RGS2 include the regulation of protein synthesis (Nguyen et al., 2009; Chidiac et 
al., 2014), as well as ATP hydrolysis by PMCA (plasma membrane Ca2+ ATPase) and SERCA 
(sarco/endoplasmic reticulum Ca2+) pumps (Wang et al., 2004), which altogether suggests an 
important role for RGS2 in body metabolism. 
 
  Rgs2-/- mice display a lean phenotype and are hyperphagic 
 Rgs2-/- mice, which are a well-established strain, demonstrate normal circadian activity and 
motor function; phenotypes include increased anxiety, decreased male aggression, reduced T 
cell proliferation and heightened sensitivity to TAC-induced cardiac hypertrophy, as well as 
mild to moderate levels of hypertension. (Oliveira-Dos-Santos et al., 2000; Heximer et al., 
2003; Takimoto et al., 2009). Our lab has previously reported a novel phenotype in Rgs2-/- 
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mice, such that they are resistant to age-related, normal body weight gain until their end-of-
life (~24 months-old) (Nunn et al., 2011). In addition to decreased body weights, Rgs2-/- mice 
are hyperphagic, display increased insulin sensitivity, decreased serum lipids, smaller brown 
and white adipose tissue deposits, and smaller adipocytes. Since RGS2 appears to promote 
adipocyte differentiation (Nishizuka et al., 2001), it would follow that its loss would result in 
impaired adipocyte function. Surprisingly, Rgs2-/- mice were not resistant to high fat diet-
induced obesity, and gained weight at similar rates to WT controls. Furthermore, the increased 
insulin sensitivity observed under ad libitum diet conditions was abrogated by the high fat diet 
(Nunn et al., 2011). Our observations suggest that even though adipocytes in Rgs2-/- animals 
are significantly smaller compared to WTs, lipid metabolism may not be impaired, and that it 
is rather carbohydrate or protein metabolism which is altered. Given that our characterization 
of the lean metabolic phenotype mainly focused on adipocyte-related functions, exploring 
potential alterations in Rgs2-/- skeletal tissue, a major metabolic contributor, could lead to a 
more in-depth understanding of the role of RGS2 in energy metabolism  
 
  Diet-induced models of weight gain and loss 
1.16.1 High-fat diets 
Surrogate animal models are important for studying the molecular aspects of obesity and its 
pathophysiological effects, as patient complications can often take years to develop (Wang and 
Liao, 2012). Since their introduction three decades ago (Surwit et al., 1988), high-fat diets have 
been used extensively to study the pathophysiologies of weight gain (e.g. glucose intolerance 
and type 2 diabetes) and for the development of novel obesity treatments (Ahrén et al., 2000; 
Reimer, Holst and Ahrén, 2002). Wild-type animals on a high fat diet (particularly the 
C57/Bl/6 strain) gradually gain weight over time, and progressively develop increased 
hyperinsulinemia, which is indicative of worsening insulin resistance (Winzell and Ahrén, 
2004). While standard chow has an approximate composition of less than ~10% kcal from fat, 
high fat diets can range from ~40% to ~60% kcal from fat content (Wang and Liao, 2012). 
Numerous high-fat studies use either lard (animal fat) or shortening (hydrogenated vegetable 
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oil) (Silva et al., 2006; Lionetti et al., 2014; Fujiwara et al., 2015; Magri et al., 2015); vegetable 
shortening may also differ in their fatty acid composition depending on whether a partially 
hydrogenated soybean/palm oil or a partially hydrogenated soybean/cottonseed oil formulation 
is used (Kubant et al., 2015). Recent studies have found that lard-based high-fat diets increase 
weight gain and the development of obesity and insulin resistance to a greater extent than 
hydrogenated vegetable shortening diets (Kubant et al., 2015); this highlights the importance 
of identifying the fatty acid composition of diets used to examine the role of dietary fats.  
1.16.2 Dietary restriction  
Diet restriction models have most often been used in the context of aging and metabolism 
(Weindruch and Walford, 1982; Hursting et al., 2003; Bordone and Guarente, 2005); 30-50% 
food intake restrictions on ad libitum fed rats and mice have been shown to markedly increase 
longevity and delay the onset of age-associated diseases (Masoro, 2000). Intermittent fasting 
(e.g. 24 hours with/without access to food) has been shown to reduce serum glucose and insulin 
levels as well as neuronal resistance to injury (Anson et al., 2003). Chronic diet restriction, in 
which a group of animals is taken down to a set percentage of food intake (e.g. 70% of ad 
libitum intake), also has purported beneficial effects (McCarter, Masoro and Yu, 1985) Both 
chronic and acute (fasting) diet restriction conditions can be used to characterize mice with 
metabolic phenotypes; altered responses to dietary challenges compared to WT mice may 
reveal whether proteins or genes of interest are required for a normal response to caloric 
restriction (Boily et al., 2008). 
 
  Summary 
Overall, RGS2 appears to play multiple roles in both cardiovascular disease and metabolism. 
The following chapters will explore novel ways in which the in vivo expression or lack of 
RGS2 impacts cardiovascular health and metabolism. 
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2 HYPOTHESES AND SPECIFIC AIMS 
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 Specific Aim 1 
To determine if RGS2eb is cardioprotective against experimentally-induced cardiac 
hypertrophy 
Based on our previous studies and the findings of others, RGS2 is known to play a protective 
role against cardiac hypertrophy (Chidiac et al. 2014). In addition, loss of RGS2 in cell and 
animals studies is characterized by increased protein synthesis and severe cardiac hypertrophy 
(Takimoto et al. 2009). In conjunction with our previously reported cell data, in vivo studies 
would provide a more comprehensive view of the antihypertrophic and possible 
cardioprotective effects of RGS2eb under both pathological and physiological conditions.  
Our principle goal is to study the effects of RGS2eb in animal models, and thus establish its in 
vivo importance as a protective mechanism against cardiac hypertrophy and heart failure. Our 
specific objectives are: 
i) To determine whether expression of RGS2eb protects against experimentally-induced 
cardiac hypertrophy (Study 1A), 
ii) To perform loss of function studies to determine in vivo mechanisms of RGS2eb 
cardioprotection (Study 1B), 
2.1.1 Study 1A: Protective effect of RGS2eb in animal models of cardiac 
hypertrophy 
Regardless of the initial stimulus, de novo protein synthesis is required for cardiomyocyte 
hypertrophy. We have previously shown that expression of RGS2eb in cultured neonatal rat 
cardiomyocytes can inhibit hypertrophy via the attenuation of mRNA translation (Chidiac et 
al. 2014). However, it is unknown whether the protective effect of RGS2eb extends to whole 
animals with experimentally-induced cardiac hypertrophy.  
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The objectives of this study are: 
i) To determine whether animals with targeted myocardial expression of RGS2eb show 
resistance to the development of pressure overload induced cardiac hypertrophy in 
comparison to wild-type controls. 
ii) To determine whether animals with targeted myocardial expression of RGS2eb 
demonstrate improved cardiovascular function in an experimental pressure overload 
model in comparison to wild-type controls.  
We hypothesize that due to the ability of RGS2eb to inhibit protein synthesis, transgenic mice 
will show decreased severity of cardiac hypertrophy and potentially improved cardiac function 
in comparison to wild type mice. 
2.1.2 Study 1B: Rescue effect of RGS2eb in RGS2 knockout animals  
Rgs2-/- mice are characterized by severe cardiac hypertrophy and heart failure following 
experimentally induced pressure overload (Takimoto et al. 2009). This demonstrates the 
protective cardiac effects of RGS2. However, the degree to which the inhibition of global 
protein synthesis by RGS2eb contributes to this effect is unknown. In addition, the possible 
protective effect of RGS2eb against drug-induced hypertrophy has not been explored.  
The objectives of this study are: 
 i) To determine whether expression of RGS2eb in Rgs2-/- mice can compensate for the 
 loss of the full length RGS2 protein in comparison to null RGS2 mice following 
 experimentally-induced pressure overload.  
 
 ii) To characterize the effects of drug-induced hypertrophy in Rgs2-/- with cardiac-
 specific expression of RGS2eb.  
We hypothesize that via its inhibition of protein synthesis, RGS2eb will, to some extent, 
decrease the severity of cardiac hypertrophy and heart failure resulting from experimentally 
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induced pressure overload or drug-induced hypertension and hypertrophy, thereby 
compensating for the absence of full-length RGS2. 
 
 Specific Aim 2 
To determine the metabolic effects of RGS2 under multiple diet modalities 
Aside from an increased sensitivity to pressure-induced cardiac hypertrophy (Takimoto et al. 
2009), Rgs2-/- mice display several additional phenotypes, including decreased male 
aggression, increased anxiety, elevated blood pressure, and reduced T-cell proliferation 
(Oliveira-Dos-Santos et al. 2000; Heximer et al. 2003). Our lab has previously determined that 
Rgs2-/- mice exhibit a weight-related phenotype, such that they fail to develop the gains in body 
fat that normally occur in freely-feeding laboratory mice (Nunn et al. 2011). We demonstrated 
that resistance to age-related body weight gain was accompanied by smaller adipose tissue 
deposits and adipocytes, lower levels of serum lipids, and increased insulin sensitivity; these 
data suggest that RGS2 may play a novel role in the regulation of fat production and energy 
metabolism. Rgs2-/- mice were found to be slightly hyperphagic over time in comparison to 
WT controls, and did not have impaired nutrient absorption. However, measurements of resting 
O2 consumption (VO2) using a basic open flow respirometry system suggested a lower 
metabolic rate in Rgs2-/- mice compared to WT animals (Nunn et al. 2010). Thus, it would 
seem that although Rgs2-/- mice expend less energy at rest, eat more, and absorb the same 
amount of nutrients, they still weigh less in comparison to WT controls. Furthermore, we were 
not able in our previous studies to detect any increase in resting VO2 in Rgs2
-/- mice using a 
basic open flow respirometry system. Our previous studies have provided contradictory 
evidence for the reduction of weight gain in RGS2 KO mice. To resolve this seeming paradox, 
extended and acute measurements of metabolic indicators may provide a more comprehensive 
understanding of RGS2 and its role in metabolism and weight gain. 
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Our principle goal is to understand the effects of loss of RGS2 on body metabolism, and thus 
establish its in vivo role. Our specific objectives are: 
i) To determine baseline metabolic characteristics of Rgs2-/- mice in comparison to age-
matched WT controls (Study 2A), 
ii) To perform diet restriction studies to further characterize the Rgs2-/- metabolic 
phenotype (Studies 2B and 2C) 
2.2.1 Study 2A: Baseline characterization of the Rgs2-/- metabolic 
phenotype 
In comparison to WT controls, Rgs2-/- mice are resistant to age-related weight gain. However, 
previous measurements of metabolic activity have offered paradoxical evidence on the 
potential reasons for this lean phenotype. The objective of this study is: 
i) To determine whether metabolism in Rgs2-/- is altered, particularly during the dark 
phase of a 12 hour light-dark cycle in comparison to WT controls, as measured via 
Comprehensive Laboratory Animal Monitoring System (CLAMS) metabolic cages 
We hypothesize that Rgs2-/- will display increased metabolism as demonstrated by various 
metabolic and biological indices in comparison to WT controls. 
2.2.2 Study 2B: Chronic diet restriction model 
We have previously shown that while Rgs2-/- mice are resistant to age-related weight gain on a 
standard rodent diet (Teklad Global 18% Protein Rodent Diet), they still gain at least as much 
weight as WT mice when placed on a high fat diet. However, it is currently unknown how 
Rgs2-/- mice would respond metabolically to a diet restriction. The objective of this study is:  
i) To determine whether metabolism in Rgs2-/- mice is altered in response to dietary 
restriction in comparison to WT controls. 
We hypothesize that Rgs2-/- mice will display greater metabolism than their counterpart WT 
controls, as demonstrated by various metabolic and biological indices. 
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2.2.3 Study 2C: Acute diet restriction model 
It is also currently unknown how Rgs2-/- mice would respond metabolically to acute dietary 
restriction (i.e. fasting conditions); this may also potentially offer insight into the resistance of 
Rgs2-/- mice to age related weight gain. The objective of this study is:  
 i) To determine whether Rgs2-/- metabolism is altered after acute fasting in 
 comparison to WT controls. 
We hypothesize that Rgs2-/- mice will display greater metabolism under acute caloric restriction 
than corresponding WT controls. 
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 Introduction 
Pathological cardiac hypertrophy is a maladaptive growth response of the heart to a variety of 
disease stimuli. Induced by factors such as hypertension or valvular diseases, prolonged 
pathological hypertrophy has been associated with an increased risk of sudden death, as well 
as myocardial infarctions and arrhythmias (Levy et al., 1990; Weber and Brilla, 1991; Heineke 
and Molkentin, 2006). Moreover, maladaptive hypertrophy is a major risk factor for heart 
failure (Heineke and Molkentin, 2006). Given the high mortality rates following heart failure 
diagnoses and the current lack of a cure, reducing risk factors such as pathological cardiac 
hypertrophy may prove therapeutically beneficial.  
G protein-coupled receptors (GPCRs) which signal via heterotrimeric Gαq and Gαs proteins are 
well established as critical players in the induction of pathological hypertrophy (Dorn and 
Force, 2005; Heineke and Molkentin, 2006; Hendriks-Balk et al., 2008). Clinically effective 
treatments for heart failure, such as angiotensin II converting enzyme (ACE) inhibitors and 
beta-adrenergic receptor antagonists, demonstrate the effectiveness of targeting Gq- and Gs- 
coupled receptors (Campbell et al., 2001). However, the effectiveness of these drugs is limited 
to slowing, rather than reversing, the progression of heart failure. Regulator of G protein 
signalling 2 (RGS2) is a GTPase accelerating protein (GAP) found ubiquitously throughout 
the body. RGS2 selectively inhibits Gq- and Gs-mediated signalling (some effects on Gi/o 
signalling have also been reported (Anger et al., 2007; Chakir et al., 2011), thus making it an 
important target in the study of cardiovascular disease (Heximer et al., 1997, 1999; Roy, 
Baragli, et al., 2006). Studies in vivo and in cardiomyocytes have shown that hypertrophy 
caused by prolonged Gq-coupled receptor stimulation, such as that induced by phenylephrine, 
can be blocked by the overexpression of RGS2 (Roy, Nunn, et al., 2006; Zou et al., 2006). A 
similar effect has been seen against Gs-mediated cardiomyocyte hypertrophy induced by 
isoproterenol (Nunn et al., 2010). These observations suggest that RGS2 plays an important 
role in the regulation of hypertrophy; This has been further demonstrated in knockout animal 
studies. In RGS2 null mice, experimentally induced pressure overload causes marked 
hypertrophy, heart failure, and death, as well as increased expression of cardiac fetal genes 
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(Takimoto et al., 2009). Thus, RGS2 is an essential element in the prevention of pathological 
cardiac hypertrophy.  
While the G protein inhibitory effects of RGS2 are well established, studies have also shown 
that RGS2 can bind to and regulate other targets, including TRPV6 calcium channels and 
tubulin (Wang et al., 2005; Heo et al., 2006; Schoeber et al., 2006). We have previously shown 
that RGS2 can bind to the ε subunit of eukaryotic initiation factor 2B (eIF2B), a component of 
the rate-limiting step of the initiation of mRNA translation (Nguyen et al., 2009). By 
interacting with eIF2Bε, RGS2 limits GDP dissociation on eukaryotic initiation factor 2 (eIF2), 
which ultimately leads to the attenuation of de novo protein synthesis. This property of RGS2 
has been mapped to a 37 amino acid domain (residues 79-115) termed RGS2eb, that is 
homologous to a region in the β subunit of eIF2 (Nguyen et al., 2009).  
Since the heart is considered to be a post-mitotic organ (Anversa et al., 2007), hypertrophic 
growth is thought to be dependent on the enlargement of a pre-existing cardiomyocyte 
population rather than cell division (Carvalho, 2010). Therefore, regardless of the initial stimuli 
and receptors involved, all hypertrophic signals will ultimately result in increased mRNA 
translation and de novo protein synthesis. Our previous studies have shown that RGS2eb 
expression in cultured neonatal cardiomyocytes is able to inhibit both protein synthesis and 
agonist induced hypertrophy at levels comparable to full-length RGS2 (Chidiac et al., 2014). 
Based on these previous findings, we hypothesized that the in vivo expression of RGS2eb in the 
murine heart could attenuate the development of pathological cardiac hypertrophy.  
To determine whether RGS2eb could act as an in vivo anti-hypertrophic agent, we developed a 
line of transgenic mice with cardiomyocyte-specific overexpression of RGS2eb, and used 
transverse aortic constriction (TAC) to induce pressure overload on the heart. Here we report 
that following 4 weeks of aortic constriction, RGS2eb transgenic mice were protected not only 
from pressure overload-induced cardiac hypertrophy, but were able to maintain heart function 
at significantly improved levels compared to WT TAC mice. Moreover, reactivation of the 
“fetal gene program”, an indicator of hypertrophy and heart failure, was suppressed. Notably, 
cardiomyocyte size was decreased in RGS2eb TG compared to WT TAC controls, further 
supporting our earlier in vitro studies which showed RGS2eb inhibition of de novo protein 
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synthesis. Together, these findings suggest that in addition to its G-protein inhibitory actions, 
the RGS2eb region may be contributing to the cardioprotective effects of full-length RGS2 in 
vivo via the inhibition of de novo protein synthesis.  
 
 Methods 
3.2.1 Generation of myosin heavy chain promoter (MHC) – RGS2eb 
 transgenic mice 
The RGS2eb gene was targeted to the heart using the mouse α-MHC promoter (kindly provided 
by Jeffrey Robbins, Cincinnati Children’s Hospital Medical Center)(Subramaniam et al., 
1991). Transgenic mice were generated in the FVB background (London Regional Transgenic 
and Gene Targeting Facility) and identified by polymerase chain reaction (PCR). Briefly, ear 
biopsies were taken from three-week old mice and purified for genomic DNA using the 
QIAquick PCR purification kit (Qiagen). PCR was performed using DreamTaq Green PCR 
Master Mix (Thermo Scientific). Primers for detection of transgenic mice 
(CTGCTAGCCAGCAAATATGGTC forward, CCTACAGGTTGTCTTCCCAACT reverse) 
and control primers for endogenous RGS2 expression 
(CCGAGTTCTGTGAAGAAAACATTG forward, ATGCTACATGAGACCAGGAGTCCC 
reverse) were designed using the OligoPerfect Designer (ThermoFisher), OligoCalc (Kibbe, 
2007), and Primer-BLAST (NCBI) programs, resulting in a 293 bp and 342 bp fragment, 
respectively. RGS2eb TG transgenic mice were back-crossed with C57Bl/6 mice (Charles 
River) for at least seven generations before animal experiments were performed. Animals were 
maintained in accordance with the Institute of Laboratory Animal Research Guide for the Care 
and Use of Laboratory Animals. These studies were approved by the Animal Care Committee 
at the University of Western Ontario, and complied with the guidelines of the Canadian 
Council on Animal Care.  
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3.2.2 Transverse aortic constriction (TAC) 
TAC was used to induce pressure overload on the hearts of 12 week old male C57BL/6 wild-
type mice and RGS2eb TG littermates. Mice were anaesthetized with a ketamine (50 mg/kg) 
and xylazine (12.5 mg/kg) cocktail intramuscularly, intubated, and ventilated with a respirator 
(SAR-830, CWE, Ardmore, PA, USA). To access the chest cavity, thoracotomy was performed 
at the second intercostal space under a surgical microscope (Rockman et al., 1991). A 6-0 silk 
suture was placed between the brachiocephalic and left carotid arteries. Two knots were tied 
against a 25-gauge blunt needle placed parallel to the transverse aorta. The needle was removed 
immediately after the second tied knot followed by closure of the chest. Control WT and 
RGS2eb TG mice were subjected to sham operations without aortic constriction. 
3.2.3 Assessment of cardiac function 
Hemodynamic measurements were performed as previously described (Detombe et al., 2008; 
Pacher et al., 2008) : four weeks post-surgery, mice were again anaesthetized with a ketamine 
and xylazine cocktail and ventilated. A Millar micro-tip pressure catheter was inserted into the 
left carotid artery to assess carotid artery pressure, followed by removal of the catheter and 
insertion into the right carotid artery for pressure readings, and then advanced into the left 
ventricle (LV) to measure LV pressures, volumes, and heart rate at steady state and during 
transient preload reduction via mechanical occlusion of the inferior vena cava. All data were 
recorded using a PowerLab data acquisition system and analysed by LabChart 7.0 
(ADInstruments) and PVAN 3.4 software (Millar).  
3.2.4 Heart weight/body weight ratios 
Upon completion of hemodynamic recordings, mice were immediately euthanized via a 10% 
KCl injection into the left jugular vein to ensure cardiac arrest in the diastolic state. Hearts 
were excised, weighed after removal of the atria, then cut transversely into three equal sections, 
with the middle section reserved for histological analysis, and the remaining tissue sections 
stored at -80°C for subsequent RNA isolation. 
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3.2.5 Histological analysis 
Heart samples were fixed in 4% paraformaldehyde overnight at 4°C, dehydrated, and paraffin 
embedded. Samples were sectioned into 5 µm thick slices with a Leica RM2255 microtome, 
mounted onto positively charged slides, and then stained with haematoxylin and eosin. Images 
of left ventricles were captured at 400X magnification with a Zeiss Observer D1 microscope 
using AxioVision 4.7 software (Zeiss) for cardiomyocyte size measurements and 
immunohistochemical imaging; images of the LV for wall thickness measurements were 
captured at 100X magnification.  
3.2.6 Cardiomyocyte Cell Size and LV wall thickness 
Haematoxylin and eosin stained tissue sections were used to determine left ventricular 
cardiomyocyte cell size and wall thickness of LV free walls and septum. The size of an 
individual cardiomyocyte was determined by measuring its cross-sectional area. All 
cardiomyocytes with a well-defined border were manually outlined and then filled in the open 
source GNU Image Manipulation Program (GIMP). Images were then opened in the image 
processing program ImageJ and analyzed after setting the threshold. Cardiomyocytes with a 
circularity ratio of ≥1.2 were excluded to eliminate cells sectioned tangentially (Helms et al., 
2010). Areas of at least 33 cells per animal were measured, and were scored blind to surgeries 
and strain.  
Heart wall thickness of the LV free wall was measured using AxioVision 4.7 software (Zeiss) 
in three distinct areas within and between the anterior and posterior regions of the free wall; 
three measurements were taken from each area for a total of 9 averaged measurements per 
sample. For the septal wall, single measurements were taken from three distinct areas of the 
wall and averaged for each sample. 
3.2.7 Immunohistochemistry 
Immunohistochemical staining was performed on 5 µm thick paraffin heart sections. Samples 
underwent a deparaffinisation process and antigen retrieval was carried out in sodium citrate 
buffer (pH 6.0) at 92°C using a BP-111 laboratory microwave (Microwave Research and 
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Applications). Sections were incubated with primary antibody anti-6X His tag-ChIP Grade 
(Abcam) overnight followed by biotinylated secondary antibody, and signal was detected using 
avidin-biotin complex (ImmunoCruz ABC staining kit, Santa Cruz). Diaminobenzidine (DAB) 
substrate solution was used for antigen visualization with haematoxylin as a counterstain. 
Following staining, the LV free wall was imaged in three distinct locations within and between 
the anterior and posterior walls. Slides were imaged at 400X magnification with a Zeiss 
Observer D1 microscope using AxioVision 4.7 software. To ensure accurate comparisons of 
antigen visualization, sections from WT and RGS2eb TG genotypes were stained 
simultaneously and all images were captured using the same microscopic parameters. 
3.2.8 Dot blotting 
Using mechanical disruption (Sonic Dismembrator Model 100, Fisher Scientific), LV heart 
and kidney tissues from RGS2eb TG and WT mice were lysed in 20mM, pH 7.5 Tris-HCl buffer 
containing cOmplete Mini protease inhibitor cocktail (Sigma). Samples were centrifuged at 
100,000 g for 1 hour at 4°C in an Optima TLX micro-ultracentrifuge (Beckman Coulter), and 
supernatants were kept for experiments. Following protein concentration determination by 
Bradford assay, equal amounts of sample protein were spotted directly on to Amersham 
Protran 0.2 µm pore size nitrocellulose membrane (GE Healthcare Life Sciences). Purified 
histidine-tagged RGS-16 (His-RGS16) was also dotted on to membranes to serve as a positive 
control. Dried membranes were blocked in 5% milk-TBST, followed by overnight incubation 
in 1:2000 ChIP grade anti-6X Histidine primary antibody (Abcam) and then 1:5000 goat anti-
rabbit secondary antibody HRP conjugate (Invitrogen). Signal was detected using SuperSignal 
West Pico chemiluminescent substrate (Thermo Fisher Scientific) and imaged with the 
Versadoc MP 5000 system and Quantity One software (Bio-Rad). 
3.2.9 Quantitative reverse transcriptase qPCR 
Total RNA was isolated from heart tissue using the TriZol (Invitrogen) extraction method. 
Reverse transcription reaction was performed using the High-Capacity cDNA Reverse 
Transcription Kit with RNase Inhibitor (Invitrogen). SensiFAST SYBR No-ROX Kit 
mastermix (FroggaBio) was used for real-time thermal cycling. Primers for RGS2 
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(TGGGATTATGTGGCCTTAGC forward, AAGAACGTCAACACCCTTGC reverse), hGH 
(TGGGAAGACAACCTGTAGGG forward, AATCGCTTGAACCCAGGAG reverse), β-
MHC (CTGAGACGGAGAATGGCAAGAC forward, 
ACTTGTTAGGGGTTGACGGTGAC reverse), ANP (ATTCCTGAGACGTCCCCTTT 
forward, CATTTCCATCCACAGCTCCT reverse), and BNP 
(TGGGAATTAGCCATGTGAGAG forward, TTTGGGTGTTCTTTTGTGAGG reverse) 
were designed using the OligoPerfect Designer (ThermoFisher), OligoCalc (Kibbe, 2007) and 
Primer-BLAST (NCBI) programs. Samples were amplified for 35 cycles using the Eppendorf 
Mastercycler Realplex Real-Time PCR machine. The mRNA quantity for each gene of interest 
was determined using standard curve analysis and normalized to 28S ribosomal expression. 
3.2.10 Statistical analysis 
All data were analyzed using GraphPad Prism 6.01 (GraphPad). All statistical analyses were 
performed using two-way ANOVA followed by Bonferroni post-tests and presented as mean 
± SEM. Differences were considered significant at P<0.05. 
 
 Results 
3.3.1 Generation of transgenic mice with cardiomyocyte specific 
expression of RGS2eb 
We previously demonstrated that the in vitro expression of RGS2eb was sufficient to inhibit 
drug-induced hypertrophy in isolated neonatal rat cardiomyocytes (Chidiac et al., 2014). To 
elucidate the potential in vivo protective role of RGS2eb, we developed a novel strain of 
transgenic mice with targeted myocardial overexpression of polyhistidine-tagged RGS2eb 
under the control of the α-myosin heavy chain promoter (Fig. 3.1A). Genotyping with primers 
for a portion of the hGH polyA region, which was only present in the transgenic sequence of 
RGS2eb mice, was used to differentiate between RGS2eb TG and wildtype mice. Both RGS2eb 
TG and WT controls displayed a band at 342 bp indicating the presence of endogenous full-
length RGS2 (Fig. 3.1B); Only RGS2eb transgenic mice displayed an additional 293 bp band, 
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which indicated the presence of the hGH poly A region. Due to the short length of the RGS2eb 
transgene and difficulty in immunoblotting (Chidiac et al., 2014) , immunohistochemical 
staining, qPCR for RGS2 and the human growth hormone (hGH), as well as dot blot 
visualization for the polyhistidine tag was used to confirm expression of the RGS2eb transgene. 
Following DAB visualization, WT mice showed an absence of staining for polyhistidine, 
whereas RGS2eb TG mice displayed positive antigen staining (Fig. 3.1C). Endogenous RGS2 
appears to be decreased in both WT and RGS2eb TG mice following TAC (Fig. 3.1D), which 
has been previously demonstrated (Zhang et al., 2006); Expression of a region of hGH, which 
should only be present in transgenic mice, is significantly higher in RGS2eb TG mice than in 
WT animals (Fig 1E). In addition, LV heart tissues from RGS2eb TG mice showed positive 
signal for polyhistidine when visualized on dot blots, whereas no signal was detected in non-
cardiac tissue (i.e. kidney) and LV samples from WT mice (Fig. 3.2F). Together, these results 
indicate successful generation of transgenic mice with cardiomyocyte specific overexpression 
of RGS2eb. 
3.3.2 Improved cardiac function in RGS2eb transgenic mice following 
pressure overload 
Transverse aortic constriction (TAC) was used to induce experimental pressure overload on 
wildtype and RGS2eb TG hearts. Following 4 weeks of constriction, systolic pressure was 
significantly increased in the right carotid artery, but significantly reduced downstream of the 
TAC site in the left carotid artery in both WT and RGS2eb TG mice (Fig. 3.3A and 3.3B. This 
resulted in a 61 mmHg difference in maximal systolic pressure between the left and right 
carotid arteries of WT sham and TAC mice, and a 65 mmHg difference between RGS2eb TG 
sham and TAC mice (Fig. 3.3C). These data, as well as summary hemodynamic parameters in 
Table 3.1, confirm that pressure overload had indeed been induced upon TAC hearts. Increased 
vascular resistance was reflected by significantly higher end-systolic pressures in TAC mice; 
increased afterload as well as cardiac dilation or hypertrophy in TAC mice was also suggested 
by significant increases in the end systolic and end diastolic volumes (Table 3.1). Heart rate 
under anaesthesia was maintained at similar levels in all surgery groups (Fig. 3.3D). Following 
pressure-volume loop analysis, RGS2eb TG mice demonstrated improved cardiac function as 
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measured by various systolic and diastolic indices. Summary data for contractility and 
relaxation (maximal elastance, ejection fraction, left ventricular systolic pressure, arterial 
elastance, LV +dP/dt, LV –dP/dt, and time constant tau) are provided in Figure 3. Notably, 
Millar catheter measurements of the maximal and minimal rates of pressure change in the left 
ventricle (LV +dP/dt and LV –dP/dt, respectively), which are important indices of cardiac 
contractility, were significantly greater in RGS2eb TG TAC mice compared to WT TAC 
counterparts (Fig. 3.4F and 3.4G). In addition, WT TAC mice had significant increases in the 
Tau relaxation constant (Fig. 3.4H), indicating impairment of active properties of diastolic 
relaxation. These data suggest that RGS2eb TG mice demonstrated improved compensation 
following 4 weeks of TAC compared to WT TAC animals. 
3.3.3 Cardiac hypertrophy is inhibited in RGS2eb transgenic mice 
following pressure overload 
Following 4 weeks of TAC, heart weight/body weight (HWT/BWT) ratios, LV and septal wall 
thickness, and the cross-sectional areas of cardiomyocytes were used to evaluate the 
development of cardiac hypertrophy. Although WT TAC mice developed significant cardiac 
hypertrophy (as measured by HWT/BWT) compared to sham controls, RGS2eb TG mice 
displayed limited hypertrophic growth compared to WT TAC animals (Fig 3.5A). Some 
hypertrophy does still appear to have occurred, as both WT and RGS2eb TG mice had 
significantly increased LV free wall thickness compared to sham controls (Fig. 3.5B, 3.5F and 
Fig. 3.6A (representatives)); Septal wall thickness was not significantly changed in TAC 
surgery groups compared to sham controls (Fig 3.5D). In addition, RGS2eb TG TAC mice did 
not show marked changes in LV free wall cardiomyocyte size compared to TG sham controls, 
and were significantly smaller in size than cardiomyocytes from WT TAC mice (Fig. 3.5E and 
3.6B (representative)). No changes were observed in measured cardiomyocytes from the septal 
wall (Fig. 3.5F). These data suggest that RGS2eb may confer a protective effect in 
cardiomyocytes against pressure-induced cardiomyocyte hypertrophy.  
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3.3.4 Expression of cardiac hypertrophy markers is suppressed in 
RGS2eb transgenic mice  
Induction of “fetal” cardiac genes is often a common feature in animal models of pathological 
hypertrophy and heart failure (Parker, Packer and Schneider, 1990; Razeghi et al., 2001). RNA 
was isolated from left ventricular tissue after 4 weeks of TAC or sham surgery, and qPCR was 
performed to determine expression levels of β-myosin heavy chain (β-MHC), atrial natriuretic 
peptide (ANP), and brain natriuretic peptide (BNP). WT mice which underwent TAC showed 
significantly increased levels of both β-MHC and ANP compared to sham controls (Fig. 3.7A 
and B). In contrast, β-MHC and ANP expression in RGS2eb TG mice after TAC was 
comparable to sham levels (Fig. 3.7A and B). BNP expression demonstrated a similar trend to 
that seen with β-MHC and ANP, but this did not attain statistical significance between RGS2eb 
TG and WT mice after TAC (Fig. 3.7C). Since the expression of fetal cardiac genes is 
postulated to be indicator of cardiac dysfunction, the absence of elevated levels in RGS2eb TG 
mice after TAC suggests that the presence of RGS2eb is cardioprotective in a pressure overload 
model of cardiac hypertrophy. 
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Figure 3.1. Generation of transgenic mice with cardiomyocyte specific expression of 
RGS2eb 
A 
 
 
B 
 
C            D 
 
 
            E 
 
 
 
 (A) Construct used for the generation of mice with cardiomyocyte-specific overexpression of 
RGS2eb under the control of α-myosin heavy chain. (B) Genotyping for a region which includes 
the hGH PolyA sequence results in a positive band for RGS2eb TG mice and the absence of a 
band in WT controls (lanes 8 and 10), while genotyping for endogenous RGS2 resulted in 
bands for both RGS2eb TG and WT controls (lanes 1, 3, 5, 7, and 9). (C) Representative 
immunostaining in the left ventricle of WT mice shows an absence of polyhistidine staining, 
whereas RGS2eb TG mice display positive immunostaining for polyhistidine. (D) RGS2 and 
(E) hGH qPCR expression in WT and RGS2eb TG mice following sham or TAC surgery. Data 
represent means ± SEM, n = 5-6 per group. **P<0.01, and ***P<0.001 using two-way 
ANOVA with Bonferroni’s post hoc test for multiple comparisons. 
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Signal for polyhistidine was only detected in the LV tissue of RGS2eb TG mice and His-RGS16 
positive controls, with no signal detected in non-cardiac tissue or WT mice. 
 
 
 
 
 
 
Figure 3.2. Dot blot detection of histidine-tagged RGS2eb  
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Figure 3.3. Pressure overload model of cardiac hypertrophy 
A      B 
 
 
 
  
C      D 
 
 
 
 
 
 
(A) Following 4 weeks of aortic constriction between the left and right carotid arteries, systolic 
pressure in the LCA was reduced while (B) systolic pressure in the RCA was significantly 
increased. (C) Change in systolic pressure between the RCA and LCA following 4 weeks TAC 
was significantly increased in both WT and RGS2eb TG mice. (D) Heart rate remained at 
similar levels for all experimental and genotype groups. Data represent means ± SEM, n = 7-
9 per group. *P<0.05 and ***P<0.001 using two-way ANOVA with Bonferroni’s post hoc test 
for multiple comparisons. 
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Data represent means ± SEM **P<0.05 and **P<0.001 vs. sham controls using two-way 
ANOVA with Bonferroni’s post hoc test for multiple comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Hemodynamic parameters in 4 week sham and TAC mice. 
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Figure 3.4. Indices of systolic and diastolic function 
A        B 
 
 
 
C    D    E 
 
 
 
F    G    H 
 
 
 
 
(A) Representative PV loops during preload reduction by inferior vena cava occlusion in sham 
(solid line) and 4 week TAC animals (dotted line). (B) Slope of left upper relation (maximal 
elastance [Emax]) reflected contractile function. (C) Ejection fraction was significantly reduced 
in WT but not RGS2eb TG mice following pressure overload, while (D) LV systolic pressure 
(LVSP) was significantly elevated following TAC in both WT and RGS2eb mice. (E) Effective 
arterial elastance (Ea; an index of total ventricular afterload) was also increased following 
TAC. (F) LV +dP/dt and (G) –dP/dt were significantly improved in RGS2eb mice following 
TAC, and (H) Tau relaxation time constant remained comparable to sham groups. Data 
represent means ± SEM, n = 6-9 per group. *P<0.05 and ***P<0.001 using two-way ANOVA 
with Bonferroni’s post hoc test for multiple comparisons. 
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Figure 3.5. Cardiac hypertrophy is reduced in RGS2eb transgenic mice 
following pressure overload 
A     B 
 
 
 
C     D 
 
 
 
E     F 
 
 
 
 
 
(A) After 4 weeks of aortic constriction, cardiac hypertrophy in RGS2eb TG mice was 
significantly less than WT TAC. (B) Representative whole hearts for WT and RGS2eb TG mice 
following 4 weeks of sham or TAC surgery; (C) LV free wall thickness was increased in both 
TAC groups; (D) septal wall thickness did not increase. (E) Cardiomyocyte size was 
significantly reduced in RGS2eb TG mice compared to WT TAC in the LV free wall, with (F) 
no noticeable changes to size in the septal wall.  
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A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
A) Representative H&E staining of WT and RGS2eb LV cross sections of WT and RGS2eb TG 
cardiomyocytes following sham or TAC surgery. (B) Representative H&E staining of WT and 
RGS2eb cardiomyocytes. 
 
Figure 3.6. LV cross sections and cardiomyocytes 
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Figure 3.7. Markers of cardiac hypertrophy 
A      B 
 
 
 
 
 
C 
 
 
 
 
 
 
(A) β-MHC expression was significantly increased in WT TAC but not RGS2eb TG mice after 
4 weeks of aortic constriction. (B) ANP expression was also significantly elevated in WT TAC 
mice, while RGS2eb TG mice maintained near-sham levels of expression. (C) BNP expression. 
Data represent means ± SEM, n = 4-8 per group. *P<0.05, **P<0.01, and ***P<0.001 using 
two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons. 
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 Discussion 
In order for maladaptive cardiac hypertrophy to occur, individual cardiomyocytes must 
increase in size; such growth requires increased global protein synthesis, the rate of which is 
controlled primarily at the initiation level (Sugden et al., 2009). Of particular importance is the 
heterotrimeric initiation factor eIF2, which is activated by the heteropentameric protein eIF2B 
(Abbott and Proud, 2004). Notably, eIF2B has been shown to play a critical role in the 
development of -adrenergic receptor induced hypertrophy in cultured cardiomyocytes (Hardt 
et al., 2004). A major role for eIF2Bε in controlling cell size is also evident from its regulation 
by glycogen synthase kinase 3β (GSK3β), which constitutively phosphorylates eIF2Bε at 
serine 540 in intact cells, thereby inhibiting its GEF activity by up to 80% (Welsh et al., 1998). 
In a cultured cardiomyocyte model, overexpression of a mutant eIF2Bε which could not be 
phosphorylated by GSK3β increased cell size and abolished the antihypertrophic effects of 
GSK3β, suggesting that eIF2Bε is a direct mediator of cardiac myocyte hypertrophy (Hardt et 
al., 2004). Importantly, further expression of a dominant-negative mutant of eIF2Bε inhibited 
isoproterenol-induced cardiac hypertrophy, indicating the critical role of eIF2Bε in protein 
synthesis and cell growth (Hardt et al., 2004). 
We have previously shown that the cellular effects of eIF2Bε are blocked by RGS2eb as well 
as by full length RGS2 (Nunn et al., 2010; Chidiac et al., 2014). The goal of the present study 
was to determine whether the ability of RGS2 to inhibit protein synthesis and cardiomyocyte 
growth in vitro could be extended to an animal model of pathological cardiac hypertrophy. We 
therefore developed a mouse line with cardiomyocyte specific expression of RGS2eb, and 
examined the functional, histological, and biochemical consequences of experimental pressure 
overload in our transgenic mice and WT littermates. To the best of our knowledge, this is the 
first study to demonstrate that expression of a portion of RGS2, namely the RGS2eb binding 
domain, can reduce pathogenic growth without adversely affecting in vivo cardiac function. 
Although a random insertion effect cannot be entirely excluded, expression of this transgene 
inhibited TAC-induced increases in heart weight/body weight ratio (Fig. 3.5A) and expression 
of hypertrophy-related gene markers (Fig. 3.7), as well as associated functional loss (Fig. 3.4). 
 98 
 
These results likely reflect the ability of RGS2eb to inhibit protein synthesis in vivo, and the 
consequent suppression of the hypertrophic response and cardioprotective effects. 
Using qPCR, immunohistochemistry and dot blotting methods, we have demonstrated the 
cardiac-specific expression of RGS2eb in our transgenic mice (Fig. 3.1). However, due to the 
short length of the RGS2eb transgene and difficulty in immunoblotting (Chidiac et al., 2014), a 
limitation of our study is our inability to fully demonstrate an eIF2B-RGS2eb complex. 
Although RGS2eb expression is associated with a decrease in cardiac hypertrophy and 
improved cardiac function, and our previous in vitro studies suggest that this is due to the 
inhibition of eIF2Bε, we cannot definitively attribute our in vivo observations to the direct 
inhibition of protein synthesis, and thus cannot exclude other off target effects as the 
mechanism behind our observed cardioprotection.  
Although LV free wall thickness was significantly increased in both WT and RGS2eb TG mice 
following 4 weeks of TAC (Fig. 3.5C), HWT/BWT ratios indicated the development of 
significant TAC-associated cardiac hypertrophy in WT, but not RGS2eb TG mice (Fig. 3.5A). 
Furthermore, measurements of cardiomyocyte cross-sectional after area showed a 
corresponding increase in cell size for WT TAC but not RGS2eb TG mice (Fig. 3.5E). These 
data suggest that de novo protein synthesis in response to pressure overload, and thus 
hypertrophy, is inhibited in RGS2eb TG mice.  
Our previous work showed that the adenoviral expression of RGS2eb in neonatal ventricular 
myocytes was able to attenuate the expression of genetic markers of hypertrophy to a 
comparable extent as full-length RGS2 (Chidiac et al., 2014). Thus, we examined whether 
RGS2eb could also attenuate in vivo increases in the “fetal gene program”, a group of molecular 
markers associated with the hypertrophy phenotype, including β-MHC, ANP, and BNP 
(Molkentin and Dorn, 2001; Frey and Olson, 2003; Petrich and Wang, 2004). Four weeks of 
aortic constriction induced an increase in the levels of β-MHC and ANP in WT mice (Fig. 3.7). 
These increases were completely abrogated in RGS2eb TG animals. Reactivation of fetal gene 
expression during cardiac hypertrophy is initially an adaptive process which increases the 
excitability, contractility, and plasticity of cardiac myocytes in response to pathological stress 
(Kuwahara, Nishikimi and Nakao, 2012). However, sustained fetal gene expression plays a 
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causative role in maladaptive cardiac remodelling, leading to cardiac dysfunction and often the 
pathogenesis of heart failure (Hannenhalli et al., 2006). In addition, our assessment of cardiac 
function obtained from pressure-volume loop analyses also suggests that RGS2eb TG mice 
were able to maintain significantly improved cardiac function after TAC compared to WT 
mice, as evidenced by both systolic and diastolic indices (Fig. 3.4). Our data suggest that the 
expression of RGS2eb appears to not only inhibit cardiac hypertrophy, but also improves 
cardiac function without activation of fetal cardiac genes after 4 weeks of TAC, although the 
effect on fetal gene expression may more likely be due to an indirect effect of the inhibition of 
cardiac hypertrophy and apparent improvement in cardiac function, rather than a direct 
mechanistic connection between RGS2eb and the re-expression of fetal genes. Further studies, 
such as prolonged exposure to TAC, may clarify the extent to which these effects are sustained. 
Following transverse aortic constriction, RGS2 knockout mice have been found to develop 
severe cardiac hypertrophy and heart failure, as well as increased mortality compared to 
corresponding controls (Takimoto et al., 2009). Although this clearly indicates that the 
presence of RGS2 is cardioprotective in vivo, many details of this beneficial effect remain to 
be elucidated (Chidiac et al., 2014). In cultured ventricular myocytes, RGS2 is acutely and 
selectively upregulated in response to activators of Gq and Gs signalling (Hao et al., 2006; Zou 
et al., 2006; Nunn et al., 2010). However, RGS2 has been found to be ultimately 
downregulated in vivo following experimentally-induced hypertrophy and heart failure (Zhang 
et al., 2006). Furthermore, cardiac-specific overexpression of full-length RGS2 does not result 
in demonstrable cardioprotective effects in mice subjected to TAC (Park-Windhol et al., 2012). 
Conversely, the overexpression of either RGS4, RGS5, or RGS10 has been shown to reduce 
cardiac hypertrophy (Rogers et al., 1999, 2001; Li et al., 2010; Miao et al., 2016), although it 
may be noted that unlike RGS2, these proteins tend to localize to the atria rather than the 
ventricles (Doupnik, Xu and Shinaman, 2001; Mittmann et al., 2002; Larminie et al., 2004; 
Gu et al., 2009; Miao et al., 2016) . It is possible that the optimal level of RGS2 is decreased 
under conditions of hypertrophic stress, however a complete lack of RGS2 is clearly 
detrimental under pressure overload (Takimoto et al., 2009).  
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The lack of an observable protective effect of full-length RGS2 overexpression in the 
myocardium (Park-Windhol et al., 2012) stands in contrast to the present findings that 
expression of its isolated eIF2B-interacting domain (RGS2eb) can protect against pathological 
cardiac hypertrophy and dysfunction in vivo. We have previously shown that the ability of 
RGS2eb to inhibit drug-induced cell hypertrophy is independent of the G-protein inhibitory 
effects of full-length RGS2 (Chidiac et al., 2014). Along with our current findings, it follows 
that the RGS2eb region may be an important contributor to the reported beneficial cardiac 
effects of RGS2. Since our previous studies suggest that the RGS2eb region specifically binds 
to eIF2B and thereby inhibits protein synthesis (Nguyen et al., 2009), it is possible that some 
function of full length RGS2 may produce detrimental effects in the context of pathological 
hypertrophy, consistent with its observed downregulation in the latter condition (Zhang et al., 
2006). Negative RGS2 effects could conceivably arise from its inhibition of beneficial G 
protein-mediated signals (e.g. the protective effects of adenosine) or alternatively via its effects 
on non-G protein targets such as tubulin or TRP channels (Heo et al., 2006; Schoeber et al., 
2006). To examine the importance of the RGS2eb region per se, future studies would be in 
order, with expression of this truncated form targeted to the myocardium of full-body or 
cardiac-specific RGS2 knockout mice.  
 
 Conclusions 
The present results suggest that expression of the eIF2B-interacting domain of RGS2, RGS2eb, 
can protect against pathological cardiac hypertrophy and dysfunction in vivo, and that this may 
be via the direct inhibition of protein synthesis. We have previously shown the ability of 
RGS2eb to inhibit drug-induced cardiomyocyte hypertrophy; along with our current findings, 
this suggests that the RGS2eb region is an important contributor to the reported beneficial 
cardiac effects of RGS2.  
Currently, the majority of drugs for cardiovascular diseases target GPCRs. Although these 
medications can offer significant benefits to patients, heart failure continues to be a global 
leading cause of morbidity and mortality. A better understanding of the various components 
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that are part of the GPCR signaling pathways may lead to improved therapeutics, and interest 
in RGS2 and other RGS proteins as possible drug targets is on the rise (Le and Coffman, 2003; 
Sjögren and Neubig, 2010; Sjögren, Blazer and Neubig, 2010; Sjogren et al., 2012; Turner et 
al., 2012; Go et al., 2013; Sjögren et al., 2016). In summary, this study has demonstrated that 
RGS2eb is important in regulating in vivo cardiac hypertrophy and physiology, and suggests 
that this region of full-length RGS2 may be a key component of its reported cardioprotective 
effects. 
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 Introduction 
Regulator of G protein signalling (RGS) proteins function as GTPase activating proteins 
(GAPs) to limit the intensity and duration of GPCR-mediated signalling. RGS2 is a member 
of the R4 subfamily of RGS proteins, and selectively inhibits Gq-mediated signalling via its 
GAP activity and also via a GAP-independent mechanism (Abramow-Newerly et al., 2006). 
RGS2 can also inhibit Gs signalling through its direct binding to some adenylyl cyclase 
isoforms and possibly also via its binding to Gαs (Abramow-Newerly et al., 2006). 
Additionally, effects on Gi/o have also been reported (Chakir et al., 2011) notwithstanding the 
relatively low affinity of RGS2 for Gαi/o proteins (Heximer et al., 1999) . Since Gq- and Gs-
mediated signalling play well established roles in the development of cardiovascular disease, 
the ability of RGS2 to selectively inhibit these pathways makes it an important target of study 
(Heximer et al., 1997, 1999; Roy, Baragli, et al., 2006). 
Pathological cardiac hypertrophy, which often results from chronic hypertension, is a leading 
risk factor for various cardiovascular conditions (Levy et al., 1990; Cipriano et al., 2001); aside 
from age, left ventricular hypertrophy is the most reliable predictor of poor cardiovascular 
outcomes in hypertensive patients, and is an independent risk factor for sudden death, stroke, 
coronary heart disease, and heart failure (Gardin et al., 2001; Verdecchia et al., 2001; Gradman 
and Alfayoumi, 2006). Thus, identifying regulators of pathological hypertrophy is of great 
interest and importance. Studies in vivo and in cardiomyocyte models of hypertrophy have 
shown that increased cell growth caused by prolonged Gq-coupled receptor stimulation, such 
as that induced by phenylephrine, can be inhibited by RGS2 overexpression (Roy, Nunn, et 
al., 2006; Zou et al., 2006), with a similar effect seen against Gs-mediated cardiomyocyte 
hypertrophy induced by isoproterenol (Nunn et al., 2010). The importance of RGS2 in the 
regulation of hypertrophy has been further demonstrated in knockout animal studies. In Rgs2-
/- mice, experimentally induced pressure overload via transverse aortic constriction causes 
severe hypertrophy, heart failure, and death (Takimoto et al., 2009). In addition, chronic 
angiotensin II infusion has been shown to significantly increase blood pressures in Rgs2-/- mice 
compared to WT controls (Hercule et al., 2007) 
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While the G protein inhibitory effects of RGS2 are well established, RGS2 can also bind to 
and regulate other targets, including TRPV6 calcium channels and tubulin (Wang et al., 2005; 
Heo et al., 2006; Schoeber et al., 2006). We have previously shown that RGS2 can also bind 
to the ε subunit of eukaryotic initiation factor 2B (eIF2B), a component of the rate-limiting 
step of the initiation of mRNA translation (Nguyen et al., 2009). This property of RGS2 has 
been mapped to a 37 amino acid domain (residues 79-115) termed RGS2eb that is homologous 
to a region in the β subunit of eIF2 (Nguyen et al., 2009), and we have also demonstrated that 
RGS2eb expression in cultured neonatal cardiomyocytes is able to inhibit both protein synthesis 
and agonist induced hypertrophy at levels comparable to full-length RGS2 (Chidiac et al., 
2014).  
Recently, we reported that following four weeks of transverse aortic constriction (TAC), mice 
with cardiomyocyte specific overexpression of RGS2eb (herein referred to as Rgs2+/+(eb) mice) 
were protected from pressure overload-induced cardiac hypertrophy, and maintained heart 
function at significantly improved levels compared to WT counterparts (see Chapter 3) (Lee 
et al., 2017). Reactivation of the fetal gene response was suppressed in Rgs2+/+(eb) mice 
following TAC, and cardiomyocyte size was decreased in Rgs2+/+(eb) mice compared to WT 
TAC controls. These findings suggest that in addition to its G-protein inhibitory actions, the 
RGS2eb region may contribute to the cardioprotective effects of full-length RGS2 in vivo via 
the inhibition of de novo protein synthesis.  
Since full-length RGS2 was still being endogenously expressed in the Rgs2+/+(eb) mice from 
our previous studies (Lee et al., 2017), the use of Rgs2-/- mice would provide further insights 
into the cardioprotective role of the RGS2eb region. Based on our previous findings, we 
hypothesized that the cardiomyocyte-specific overexpression of RGS2eb in Rgs2-/- mice could 
decrease the severity of cardiac hypertrophy and heart failure resulting from experimentally 
induced pressure overload, thereby compensating for the absence of full-length RGS2. Here 
we report the generation of novel transgenic Rgs2-/- mice with cardiomyocyte specific 
overexpression of RGS2eb (Rgs2-/-(eb)). Unexpectedly, we observed that the mortality rate for 
Rgs2-/- animals significantly exceeded that of WT controls following 28 days of transverse 
aortic constriction (TAC), suggesting an impaired ability to recover from cardiovascular insult. 
 113 
 
Due to the unexpectedly high mortality rate of Rgs2-/ - mice, the TAC-induced model of 
pressure overload was determined to be unsuitable for the evaluation of cardiac hypertrophy, 
and discontinued before the addition of Rgs2-/-(eb) mice to the study. The effects of drug-
induced models of hypertension on Rgs2-/- mice were also evaluated. Chronic infusion of 
angiotensin II via osmotic pumps for 28 days (1.44 mg/kg/day) significantly increased blood 
pressures of experimental animals (Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb)), except for WT mice. 
Although cardiac function was impaired in Rgs2-/- animals compared to basal levels, cardiac 
hypertrophy was not observed in any experimental groups compared to saline controls. Further 
studies with angiotensin II infusion at higher concentrations (3.0 mg/kg/day for 14 days) in 
WT and Rgs2-/- mice also failed to induce clearly detectable cardiac hypertrophy. Additional 
pilot studies were subsequently performed using twice daily injections of isoproterenol (ISO) 
for 14 days, with preliminary results suggesting that a full study with prolonged injections 
beyond 14 days may result in cardiac hypertrophy. Overall, owing in large part to the general 
lack of efficacy and/or safety of established methods with respect to the induction of cardiac 
hypertrophy in our experimental animals, our results do not support our original hypothesis 
that RGS2eb expression in an RGS2 null background would provide a “rescue” effect. In 
addition, the present findings provide little if any support for the notion that mice lacking RGS2 
exhibit greater levels of experimentally-induced cardiac hypertrophy. 
 
 Methods 
4.2.1 Generation of Rgs2-/- mice with cardiac specific overexpression 
 of RGS2eb 
Rgs2+/+(eb) were crossed with Rgs2−/− mice to produce heterozygous Rgs2+/- animals with or 
without the expression of RGS2eb (Rgs2+/- (eb) or Rgs2+/-, respectively). Rgs2+/- (eb) mice were 
then crossed with Rgs2−/− mice to obtain RGS2 knockout animals expressing RGS2eb (Rgs2-/-
(eb)). Subsequent crosses of Rgs2-/-(eb) with Rgs2−/− animals enabled the establishment of a 
mouse colony which produced Rgs2-/-(eb) mice and Rgs2−/− littermates (Fig. 4.1). 
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Colonies for Rgs2-/- and Rgs2+/+(eb) mice are well established in our laboratory (Roy, Nunn, et 
al., 2006; Lee et al., 2017). Briefly, during our initial generation of Rgs2+/+(eb) mice, the RGS2eb 
gene was targeted to the heart using the mouse α-MHC promoter (kindly provided by Jeffrey 
Robbins, Cincinnati Children’s Hospital Medical Center) (Subramaniam et al., 1991). Primers 
for the detection of transgenic Rgs2+/+(eb) mice and control primers for endogenous RGS2 
expression have been previously described in Chapter 3 (Lee et al., 2017); the genotyping of 
Rgs2−/− mice has also been previously described (Oliveira-Dos-Santos et al., 2000). Three to 
five month old male mice were used for experimental studies; all mouse lines are in C57Bl/6 
backgrounds. Animals were maintained in accordance with the Institute of Laboratory Animal 
Research Guide for the Care and Use of Laboratory Animals. These studies were approved by 
the Animal Care Committee at the University of Western Ontario, and complied with the 
guidelines of the Canadian Council on Animal Care.  
4.2.2 Transverse aortic constriction (TAC) 
TAC was used to induce pressure overload on the hearts of 12 week old male C57BL/6 wild-
type (i.e., Rgs2+/+) and Rgs2-/- mice, and as described in Chapter 3 (Lee et al., 2017). Briefly, 
two knots were tied against a 25-gauge blunt needle placed parallel to the transverse aorta, 
which was immediately removed after the second tied knot followed by closure of the chest. 
Control WT and Rgs2-/- mice were subjected to sham operations without aortic constriction.  
4.2.3 Drug treatments 
28 day angiotensin (Ang) II infusion: Ang II (A9525, Sigma-Aldrich, Canada) was dissolved 
in sterile saline and added to osmotic pumps (Model 1004, Alzet, New York, NY, USA) as per 
manufacturer’s protocols (Alzet, 2017a); control pumps were filled with saline. The pump 
filling concentration of Ang II required to deliver the drug at a dose of 1.44 mg/kg/d was 
calculated using the mean pumping rates for each lot of osmotic pumps and the Alzet drug 
concentration calculator (Alzet, 2017b). Pumps were implanted subcutaneously under 
isoflurane anaesthesia. Echocardiography and blood pressure measurements were performed 
for pre-implantation (basal), 14 day, and 28 day time points. Experimental animals included 
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Rgs2-/- and Rgs2-/-(eb) animals, as well as control WT and Rgs2+/+(eb) mice. Animals were 
sacrificed after 28 days for tissue collection. 
14 day angiotensin II infusion: Ang II (12-1-34, American Peptide Company, CA, USA) was 
dissolved in sterile saline and added to osmotic pumps (Model 1002, Alzet); control pumps 
were filled with saline. The pump filling concentration of Ang II required to deliver the drug 
at a dose of 3.0 mg/kg/d was as described above. Echocardiography was performed on day 14, 
followed by animal sacrifice and tissue collection. Only Rgs2-/- and WT mice were used for 
this study.  
Isoproterenol (ISO) injections: ISO (I6504, Sigma-Aldrich) was dissolved in sterile saline and 
injected subcutaneously at a dose of 15 mg/kg or 50 mg/kg twice daily (at 0900 h and 2100 h) 
for 12 days or 14 days, respectively; control mice were injected with sterile saline. 
Experimental animals included Rgs2-/- and Rgs2-/-(eb)animals, as well as control WT and 
Rgs2+/+(eb) mice. Mice were weighed daily and sacrificed on day 12 or day 14 for tissue 
collection. 
4.2.4 Assessment of blood pressure 
Non-invasive tail-cuff blood pressures and heart rates were measured using the CODA tail-
cuff blood pressure system (Kent Scientific, USA) as previously described (Tutunea-Fatan et 
al., 2015). For angiotensin II osmotic pump studies, heart rates and tail-cuff blood pressures 
were recorded in conscious mice for basal, 14 day, and 28 day time points.  
4.2.5 Assessment of cardiac function 
M-mode (motion mode) echocardiography was performed after Ang II or saline treatments as 
previously described (Liu et al., 2014; Roy et al., 2016). Briefly, cardiac function was 
measured using the Vevo 2100 imaging system (VisualSonics, Canada). Using a dynamically 
focused 40MHz probe, 2-dimensional heart images were obtained in short-axis view for the 
left ventricle (LV).  
M-mode recordings were assessed for the determination of various cardiovascular parameters 
using the Cardiac Measurement Package (PSLAX protocol) and averaged from 3 cycles 
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(VisualSonics, 2008). Anterior and posterior wall thickness, as well as LV internal diameter 
were directly measured from M-mode recordings for both systolic and diastolic phases. 
Ejection fraction, fractional shortening, LV volume, and corrected LV mass were derived from 
established formulas calculated by the VisualSonics analysis report function (VisualSonics, 
2008). Detailed measurement and calculation definitions from VisualSonics are described in 
Supplemental Table C1. 
4.2.6 Tissue collection 
Upon completion of studies, anaesthetized mice were euthanized via a 10% KCl injection into 
the left jugular vein to ensure cardiac arrest in the diastolic state. Hearts were excised, weighed 
after removal of the atria, and stored at -80°C for subsequent RNA isolation. For 50 mg/kg 
ISO experiments, lungs were also excised and rinsed in saline, then weighed. Tibias from each 
animal were excised, cleaned, and measured for heart weight/tibia length calculations. 
4.2.7 Quantitative reverse transcriptase qPCR 
Total RNA was isolated from LV heart tissue using the TriZol (Invitrogen) extraction method 
for 1.44 mg/kg/day Ang II experiments. Reverse transcription reaction was performed using 
the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Invitrogen, 
Canada). SensiFAST SYBR No-ROX Kit mastermix (FroggaBio, Canada) was used for real-
time thermal cycling. Primers for β-MHC, ANP, and BNP were previously described in 
Chapter 3 (Lee et al., 2017), and were designed using the OligoPerfect Designer 
(ThermoFisher, Canada), OligoCalc (Kibbe, 2007) and Primer-BLAST (NCBI) programs. 
Samples were amplified for 35 cycles using a CFX384 real-time thermal cycler (Bio-Rad, 
Canada). The mRNA quantity for each gene of interest was determined using standard curve 
analysis and normalized to 28S ribosomal expression. 
4.2.8 Statistical analysis 
All data were analyzed using GraphPad Prism 6.01 (GraphPad). Statistical analyses were 
performed using two-way ANOVA followed by Bonferroni post-tests, Log rank test (for 
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survival curves), or Student’s t-test and presented as mean ± SEM. Differences were 
considered significant at P<0.05. 
 
 Results 
4.3.1 Generation of transgenic mice with cardiomyocyte-specific 
overexpression of RGS2eb 
We previously demonstrated that the vivo expression of RGS2eb inhibited pressure overload 
induced cardiac hypertrophy and improved cardiac function (Lee et al., 2017). Since 
endogenous RGS2 was still present in our previous studies, we used well established Rgs2-/- 
and Rgs2+/+(eb) mouse lines in our laboratory to develop a novel strain of Rgs2-/- mice with 
targeted myocardial overexpression of RGS2eb (Rgs2-/-(eb)) (Fig. 4.2A). As previously 
mentioned in Chapter 3, genotyping with primers for a portion of the hGH polyA region, which 
was only present in the transgenic sequence of Rgs2+/+(eb) mice, was used to identify mice 
expressing RGS2eb. Primers for endogenous RGS2 and a region of the RGS2 knockout 
construct (Oliveira-Dos-Santos et al., 2000), were used to identify wildtype and Rgs2-/- 
animals, respectively. Together, these results indicate the successful generation of Rgs2-/- mice 
with cardiomyocyte specific overexpression of RGS2eb. 
4.3.2 Increased mortality in Rgs2-/- mice following pressure overload 
Transverse aortic constriction (TAC) was used to induce experimental pressure overload on 
wildtype and Rgs2-/- mice. Since Rgs2-/- mice have been previously reported to be highly 
sensitive to pressure overload induced hypertrophy and heart failure (Takimoto et al., 2009), 
initial TAC studies were performed with Rgs2-/- animals to establish whether the previous 
surgery conditions used in Chapter 3 were suitable. Survival rates for Rgs2-/- mice subjected to 
TAC surgery were found to be significantly lower than sham controls, with 70% of Rgs2-/- 
mice dying within two days of TAC surgery (Fig. 4.2A); a similar effect was not observed for 
WT TAC mice (Fig. 4.2B). Due to the low survival rate of Rgs2-/- mice, we concluded that 
TAC was too severe of a procedure for our goal of producing a hypertrophy model. Due to 
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these observations, we did not continue this study with our remaining experimental groups (i.e. 
with Rgs2+/+(eb) and Rgs2-/-(eb) mice).  
4.3.3 28 day angiotensin II treatment at 1.44 mg/kg/day 
As an alternative to TAC, we investigated the effects of drug-induced hypertension in Rgs2-/-
(eb) and Rgs2-/- mice. Chronic Ang II infusion has been previously shown to reproducibly 
increase blood pressure and induce the development of cardiac hypertrophy in C57Bl/6 mice 
(Francois et al., 2004; Crowley et al., 2006). Tail cuff systolic and diastolic blood pressure 
measurements as well as HR were taken one to five days prior to pump implantation (basal) 
and at 14 days and 28 days following infusion of saline or Ang II at a dose of 1.44 mg/kg/day 
in WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb) mice. In Ang II treated Rgs2+/+(eb) mice, significant 
increases in systolic BP were observable by day 14 and remained elevated through day 28 
compared to basal levels (Fig. 4.3A) Similar significant systolic BP changes were observed at 
day 28 in Rgs2-/- and Rgs2-/-(eb) mice (Fig. 4.3A). However, WT systolic BP Ang II treatment 
at 28 days was not significantly increased compared to basal (P=0.062, Fig. 4.3A). Significant 
elevations in diastolic BP were observed at 28 days in Rgs2-/- and Rgs2-/-(eb) mice (Fig. 4.3B). 
No changes in systolic or diastolic BPs occurred in saline controls (Fig. 4.3C and D), and heart 
rates were comparable between all genotypes and treatment groups (Table 4.2). 
 
Although hypertension was evident in WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb) mice following 
chronic Ang II treatment, cardiac hypertrophy was not observed in any strains or treatment 
groups following the 28 day time point, as measured by either heart weight/tibia length (Fig. 
4.4A and C) or echocardiography for LV mass (Fig. 4.4C and D). In addition, 
echocardiography measurements for LV diastolic and systolic internal diameters (LVID) in 
saline and Ang II treated groups did not provide evidence for chamber dilation or hypertrophy 
(Figure 4.5). Echocardiography measurements for posterior and anterior LV wall thickness 
during diastole and systole provided further evidence for a lack of cardiac hypertrophy (Figure 
4.6 and 4.7); LV volume was also comparable to basal levels (Figure 4.8). Overall, these results 
suggest that experimental hypertension induced by Ang II infusion was insufficient for the 
development of cardiac hypertrophy in any of the groups tested.  
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4.3.4 Decreased cardiac function in Rgs2-/- mice following 28 days of 
 angiotensin II treatment 
In addition to hypertrophy parameters, cardiac function was also assessed in WT, Rgs2+/+(eb), 
Rgs2-/-, and Rgs2-/-(eb) mice following 28 days of saline of Ang II infusion. Ejection fraction 
(EF) and fractional shortening (FS) in Rgs2-/- mice were significantly decreased compared to 
Rgs2-/- basal values (Fig. 4.9A and C). No significant decreases in EF or FS were observed in 
WT, Rgs2+/+(eb), or Rgs2-/-(eb) following Ang II or saline treatment (Fig. 4.9). 
 
4.3.5 Expression of fetal genes in LV tissue of 28 day 1.44 
 mg/kg/day chronic angiotensin II treated mice 
Induction of “fetal” cardiac genes is often a common feature in animal models of pathological 
hypertrophy and heart failure (Parker, Packer and Schneider, 1990; Razeghi et al., 2001). RNA 
was isolated from left ventricular tissue after 28 days of Ang II or saline, and qPCR was 
performed to determine expression levels of β-myosin heavy chain (β-MHC), atrial natriuretic 
peptide (ANP), and brain natriuretic peptide (BNP) in WT and Rgs2-/- mice. Surprisingly, WT 
mice treated with Ang II were found to express significantly lower levels of β-MHC compared 
to Ang II Rgs2-/- animals and saline controls (Fig. 4.10 A). ANP was significantly increased in 
Rgs2-/- compared to WT Ang II mice (Fig. 4.10B), while BNP was significantly decreased in 
Rgs2-/- compared to WT saline mice (Fig. 4.10 C).  
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Figure 4.1. Breeding schematic for generation of Rgs2-/-(eb) mice 
Rgs2-/- and Rgs2+/+(eb) mouse lines were crossed to obtain heterozygous mice with transgene 
expression (Rgs2+/-(eb)). Subsequent crosses with Rgs2-/- mice produced a colony of Rgs2-/- and 
Rgs2-/-(eb) littermates. 
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A       B     
 
 
 
 
 
 
 
 
 
 
 
(A) Significantly lower survival was observed for Rgs2-/- TAC mice compared to sham 
controls, which was not seen in (B) WT TAC animals. WT survival data is based on sham and 
TAC surgeries completed for Chapter 3 studies. Data represent means ± SEM, n = 5-22 per 
group. *P<0.05 and ***P<0.001 using Log rank test for survival curves. 
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C)       D) 
 
 
 
 
 
 
 
TG and KOT designations indicate Rgs2+/+(eb) and Rgs2-/-(eb) mice, respectively. (A) Systolic 
and (B) diastolic blood pressures (BP) were significantly altered at multiple time points in Ang 
II treated mic. (C) Systolic and (D) diastolic BPs for saline treated mice remained stable 
throughout the 28 days. Data represent means ± SEM, n=8-18 per genotype group for Ang II, 
and n=2 per genotype group for saline treated. *P<0.05 and ***P<0.001 using two-way 
ANOVA with Bonferroni’s post hoc test for multiple comparisons. 
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Figure 4.3. Tail-cuff blood pressure measurements for basal, 14 day, and 28 days 
during saline of Ang II 1.44 mg/kg/day 
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Table 4.1. Heart rates for Ang II and saline treated WT, Rgs2+/+(eb) , Rgs2-/-, and Rgs2-/-(eb) 
mice (beats per minute) 
Saline WT TG KO KOT 
n 2 2 2 2 
Basal  673 670 639 636 
14 day 687 645 641 617 
28 day 632 672 671 607 
     
Ang II WT TG KO KOT 
n 5-16 6-9 5-15 7-9 
Basal  690± 14 670± 12 639± 19 636± 47 
14 day 704± 25 660± 31 651± 22 607± 27 
28 day 681± 42 707± 42 653± 43 604± 23 
TG and KOT columns indicate Rgs2+/+(eb) and Rgs2-/-(eb) mice, respectively. 
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C       D 
 
 
 
 
 
 
 
 
 
 
 
Heart weight/tibia length was measured for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb) 
(KOT) mice in Ang II and saline treated after 28 days. LV mass was also measured from 
echocardiography images at basal, 14 days, and 28 days of treatment. Data represent means ± 
SEM, n=3 (saline) or 8 (Ang II-treated) per genotype group. Statistical analysis was performed 
using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons. 
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Figure 4.4. Heart weight/tibia length ratios and LV mass, 1.44 mg/kg/day Ang II or saline 
treatment 
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(A) (B) LVID;d and (C 
 
(A)(B) LVID;d (C)(D) LVID;s were comparable between both Ang II and saline treatment 
groups, as well as between genotypes for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb) 
(KOT) mice. LVID was measured from echocardiography images at basal, 14 days, and 28 
days of treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype 
group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc 
test for multiple comparisons. 
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Figure 4.5. LV internal diameters (LVID) at diastole and systole, 1.44 mg/kg/day Ang II or 
saline treatment 
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(A) (B) AW;d and (C) (D) AW;s were comparable between both Ang II and saline treatment 
groups, as well as between genotypes for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb) 
(KOT) mice. AW was measured from echocardiography images at basal, 14 days, and 28 days 
of treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype 
group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc 
test for multiple comparisons. 
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Figure 4.6. Anterior wall (AW) thickness, diastole and systole, 1.44 mg/kg/day Ang II or 
saline treatment 
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(A) (B) PW;d and (C) (D) PW;s were comparable between both Ang II and saline treatment 
groups, as well as between genotypes for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb) 
(KOT) mice. PW was measured from echocardiography images at basal, 14 days, and 28 days 
of treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype 
group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc 
test for multiple comparisons. 
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Figure 4.7. Posterior wall thickness (PW), diastole and systole, 1.44 mg/kg/day Ang II 
or saline treatment 
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(A) (B) LV;d and (C) (D) LV;s were comparable between both Ang II and saline treatment 
groups, as well as between genotypes for WT, Rgs2+/+(eb) (TG) , Rgs2-/- (KO) and Rgs2-/-(eb) 
(KOT) mice. LV was measured from echocardiography images at basal, 14 days, and 28 days 
of treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype 
group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc 
test for multiple comparisons. 
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Figure 4.8. LV vol, diastole and systole, 1.44 mg/kg/day Ang II or saline treatment 
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(A) EF in Rgs2-/- (KO) was significantly reduced after 28 days of ang compared to basal Rgs2-
/- (KO) levels. Changes to EF compared to basal were not observed for WT, (B) Rgs2+/+(eb) 
(TG) or Rgs2-/-(eb) (KOT) mice. Similarly, (C) FS was significantly reduced in Rgs2-/- (KO) was 
significantly reduced after 28 days of ang compared to basal, with no changes observed in WT, 
(D) Rgs2+/+(eb) (TG) or Rgs2-/-(eb) (KOT) mice. EF and FS were calculated from LV vol and 
LVID parameters (see Suppl. Table C1 for equations) at basal, 14 days, and 28 days of 
treatment. Data represent means ± SEM, n=3 (saline) or 8 (Ang II treated) per genotype group. 
Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc test for 
multiple comparisons. 
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Figure 4.9. Ejection fraction and fractional shortening, 1.44 mg/kg/day Ang II or 
saline treatment 
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(A) After 28 days of Ang II or saline, WT mice treated with Ang II were found to express 
significantly lower levels of β-MHC compared to Ang II Rgs2-/- animals and saline controls. 
(B) ANP was significantly increased in Rgs2-/- compared to WT Ang II mice, while (C) BNP 
was significantly decreased in Rgs2-/- compared to WT saline mice (Fig. 4.10 C). Data represent 
means ± SEM, n=6 per group. *P<0.05 and **P<0.01 using two-way ANOVA with 
Bonferroni’s post hoc test for multiple comparisons. 
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Figure 4.10. Markers of cardiac hypertrophy 
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4.3.6 14 day angiotensin II treatment at 3.0 mg/kg/day  
Since Ang II treatment at 1.44 mg/kg/day was sufficient to increase blood pressure, but did not 
appear to induce cardiac hypertrophy, 3.0 mg/kg/day of Ang II was tested in WT and Rgs2-/- 
mice for 14 days to determine whether an increase in drug dosage could produce a hypertrophic 
response. Significant cardiac hypertrophy did not occur in either WT or Rgs2-/- mice compared 
to saline controls (Fig. 4.11A). Furthermore, echocardiography for systolic and diastolic 
diameters (Fig. 4.11 B and C), as well as EF and FS (Fig. 4.11D and E), were similar between 
all treatment groups and strains.  
4.3.7 Effect of twice daily isoproterenol injections 
Due to a lack of inducible cardiac hypertrophy in our Ang II models, we tested whether a 
different drug and mode of delivery could improve our attempts to characterize the Rgs2-/-(eb) 
mouse. Isoproterenol was injected subcutaneously at a dose of 15 mg/kg for 12 days. To 
determine feasibility, initial tests were performed only in WT mice. Following ISO injection, 
WT heart rates (under anaesthesia) rapidly increased from approximately 400 bpm to 700 bpm 
thirty seconds after injection and plateaued at that level (Fig. 4.12A), indicating that a 
pharmacologically relevant dose was used. HR measurements 8 hours and 24 hours after ISO 
delivery showed a gradual return to baseline, suggesting that twice daily doses of ISO would 
be appropriate to maintain animal HRs at elevated levels (Fig. 4.12A). Following twelve days 
of ISO or saline injections, statistically significant levels of hypertrophy were not observed 
(data not shown). Therefore, ISO dosage was subsequently increased to 50 mg/kg twice daily 
for 14 days to WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb) mice; body weights were recorded daily 
and animals were tracked for survival (Suppl. Fig. C1). Wet lung weight/tibia length was 
similar between all strains and conditions, and did not suggest the development of congestion 
(Fig. 4.13A).  Similar to the twelve day ISO studies, the development of hypertrophy in Rgs2-
/- mice compared to saline controls was not statistically significant (P=0.08) (Fig. 4.13B).  
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 Discussion 
Maladaptive cardiac hypertrophy is a common condition that often develops in settings of 
hypertension, and is a major risk factor for heart failure and sudden death. Since the heart is 
thought to be an essentially post mitotic organ, cardiomyocyte growth requires de novo protein 
synthesis, which is controlled primarily at the initiation of mRNA translation stage (Sugden et 
al., 2009). We have previously shown that the in vitro expression of RGS2eb, a region of full-
length RGS2, can block protein synthesis and cultured cardiomyocyte growth by inhibiting 
eIF2B, a key component of the rate-limiting step of protein synthesis initiation (Nguyen et al., 
2009; Chidiac et al., 2014). Furthermore, we recently developed a transgenic mouse line with 
cardiomyocyte specific overexpression of RGS2eb (i.e. Rgs2+/+(eb) mice). Using a pressure 
overload model, we demonstrated that expression of RGS2eb inhibited TAC-induced increases 
in cardiac hypertrophy and the expression of hypertrophy-related gene markers, as well as 
associated functional loss (Lee et al., 2017). These results likely reflected the ability of RGS2eb 
to inhibit protein synthesis in vivo, and the consequent suppression of the hypertrophic 
response and cardioprotective effects. In the present studies, we attempted to extend our earlier 
work to study the potential protective effect of RGS2eb expression targeted to the myocardium 
in whole body RGS2 knockout mice, but this effort was abandoned due to unacceptably high 
mortality of the TAC procedure in Rgs2-/- animals. We also were unable to establish whether 
the hypothesized protective/rescue effect could be observed with drug-induced experimental 
cardiac hypertrophy due to generally poor efficacies of established hypertrophy-inducing drug 
treatments in our experimental animals. Finally, the majority of our results do not support the 
notion the Rgs2-/- mice are prone to more severe experimental hypertrophy, in contrast to the 
previous findings of Takimoto and colleagues (Takimoto et al., 2009). 
Our previous work demonstrated the anti-hypertrophic effects of RGS2eb expression in a 
C57Bl/6 background where endogenous expression of full-length RGS2 (which contains the 
RGS2eb region) was still present. The goal of the present study was to determine whether the 
apparent ability of RGS2eb to confer cardioprotection could be extended in part to Rgs2-/- mice, 
which have previously been reported to be highly sensitive to TAC induced pressure  
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(A) Significant cardiac hypertrophy did not occur in WT or Rgs2-/- mice compared to saline 
controls. Echocardiography for (B) diastolic and (C) systolic parameters, as well as (D) 
ejection fraction (EF) and (E) fractional shortening (FS) were similar between all treatment 
groups and strains. Data represent means ± SEM, n=3-8 per group. Statistical analysis was 
performed using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons. 
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Figure 4.11. Heart weight/tibia length, LVID, EF, and FS in 3.0 mg/kg/day Ang 
II or saline treated WT and Rgs2-/- mice 
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Following ISO injection, WT heart rates (under anaesthesia) rapidly increased from 
approximately 400 bpm to 700 bpm thirty seconds after injection, and plateaued at that level. 
HR measurements 8 hours and 24 hours after ISO delivery showed a gradual return to baseline, 
suggesting that twice daily doses of ISO would be appropriate to maintain animal HRs at 
elevated levels. Data points represent individual animals. 
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 135 
 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
(A) Wet lung weight/tibia length was similar between all strains and conditions, and did not 
suggest the development of congestion. (B) Although statistical significance was not attained, 
heart weight/tibia length ratios indicated the development of hypertrophy in Rgs2-/- (KO) and 
Rgs2-/-(eb) (KOT) mice. Data represent means ± SEM, n=3-8 per group. Statistical analysis was 
performed using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons. 
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Figure 4.13. Lung weight/tibia length and heart weight/tibia length in 14 day saline 
or 50 mg/kg ISO treated mice 
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overload (Takimoto et al., 2009). In order to develop a line of Rgs2-/- mice with cardiomyocyte 
specific overexpression of RGS2eb (Rgs2-/-(eb)), we crossed Rgs2+/+(eb) and Rgs2-/- mice from 
well-established mouse lines in our laboratory to obtain intermediate animals with 
heterozygous RGS2 expression. Mice were genotyped to identify those with expression of the 
RGS2eb transgene, then crossed back with Rgs2-/- animals to obtain Rgs2-/-(eb) mice, which were 
subsequently crossed with Rgs2-/- animals to establish a novel Rgs2-/-(eb) / Rgs2-/- mouse line 
(Figure 4.1). 
High mortality rates of Rgs2-/- mice after TAC led to the discontinuation of our initial TAC 
studies. However, this was an interesting observation in itself (Fig. 4.2B). Previous studies 
using a more severe TAC model have also demonstrated lower survival rates in Rgs2-/- animals, 
albeit to a much smaller extent than our observations (60% survival versus 30%, respectively) 
(Takimoto et al., 2009). A possible explanation for these low survival rates is that Rgs2-/- mice 
have been shown to have increased susceptibility to atrial fibrillation (AF) via enhanced M3 
muscarinic receptor activity, which is known to be involved in vagally induced atrial 
fibrillation (Tuomi, Chidiac and Jones, 2010; Jones, Tuomi and Chidiac, 2012). Studies have 
also shown that AF can be induced more frequently via electrical stimulation in wild-type TAC 
hearts compared to sham surgeries, and that this may be due to mast cell infiltration and fibrosis 
in the atrium following TAC (Liao et al., 2010). In addition, the use of a ketamine/xylazine 
anaesthetic mix, which depresses cardiac function (Kohn, 1997; Roth et al., 2002), may have 
also had an adverse effect. Thus, it is possible that after TAC surgery, a combination of the 
loss of RGS2 and additional physiological stressors induced atrial fibrillation and cardiac 
dysfunction, from which a majority of our Rgs2-/- animals did not recover.  
Chronic Ang II infusion via osmotic pumps at both pressor and sub-pressor doses has been 
shown to induce hypertension and cardiac hypertrophy in various mouse lines including C57 
Bl/6 mice (Griffin et al., 1991; Bendall et al., 2002; Schultz et al., 2002; Choi et al., 2016; 
Tsuruda et al., 2016). Although we observed hypertension in our experimental mice after 28 
days of Ang II at 1.44 mg/kg/day (Fig. 4.3), we did not observe cardiac hypertrophy in any of 
our experimental or control mice (WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb)). However, functional 
echocardiography data suggested significantly decreased ejection fraction and fractional 
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shortening in Rgs2-/-Ang II animals compared to basal Rgs2-/- levels, which was not observed 
in the other experimental groups (Fig. 4.9). Levels of ANP were also significantly elevated in 
Rgs2-/- mice compared to WT controls (Fig. 4.10B). These data suggested that although Ang 
II infusion was sufficient to increase blood pressure over 28 days, it was not, at least in our 
hands, able to reliably deliver a robust hypertension-induced model of cardiac hypertrophy. 
Therefore, we tested approximately double the concentration of Ang II (3.0 mg/kg/day) in WT 
and Rgs2-/- mice for 14 days to assess whether a higher dose could induce cardiac hypertrophy 
and thus be used for additional studies; no statistically significant increases in heart weight 
were observed (Fig. 4.11). It is possible that our Rgs2-/- (and potentially WT) mouse strains 
are, for currently unknown reasons, resistant to the development of cardiac hypertrophy, as the 
pressure overload and hypertrophy models used in our experiments are well established in the 
literature and in our own laboratories (Roy et al., 2016; Lee et al., 2017). Further studies, such 
as prolonged or higher doses of Ang II, may clarify the parameters required for a robust model 
of Ang II-induced cardiac hypertrophy.  
Following a lack of significant hypertrophy in all our mouse strains after chronic Ang II 
treatment, we hypothesized that acute delivery of a hypertrophic agent could potentially result 
in the development of cardiac hypertrophy. Since our previous study used Ang II, which 
activates Gq-stimulated hypertrophic signalling pathways, we selected isoproterenol, a Gs 
activating agonist (via β-adrenergic receptors), to ultimately administer in a pilot study at twice 
daily doses of 50 mg/kg for 14 days to WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb) mice. Initial heart 
weight/tibia length ratios following ISO treatment demonstrated no statistically significant 
differences between genotype or treatment groups, although ISO (Fig. 4.13B) has been 
previously shown to induce cardiac hypertrophy at concentrations ranging from 15 mg/kg to 
100mg/kg (Zhang et al., 2005; Brooks and Conrad, 2009; Sjögren et al., 2016). Future studies 
with blood pressure monitoring as well as echocardiography analysis may help determine 
whether an isoproterenol model is the appropriate drug of choice for a hypertrophy model in 
our studies with Rgs2-/-(eb) mice. 
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 Conclusions 
The present results are generally consistent with studies in the literature that suggest impaired 
cardiovascular function in Rgs2-/- mice may be due to enhanced susceptibility to atrial 
fibrillation. However, our objective of determining whether the expression of RGS2eb in Rgs2-
/- mice (Rgs2-/-(eb)) could decrease previously reported deleterious outcomes following pressure 
overload was limited by our inability to achieve a robust cardiac hypertrophy model with 
appropriate experimental controls. Subsequent studies using well-established angiotensin and 
isoproterenol hypertrophy models also did not produce significant increases in heart weight in 
any of our mouse strains. It is possible that future studies with prolonged isoproterenol or 
angiotensin II treatment could result in conditions leading to a robust cardiac hypertrophy 
model in which the role of RGS2eb in Rgs2-/- mice could be appropriately characterized. 
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5 LOSS OF REGULATOR OF G PROTEIN SIGNALLING 2 
 (RGS2) ALTERS THE EFFECTS OF ACUTE AND 
 CHRONIC DIET RESTRICTION ON METABOLIC 
 OUTCOMES IN C57 BL/6 MICE 
 
 
 
 
 
 
 
 
 
 
 
The material in this chapter is based on a manuscript: Lee KN, Gros R, and Chidiac P (2017), 
Loss of regulator of G protein signalling 2 (RGS2) alters the effects of acute and chronic diet 
restriction on metabolic outcomes in C57 Bl/6 mice. Submitted to International Journal of 
Obesity. Manuscript number: 2017IJO01137. 
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 Introduction 
Regulator of G protein signalling (RGS) proteins are a family of GTPase-activating proteins 
(GAPs) that bind to G proteins and inactivate them by increasing the intrinsic rate of GTP 
hydrolysis and/or act as “effector antagonists”, thus limiting the intensity and duration of 
GPCR-initiated signalling (Popov et al., 1997; Ross and Wilkie, 2000; Abramow-Newerly et 
al., 2006). RGS2 is part of the B/R4 family of RGS proteins and is found ubiquitously 
throughout the body (Schoeber et al., 2006). RGS2 selectively inhibits Gαq- and Gαs-mediated 
signalling (some effects on Gαi/o signalling have also been reported) (Heximer et al., 1999; 
Anger et al., 2007; Chakir et al., 2011), and can bind to and regulate other non-G protein targets 
including eIF2B, TRPV6 calcium channels and tubulin (Wang et al., 2005; Heo et al., 2006; 
Schoeber et al., 2006). RGS2 has also been shown to modulate adipocyte differentiation and 
proliferation (Imagawa, Tsuchiya and Nishihara, 1999; Nishizuka et al., 2001; Cheng et al., 
2008), and may also regulate basal metabolism via the inhibition of thyroid hormone receptor-
induced Gαq signalling (Eszlinger et al., 2004). Furthermore, human polymorphisms leading to 
increased RGS2 expression have been associated with metabolic syndrome and an increased 
risk for weight gain or obesity in hypertensive patients (Freson et al., 2007; Sartori et al., 2008). 
Conversely, Rgs2 deficiency in mice leads to impaired T cell activation, increased anxiety, 
reduced male aggression, and moderate hypertension under basal conditions (Oliveira-Dos-
Santos et al., 2000; Heximer et al., 2003).  
We have previously reported that Rgs2-/- mice exhibit a lean phenotype, and demonstrated that 
resistance to age-related weight gain was accompanied by reduced adipose tissue deposits and 
smaller adipocytes, lower levels of serum lipids, and increased insulin sensitivity; a subset of 
genes involved in adipocyte differentiation and proliferation were also reduced (Nunn et al., 
2011). In addition, Rgs2-/- mice were found to be hyperphagic in comparison to C57 Bl/6 
wildtype (WT) controls, and the two strains exhibited equivalent nutrient absorption (Nunn et 
al., 2011). A lean phenotype in the presence of hyperphagia and normal nutrient absorption 
would appear to suggest increased physical activity and/or metabolism, however we were not 
able in our previous study to detect any increase in resting VO2 in Rgs2
-/- mice using a basic 
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open flow respirometry system where animals were held in a small chamber and had limited 
mobility (Nunn et al., 2011). 
Although the lean Rgs2-/- habitus was maintained throughout the mouse lifespan on an ad 
libitum standard rodent diet, these animals nonetheless became obese and insulin-resistant 
under high-fat diet conditions (Nunn et al., 2011). This suggests that Rgs2-/- mice do not have 
a major impairment with respect to their ability to accumulate adipose tissue (evidence for a 
role of RGS2 in adipocyte differentiation notwithstanding). It follows that the observed lean 
phenotype may reflect underlying changes in energy utilization that limit substrate availability 
with respect to adipose formation under normal dietary conditions.  
To better understand the role of RGS2 in metabolism and body weight regulation 
Comprehensive Laboratory Animal Monitoring System (CLAMS, Columbus Instruments, 
Columbus, OH, USA) metabolic cages were used in the present study to simultaneously assess 
indirect calorimetry parameters and ambulatory activity in freely moving age-matched control 
and Rgs2-/- mice under normal and diet-restricted conditions. Here we report that Rgs2-/- mice 
displayed significantly increased metabolism compared to WT controls, and that these 
differences were exacerbated both by chronic and by acute caloric restriction. No changes in 
ambulatory activity were observed, suggesting that internal metabolism, rather than overt 
physical activity, is the major contributor to the lean Rgs2-/- phenotype. On ad libitum diets, 
although metabolic parameters were observed to decrease over time as mice aged, Rgs2-/- mice 
displayed consistently higher rates of metabolism compared to WT animals. In combination 
with our previous findings which extensively evaluated the effects of the loss of RGS2 on 
various physiological parameters, collectively our data resolve the erstwhile paradox 
concerning nutrient intake and metabolic rates in Rgs2-/- mice, and demonstrate an important 
role for RGS2 in the regulation of weight and body metabolism. 
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 Methods 
5.2.1 Animals 
The generation and genotyping of Rgs2−/− mice have been previously described(Oliveira-Dos-
Santos et al., 2000; Roy et al., 2006). Briefly, Rgs2-/- mice used for experimental procedures 
came from congenic Rgs2-/- and WT control (rgs2+/+) colonies that are well established in our 
laboratory(Roy et al., 2006). Prior to CLAMS metabolic cage measurements and diet 
restriction studies, animals were housed in individual standard shoebox cages and provided ad 
libitum access to standard rodent chow pellets containing 18.6% protein, 6.2% fat, and 44.2% 
carbohydrates (2018 Teklad global 18% protein diet, Envigo, United Kingdom) and water on 
a standard 12:12 h light-dark cycle (light period: 0700 – 1900 h). Male Rgs2-/- and WT controls 
in C57 Bl/6 backgrounds were used for all studies. Animals were maintained in accordance 
with the Institute of Laboratory Animal Research Guide for the Care and Use of Laboratory 
Animals. These studies were approved by the Council on Animal Care at the University of 
Western Ontario, and complied with the guidelines of the Canadian Council on Animal Care. 
5.2.2 Study design 
Animals were monitored using Oxymax CLAMS metabolic cages (Columbus Instruments, 
Columbus, OH, USA). During diet studies, individually housed mice were maintained in 
CLAMS cages at 24 ± 1°C on a standard 12:12 h light-dark cycle (light period: 0700–1900 h) 
with airflow of 0.35L/min(Guzman et al., 2013). Water was available ad libitum in all studies, 
while powdered standard rodent chow (2018 Teklad) was available depending on the diet study 
performed. Animals were individually housed in plexiglass cages and were acclimatized to 
their CLAMS cages for 16-24 hours prior to data acquisition (Guzman et al., 2013).  
5.2.3 Assessment of indirect calorimetry and activity 
Volume of oxygen consumption (VO2), volume of carbon dioxide production (VCO2), 
respiratory exchange ratio (RER), cumulative food and water intake, and physical (ambulatory) 
activity were simultaneously measured using CLAMS and Oxymax software (Columbus 
Instruments). Measurements for all described parameters were taken every 10 minutes for 24 
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hours on a standard 12:12hr light-dark cycle (light period: 0700 – 1900h), and collected data 
were averaged to produce both one hour time points as well as 12 hour light and dark averages. 
VO2 and VCO2 were normalized to body mass (mL/kg/hr). Cumulative food and water intake 
were normalized to 1900 h starting values. RER, an indicator of which macronutrients are 
being metabolized, was calculated by dividing VCO2/VO2. An RER of ~1.0 or ~0.8 indicates 
almost complete carbohydrate or fat oxidation, respectively, while values that fall between 
these extremes suggest a mixture of the energy sources are being metabolized (Richardson, 
1929). Energy expenditure (heat) was calculated from RER and VO2, and corrected for body 
mass (kcal/hr/kg). Ambulatory activity was obtained using Opto-M3 Activity Monitor and 
Oxymax software algorithms (Columbus Instruments). Infrared photo beam breaks were 
monitored as counts on the X- and Y-axes; consecutive beam breaks were assessed as 
ambulatory activity. 
5.2.4 Ad libitum studies 
1 month, 3 month, and 12 month-old Rgs2-/- and WT controls were placed on ad libitum 
standard chow diets (2018 Teklad) following weaning. Animals were placed in CLAMS cages 
for 12 hours of acclimatization followed by 24 hours of data acquisition (start time: 1900 h) 
on a standard 12:12 h light-dark cycle (light period: 0700 – 1900 h). Ad libitum diet in CLAMS 
cages was provided in powdered form via a freely accessible center feeder. 
5.2.5 Chronic diet restriction studies 
Individual food intake for 8 week old Rgs2-/- and WT mice was measured daily for two 
consecutive weeks to determine average consumption of standard rodent diet (2018 Teklad) 
for each animal. Based on measured daily amounts, food intake was reduced by 10% every 
two weeks to reach a final daily diet restriction of 30% after six weeks (i.e. 2 weeks each of 
10%, 20%, and 30% reduction); body weights were measured weekly. Daily food allowance 
was provided in pellet form to all mice at 1100 h. Daily food intake over time was measured 
by weighing food pellets at 30 min and 1 to 24 hours after introduction of food. During 30% 
diet restriction, blood glucose levels were measured using a glucometer (OneTouch UltraMini 
system, Johnson & Johnson, Canada) on tail snip collected blood immediately prior to the 
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introduction of food, as well as 15 min, 30 min, 1 h, 2 h, and 3 h after the introduction of food. 
Following two weeks of 30% restriction, at which time mice were 3.5 month (14 weeks) old, 
animals were placed in CLAMS cages for 12 hours of acclimatization followed by 24 hours of 
data acquisition (start time: 1900 h), with access to pre-weighed food pellets at 1100 h.  
5.2.6 Acute diet restriction studies 
3 month-old Rgs2-/- and WT mice on standard ad libitum rodent diet (2018 Teklad) were placed 
in CLAMS cages for 16 hours of acclimatization followed by 36 hours of data acquisition. 
Cage feeders with powdered food were replaced with empty feeders for 12 hours (start time: 
1900 h), with ad libitum food access returned at 1100 h the following day for another 20 hours 
(end time: 1900 h). 
5.2.7 Microarray analysis 
Total RNA was isolated from the gastrocnemius tissue of ad libitum fed 12 week old male 
Rgs2-/- (n=2) and WT (n=2) mice using the TriZol (Invitrogen) extraction method; RNA 
integrity was confirmed with Agilent 2100 BioAnalyzer Data Review Software (Agilent, USA) 
at the London Regional Genomics Centre. Samples with RNA integrity number (RIN) values 
greater than 8 were used for microarray, which was performed at the London Regional 
Genomics Centre as previously described (Ratneswaran et al., 2017). Briefly, total RNA was 
hybridized to the Affymetrix GeneChip® Mouse Gene 2.0 ST Array containing 35 240 probes. 
Gene level, ANOVA p values, and fold changes were calculated using Partek Genomics Suite 
version 6.6. Genes with at least a 1.4 fold change and with p<0.05 were used to generate gene 
ontology biological processes and cellular component processes diagrams through the 
PANTHER gene list analysis program (http://pantherdb.org/) (Mi et al., 2013). In addition, all 
genes with p<0.05 were analyzed to identify potential metabolic differences between Rgs2-/- 
and WT animals.  
5.2.8 Quantitative reverse transcriptase qPCR 
Total RNA was isolated from the gastrocnemius tissue of ad libitum fed 12 week old male 
mice using the TriZol (Invitrogen) extraction method. Reverse transcription reaction was 
 151 
 
performed using the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor 
(Invitrogen, Canada). SensiFAST SYBR No-ROX Kit mastermix (FroggaBio, Canada) was 
used for real-time thermal cycling. Primers for genes of interest (Table 5.3) were designed 
using the OligoPerfect Designer (ThermoFisher, Canada), OligoCalc (Kibbe, 2007) and 
Primer-BLAST (NCBI) programs. Samples were amplified for 35 cycles using a CFX384 real-
time thermal cycler (Bio-Rad, Canada). The mRNA quantity for each gene of interest was 
determined using standard curve analysis and normalized to 28S ribosomal expression. 
5.2.9 Statistical analysis 
All data were analyzed using GraphPad Prism 6.01 (GraphPad Software, San Diego, CA, USA) 
and presented as mean ± SEM. Statistical analyses were performed using two-way analysis of 
variance (ANOVA) followed by Bonferroni’s post-test and unpaired Student’s two-tailed t-
test. Differences were considered significant at P < 0.05. 
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Table 5.1. Primers for qPCR of metabolism-related genes 
Gene Forward primer 5'-3' Reverse primer 5'-3' 
serca1 GACGTTTGTTGGTGTTGTGG GCAATGGCTGTACCCTTGTT 
adcy2 GGAGATCGAAACCATGGAGA TGGAGGCAAACATGACACA 
adcy5 TCGTGCTGGCTCTGTATCTG GTCCTTGGGCAGAATGTTGT 
adrb1 CAGGCGCTGAGTCTCTCTCT TGCCGTCTTTGTTTTTAGCC 
adrb2 AAAGAGCACAAAGCCCTCAA GTTGACGTAGCCCAACCAGT 
atp5g1 AGGAACCCATCTCTCAAGCA AGGCGACCATCAAACAGAAG 
cs AGGATCCCATGTTCAAGCTG TTCATCTCCGTCATGCCATA 
dio2 GATGCTCCCAATTCCAGTGT TGAACCAAAGTTGACCACCA 
hk2 GGGTAGCCACGGAGTACAAA TGGATTGAAAGCCAACTTCC 
pygm GACATGGAGGAGTTGGAGGA CATAGCGAAGCCAGTCATCA 
ryr1 CTCCTGGTGATGGGTGTCTT TTCCTTCTCGTGTGCCTCTT 
slc16a2 TCCCTTCCTCATCAAAATGC GCCGGTAAGTGAGTGAGAGC 
slc2a4  GATTCTGCTGCCCTTCTGTC ATTGGACGCTCTCTCTCCAA 
thra CAAGATCACCCGGAATCAGT TGCAGTGAGCGAATCATCTC 
ucp3 TCAAAGCAGCAGGACTCAGA GAGAGCAGGAGGAAGTGTGG 
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 Results 
5.3.1 Increased metabolism over time in Rgs2-/- mice on ad libitum diet 
To determine the effects of loss of RGS2 on basal metabolism, indirect calorimetry, activity, 
as well as food and water intake were measured in 1 month, 3 month, and 12 month-old Rgs2-
/- and WT mice. In newly weaned 1 month-old Rgs2-/- and WT animals, VO2, VCO2, energy 
expenditure (heat), ambulatory activity, as well as food and water intake were comparable 
between phenotypes (Fig. 1A, B, C, D and Fig. 2A and B). Although both groups were more 
metabolically and physically active during the 12 hour dark cycle (due to the nocturnal nature 
of mice), there was no significant difference between the described parameters. Interestingly, 
RER during the 12 hour light cycle was noticeably increased in Rgs2-/- mice (Fig. 1A), 
suggesting increased carbohydrate metabolism compared to WT controls. Body weights at 1 
month were still similar between groups, with significant weight separation observed at the 3 
month and 12 month time points (Table 1). 
Consistent with our previous observations (Nunn et al., 2011), lean 3 month-old Rgs2-/- mice 
were found to be hyperphagic in comparison to WT controls (Fig. 2A,), and were also found 
to consume significantly more water during the 12 hour dark cycle (Figure 2B). If increased 
metabolism is to account for the lean phenotype of Rgs2-/- mice, it would be expected that both 
O2 consumption (VO2) and CO2 production (VCO2) would be elevated to some extent. In both 
strains of mice, these parameters were increased compared to levels during the light cycle, 
indicative of the nocturnal activity of mice (Fig. 1A and B). However, Rgs2-/- mice displayed 
additional increases in dark cycle VO2 and VCO2 levels compared to WT mice. Interestingly, 
significant increases in energy expenditure (heat) between the light and dark cycles were 
detected only in Rgs2-/- mice (Fig. 1D). RER also appeared to be higher in Rgs2-/- mice at 3 
months, again suggesting increased carbohydrate metabolism (Fig. 1C). Similar to 1 month old 
mice, changes in ambulatory activity were not found between strains, implying that observed 
metabolic differences do not arise from increased physical activity (Table 1).  
Further strain separation of several metabolic parameters was observed in 12 month old 
animals. VO2, VCO2, and energy expenditure were significantly elevated during the dark cycle 
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in Rgs2-/- compared to WT animals (Fig. 1A, B, and D), although food intake was not 
statistically different at 12 months (Fig. 2A). Patterns in RER (Fig. 1C) and ambulatory activity 
(Table 1) were similar to those observed for 3 month old mice. Overall, these ad libitum data 
suggest that Rgs2-/- mice may have a higher basal metabolic demand than WT animals, and 
that this is maintained throughout their lifespan.  
5.3.2 Chronic caloric restriction unmasks metabolic differences 
between Rgs2-/- and WT mice 
Given that some but not all measured parameters pointed to higher metabolic demand in Rgs2-
/- mice under normal ad libitum diet conditions and the observed lean phenotype, we reasoned 
that reducing food intake via a chronic 30% diet restriction might reveal further differences 
between Rgs2-/- animals and WT controls. Caloric restriction was introduced gradually, with 
provided daily food reduced by 10% for the first two weeks and then 20% for two subsequent 
weeks prior to the 30% reduction (Figure 3G). Animals were weighed weekly to ensure they 
did not drop below acceptable protocol levels. Similar to other diet restriction studies 
(Weindruch et al., 1986; Faulks et al., 2006), body weights remained essentially constant in 
both Rgs2-/- and WT mice (Figure 3G). Since WT Bl/6 mice tend to steadily gain weight as 
they age (Nunn et al., 2011), the lack of such an increase over six weeks indicated that the diet 
restriction regimen was successful. All indirect calorimetry parameters were significantly 
altered in Rgs2-/- animals compared to WT controls following 30% diet restriction, with Rgs2-
/- mice exhibiting higher levels of VO2, VCO2, RERs, and energy expenditure (heat) (Fig. 3A, 
B, C, and D). Notably, RER increased substantially in both strains following the introduction 
of food and reached an elevated plateau, which was significantly higher in Rgs2-/- than WT 
mice; RER reached and remained at 1.0 or greater in Rgs2-/- mice, a level indicative of energy 
metabolism based almost entirely on carbohydrate usage (Fig. 3C). Similar to 3 month-old ad 
libitum studies, physical activity did not appear to play a role in the increased energy 
expenditure of Rgs2-/- mice (c.f. Tables 1 and 2). 
During the 30% diet restriction, the rate of food consumption by Rgs2-/- mice was more than 4 
times the rate of the WT diet-restricted mic (Figure 3E). All mice finished their food prior to 
the next daily feeding, and consequently knockout mice were essentially fasted for 
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approximately 20 hours before their next meal versus about 12 hours for WT animals, with 
significantly lower blood glucose levels than WT mice directly prior to food introduction 
(Figure 3H). Although there were clear strain-related differences evident under caloric 
restriction, it is possible that the unexpected difference in the duration of fasting might have 
had a distorting effect on the measurement of metabolic parameters. To control for behavioural 
differences in food consumption, in further experiments we subjected both WT and KO mice 
to an acute 16 hour fast and acquired CLAMS data to assess metabolic and physical activity. 
5.3.3 Decreased energy conservation in Rgs2-/- mice during and after 
acute fast 
Fasting typically results in energy conservation, which can be demonstrated via 
decreased VO2 and VCO2 levels, and indeed such changes were observed in both WT 
and Rgs2-/- animals following food removal (Figure 4A and B, respectively), along with a 
sustained decrease in RER in both strains to a level consistent with primarily fat metabolism 
(Fig. 4C). During this fasting period, Rgs2-/- mice consumed more oxygen than WT controls 
(Fig. 4A) indicating a greater metabolic rate. Upon food reintroduction, Rgs2-/- animals shifted 
from fat metabolism back towards almost complete carbohydrate metabolism (as indicated by 
RER) more rapidly than their WT counterparts (Fig. 4C), with significant difference between 
VO2, VCO2 and energy expenditure (Fig. 4A, B, and D). 
The rapid increases in VO2, VCO2, RER, energy expenditure (heat), as well as food and water 
intake that were observed in our chronic diet restriction Rgs2-/- mice were less pronounced than 
in our fasting study, suggesting that chronic caloric deprivation and/or prolonged and unequal 
fasting times may have increased strain-related metabolic differences. Similar to our ad 
libitum and chronic diet results, there was no discernable difference between genotypes 
for ambulatory activity (Table 2), suggesting again that weight loss in RGS2 
knockout mice is due to internal energy metabolism rather than overt physical activity. Taken 
together, these findings collectively suggest that Rgs2-/- plays an important role in the 
regulation of basal metabolism and energy expenditure. 
 
 156 
 
A 
 
B
         
Indirect calorimetry was performed in 1 month, 3 month, and 12 month old mice to measure 
(A) VO2, and (B) VCO2. White and black bars under time course tracings denote 12 h light 
and dark cycles, respectively. Bar graphs below time course tracings represent average 12 h 
light/dark cycles for WT and KO mice. Data represent means ± SEM, n=4, 7-8, and 7 for in 1 
month, 3 month, and 12 month old animals, respectively. Data within each graph were 
analyzed using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons, 
*P<0.05 and **P<0.01. 
Figure 5.1. Ad libitum diet, indirect calorimetry, VO2 and VCO2 
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Indirect calorimetry was performed in 1 month, 3 month, and 12 month old mice to measure 
(A) energy expenditure (heat). (B) RER was calculated from VCO2/VO2. White and black bars 
under time course tracings denote 12 h light and dark cycles, respectively. Bar graphs below 
time course tracings represent average 12 h light/dark cycles for WT and KO mice. Data 
represent means ± SEM, n=4, 7-8, and 7 for in 1 month, 3 month, and 12 month old animals, 
respectively. Data within each graph were analyzed using two-way ANOVA with Bonferroni’s 
post hoc test for multiple comparisons, *P<0.05 and **P<0.01. 
Figure 5.2. Ad libitum diet, indirect calorimetry, RER and heat 
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Figure 5.3. Ad libitum diet, food and water intake 
A 
 
B
 
 
 (A) Food and (B) water intake were measured simultaneously with indirect calorimetry in 
CLAMS cages. White and black bars under time course tracings denote 12 h light and dark 
cycles, respectively. Bar graphs below time course tracings represent average 12h light/dark 
cycles for WT and KO mice. Data represent means ± SEM, n=4, 7-8, and 7 for in 1 month, 3 
month, and 12 month old animals, respectively. Data within each graph were analyzed using 
two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons, *P<0.05 and 
**P<0.01. 
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Table 5.2. Ambulatory activity and body weights, ad libitum diet 
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Table 5.3. Ambulatory activity and body weights, chronic and fasting diets 
Abbreviations: BWT, body weight. Ambulatory activity represents combined counts from x and y 
axes. Data represent means ± s.e.m. Body weights were compared using Student’s t-test. 
Ambulatory activities were compared using two-way ANOVA with Bonferroni’s post hoc test for 
multiple comparisons,  dark vs. light cycle within genotypes and 16 h fast vs. 16 h post-fast within 
genotypes,**P<0.05, **P<0.01 and ***P<0.001. 
  WT  rgs2 -/- 
30% restriction: 
n 4 4 
BWT (g) 26.0 ± 0.9 18.8± 0.7*** 
Light activity (counts x 103) 9.9 ± 2.1 13.9± 0.3 
Dark activity (counts x 103) 22.1 ± 2.6 17.2 ± 3.1 
 
16hr fast: 
n 11 11 
BWT (g) 26.8 ± 1.0 23.5 ± 0.9* 
16hr fast activity (counts x 103) 38.3 ± 1.5 45.8 ± 8.6 
16hr post fast activity  (counts x 103) 16.7 ± 0.4** 19.9 ± 2.7** 
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C       D
Figure 5.4. Chronic diet restriction, indirect calorimetry 
 3 month old male Rgs2-/- and WT mice were subjected to 30% chronic diet restriction 
following 2 weeks each of 10% and 20% restriction. Indirect calorimetry was performed to 
measure (A) VO2, (B) VCO2, and (D) energy expenditure (heat), which were normalized to 
body weight. (C) RER was calculated from VCO2/VO2. White and black bars under time 
course tracings denote 12 h light and dark cycles, respectively. Bar graphs below time course 
tracings represent average 12 h light/dark cycles for WT and KO mice. Data represent means 
± SEM, n=4 per group. Data in individual graphs were analyzed using two-way ANOVA with 
Bonferroni’s post hoc test for multiple comparisons, *P<0.05, **P<0.01 and ***P<0.001. 
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Figure 5.5. Chronic diet restriction 
 (A) Food and (B) water intake were measured simultaneously with indirect calorimetry in 
CLAMS cages. (C) Body weights were recorded weekly to monitor effects of 10%, 20% and 
30% caloric restriction. (D) Glucose levels under 30% caloric restriction were recorded 
immediately prior and 15 min, 30 min, 1 h, 2 h, and 3 h post-feeding. White and black bars 
under time course tracings denote 12 h light and dark cycles, respectively. Bar graphs below 
time course tracings represent average 12 h light/dark cycles for WT and KO mice. Data 
represent means ± SEM, n=4 per group. Data in individual graphs were analyzed using two-
way ANOVA with Bonferroni’s post hoc test for multiple comparisons, *P<0.05, **P<0.01 
and ***P<0.001. 
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Figure 5.6. Acute 16 h fast, indirect calorimetry 
3 month old male Rgs2-/- and WT mice were subjected to a 16 h fast followed by reintroduction 
of ad libitum diet. Indirect calorimetry was performed to measure (A) VO2 and (B) VCO2. 
White and black bars under time course tracings denote 12 h light and dark cycles, respectively. 
Bar graphs below time course tracings represent average 12h light/dark cycles for WT and KO 
mice. Data represent means ± SEM, n=11 per group. Data within each graph were analyzed 
using two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons, *P<0.05, 
**P<0.01 and ***P<0.001. 
 
 
 164 
 
A 
 
 
 
B 
 
Figure 5.7. Acute 16 h fast, indirect calorimetry 
 (A) energy expenditure (heat), was normalized to body weight, and (B) RER was calculated 
from VCO2/VO2. White and black bars under time course tracings denote 12 h light and dark 
cycles, respectively. Bar graphs below time course tracings represent average 12h light/dark 
cycles for WT and KO mice. Data represent means ± SEM, n=11 per group. Data within each 
graph were analyzed using two-way ANOVA with Bonferroni’s post hoc test for multiple 
comparisons, *P<0.05, **P<0.01 and ***P<0.001. 
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Figure 5.8. 16 h fast, food and water intake 
 (A) Food and (B) water intake were measured simultaneously with indirect calorimetry in 
CLAMS cages, and normalized to body weight. White and black bars under time course 
tracings denote 12 h light and dark cycles, respectively. Bar graphs below time course tracings 
represent average 12h light/dark cycles for WT and KO mice. Data represent means ± SEM, 
n=11 per group. Data within each graph were analyzed using two-way ANOVA with 
Bonferroni’s post hoc test for multiple comparisons, *P<0.05, **P<0.01 and ***P<0.001. 
 166 
 
5.3.4 Altered expression of metabolic genes in Rgs2-/- mice 
Genes involved with calcium signalling and metabolism were examined in gastrocnemius 
tissue to determine potential differences in expression between Rgs2-/- and WT mice on an ad 
libitum diet. Metabolic genes to analyze with qPCR were chosen based on reviews of the 
current literature involving skeletal tissue metabolism (Salvatore et al., 2013), and purported 
expression changes from the performed microarray. A majority of genes reported to be 
significantly different or unchanged in the micro array could not be validated by qPCR (Suppl. 
Table C2); thus, microarray data has not been included in the results or discussion in this 
chapter, but can be viewed (along with PANTHER analysis of biological and cellular 
processes) in the Appendix (Suppl. Table C2, Suppl. Fig. C2 and C3). 
 Following qPCR of selected genes, ryanodine1 (ryr1), glycogen phosphorylase (pygm), and 
glucose transporter 4 (Glut4/Slc2a4) gene expression were all significantly increased in Rgs2-
/- mice compared to WTs (Fig. 5.9B, E, and F). Furthermore, deiodinase type 2 (Dio2) 
expression was significantly enhanced in Rgs2-/- mice (Fig. 5.10A). Gene expression for serca1 
(Atp2a1), hexokinase 2 (Hk2), citrate synthase (Cs), thyroid hormone receptor alpha (Thra), 
thyroid hormone-specific transporter MCT8 (Slc16a2), ATP synthase subunit F(0) complex 
subunit C1 (Atp5g1), mitochondrial uncoupling protein 3 (Ucp3), β1 and β2-adrenergic 
receptors, and adenylyl cyclase 2 and 5 were not found to be significantly altered in Rgs2-/- 
mice compared to WT animals (Fig. 5.9, 5.10, and 5.11).  
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Figure 5.9. Gene expression, calcium signalling and metabolic markers  
(A) Serca2a (Atp2a1), (B) ryanodine receptor type 1 (Ryr1), (C) citrate synthase (Cs), (D) 
hexokinase II (Hk2), (E) glycogen phosphorylase (Pygm), and (F) glut-4 (Slc2a4) gene 
expression was assessed by qPCR in gastrocnemius tissue of Rgs2-/- and WT mice. Data 
represent means ± SEM, n=4-6 per group. Data were analyzed by Student’s t-test, *P<0.05.  
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Figure 5.10. Gene expression, metabolic markers  
(A) Deiodinase type 2 (Dio2), (B) thyroid hormone receptor alpha (Thra) and (C) thyroid 
hormone-specific transporter MCT8 (Slc16a2), (D) ATP synthase subunit F (0) complex 
subunit C1 (Atp5g1), and (E) mitochondrial uncoupling protein 3 (Ucp3) gene expression was 
assessed by qPCR in gastrocnemius tissue of Rgs2-/- and WT mice. Data represent means ± 
SEM, n=4-6 per group. Data were analyzed by Student’s t-test, *P<0.05.  
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Figure 5.11. GPCR-related gene expression 
(A) beta-1 adrenergic receptor (Adrb1), (B) beta 2 adrenergic receptor (Adrb2), (C) adenylyl 
cyclase 2 (Adcy2), and D) adenylyl cyclase 5 (Adcy5) gene expression was assessed by qPCR 
in gastrocnemius tissue of Rgs2-/- and WT mice. Data represent means ± SEM, n=4-6 per 
group. Data were analyzed by Student’s t-test.  
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 Discussion 
The present study expands on our previous work, in which we found Rgs2-/- mice to be resistant 
to normal, age-related weight gain (Nunn et al., 2011). This observed decrease in body weight 
was also accompanied by increased insulin sensitivity, smaller adipocytes, decreased adipose 
tissue deposits, and lower levels of serum lipids. In addition, nutrient absorption was 
comparable to WT controls (Nunn et al., 2011). We were previously unable to reconcile 
obvious changes in lipid metabolism and body weight with measured metabolic rates; using 
the more sensitive CLAMS cages, we demonstrate in this study that metabolic rates as 
measured by indirect calorimetry are increased in Rgs2-/- mice. These effects are further 
enhanced by both chronic and acute diet restrictions, and also suggest that Rgs2-/- mice may 
have enhanced carbohydrate metabolism. To our knowledge, we are the first group to report a 
metabolic phenotype in Rgs2-/- mice.  
Our ad libitum studies demonstrate that basal metabolic indices in 3 month and 12 month old  
Rgs2-/- mice were elevated compared to WT controls. A lack of observable differences in VO2, 
VCO2, and energy expenditure at the 1 month time point may be age related; at this stage, both 
WT and Rgs2-/- animals are still in a rapid growth phase (Somerville et al., 2004), which could 
obscure the slight differences seen in the older age groups. When viewed collectively over 
time, VO2 and VCO2 values do fall with increasing age (Figure 1A and B), which is expected 
as body metabolism slows (LeBrasseur et al., 2009). However, Rgs2-/- mice consistently 
displayed higher VO2 and VCO2 levels compared to WT controls (Fig. 1A and B). Since 
changes in the 2-5% range can induce significant long term alterations in energy balance (Even 
and Nadkarni, 2012), the small, but sustained elevations in VO2 and VCO2, particularly during 
dark cycles, may contribute to the observed lean phenotype. 
In our previous studies, we determined that although Rgs2-/- mice had reduced fat stores and 
smaller adipocytes, they were not resistant to high fat diet-induced obesity, and developed 
insulin resistance to a similar degree as WT mice (Nunn et al., 2011). This suggested that Rgs2-
/- mice do not have major impairments with respect to their ability to accumulate adipose tissue, 
and that alterations to carbohydrate or protein rather than fat metabolism could be additional 
factors in the development of the lean phenotype. Since our ad libitum RER calculations 
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suggested that carbohydrate metabolism was slightly increased in Rgs2-/- mice (Fig. 1C), we 
challenged adult, 3 month-old animals to a chronic 30% diet restriction to further evaluate 
metabolic parameters. Both strains did not lose substantial body weight (Fig. 3G); final body 
weights after two weeks of 30% diet restriction (which was also preceded by two weeks each 
of 10% and 20% restrictions) were approximately 3% and 6% higher in Rgs2-/- and WT controls 
compared to initial starting ad libitum body weights, respectively. Although this suggested that 
a 30% restriction can be handled by both strains, and that ad libitum diet well exceeds 
necessary caloric requirements, Rgs2-/- feeding behaviour rapidly changed on the restricted 
diet, such that hyperphagia was exacerbated to such an extent that feeding and fasting times 
were significantly altered compared to control mice. RER recordings indicated that upon food 
consumption, KO mice quickly reached an almost full carbohydrate metabolizing state (RER 
around 1.0) versus WT mice who continued to demonstrate some fat metabolism (RER around 
0.9) (Fig. 3C). Even though increased fasting length due to rapid food consumption may have 
affected indirect calorimetry readings, the differences between strains is still a relevant 
observation. VO2, VCO2, RER, and energy expenditure (heat) parameters rapidly increased 
and were sustained at elevated levels for several hours during and after food consumption; 
these rapid shifts in metabolism were not observed in WT controls (Fig. 3A, B, C, and D).  
To rule out potential confounding effects of the unexpected strain-related difference in food 
consumption patterns in our chronic restriction studies, food intake was controlled via 16 hour 
acute fasting studies (Fig. 4). Overall, strain-related differences were of a similar nature under 
both caloric restriction protocols, albeit less pronounced under acute conditions. Indirect 
calorimetry recordings during the acute fasting period furthermore suggested a delay in the 
ability of Rgs2-/- mice to lower their metabolism (for energy conservation) compared to WT 
animals. Conversely, it appears that Rgs2-/- mice are able to shift to carbohydrate metabolism 
in the presence of food at a faster rate than WT mice, as evidenced by higher RERs (Fig. 4C), 
although it is possible that due to their decreased adiposity, increased carbohydrate metabolism 
is a compensatory, rather than causative response of the observed lean phenotype (Sun et al., 
2012).  
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Since physical activity was found to be similar across strains, our metabolic parameters across 
multiple diet modalities suggest that decreased body weights in Rgs2-/- mice arise instead from 
internal metabolism. qPCR analysis of gastrocnemius tissue suggests that several 
metabolically-relevant genes may be altered in Rgs2-/- compared to WT mice. Skeletal 
ryanodine receptor type 1 (Ryr1) mediates calcium release; as the main ion channel in the 
sarcoplasmic reticulum, it is a key determinant of muscle force (Beard, Wei and Dulhunty, 
2009). Cells overexpressing Ryr1 have been shown to have higher mitochondrial ATP 
concentrations, as well as increased ATP production in response to cytosolic Ca2+ elevations. 
Thus, the observed increases in Ryr1 gene expression in Rgs2-/- mice could indicate increased 
levels of ATP production, and indirectly suggest increased ATP utilization in skeletal tissue, 
which could contribute to the lean phenotype. In addition, increased Rgs2-/- gene expression of 
glycogen phosphorylase (Pygm) (the rate-limiting enzyme of glycogenolysis) (Fig. 5.9D) 
correlates with previous studies which have demonstrated that cultured human muscle cells 
overexpressing glycogen phosphorylase display increased glucose transporter (GLUT-4) 
(slc2a4) expression with no changes in hexokinase II (the rate limiting enzyme in glycolysis) 
(Baqué et al., 1998), expression patterns which we also observed in Rgs2-/- mice compared to 
WT controls (Fig. 5.9C and E).  
Changes in Dio2 gene expression also suggest increased metabolism in Rgs2-/- mice (Fig. 
5.10A). Since DIO2 catalyzes the conversion of the inactive prohormone thyroxine (3,5,3',5'-
tetraiodothyronine, T4) to the active thyroid hormone (3,5,3'-triiodothyronine, T3) (Gereben 
et al., 2008; Arrojo e Drigo et al., 2013), it would follow that local cellular production of T3 
could increase due to elevated levels of DIO2. Thyroid hormone plays a major role in energy 
expenditure and glucose homeostasis; thyroid hormone signalling can modulate metabolic rate 
by either uncoupling the ATP synthesis in the mitochondria or decreasing the metabolic 
efficiency of skeletal muscle (Salvatore et al., 2013), effectively “wasting” energy as dissipated 
heat (de Lange et al., 2001; Silva, 2006). In addition, GLUT-4 expression (and therefore 
glucose uptake in cells) is T3 dependent; in conjunction, GLUT-4 translocation to the cell 
surface is an insulin-dependent event, and normal muscle responsiveness to insulin has been 
shown to require the DIO2-mediated conversion of T4 to T3 (Mills et al., 1987; Zorzano, 
Palacin and Guma, 2005; Grozovsky et al., 2009). Altogether, the observed increases in gene 
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expression for Ryr1, Pygm, Slc2a4 (GLUT-4), and Dio2 suggest that both glucose metabolism 
and resting metabolic rate may be altered in Rgs2-/- mice compared to WT animals.  
Although the exact mechanisms behind the lean phenotype are yet to be determined, RGS2 has 
been shown to have various effects on energy storage and usage; in vitro studies have 
demonstrated the role of RGS2 in mediating GIP (glucose-dependent insulinotropic 
polypetide)-induced insulin release from pancreatic β cells (Tseng and Zhang, 1998), as well 
as GLUT-4 (insulin-responsive glucose transporter) translocation in adipocytes (Imamura et 
al., 1999). Thus, RGS2 may be involved in glucose entrance in adipocytes. RGS2 is also 
transiently and rapidly upregulated in differentiating mouse preadipocyte cells, and appears to 
promote the differentiation of adipocytes and expression of adipogenic markers (Imagawa, 
Tsuchiya and Nishihara, 1999; Nishizuka et al., 2001). Other energy-dependent processes 
affected by RGS2 include the regulation of protein synthesis (Nguyen et al., 2009; Chidiac et 
al., 2014), as well as ATP hydrolysis by PMCA (plasma membrane Ca2+ ATPase) and SERCA 
(sarco/endoplasmic reticulum Ca2+) pumps (Wang et al., 2004). Human polymorphisms which 
result in the over or under expression of RGS2 have demonstrated the clinical relevance of 
RGS2 in the context of metabolism. A common polymorphism in the 3’ untranslated region of 
RGS2 has been shown to decrease RGS2 expression, has been associated with hypertension, 
and is considered to be a genetic marker that can predict male predisposition to weight gain 
and obesity (Sartori et al., 2008). Conversely, a C to G substitution in the RGS2 promoter 
region has been shown to increase RGS2 expression in adipocytes and is associated with the 
metabolic syndrome (Freson et al., 2007). Altogether, our current findings suggest an 
important role for RGS2 in weight regulation and body metabolism. 
 
 Conclusions 
Using simultaneous measurements of indirect calorimetry and activity, we have demonstrated 
increased metabolism in Rgs2-/- mice compared to WT controls in both ad libitum and diet 
restriction studies. Obesity is a common, costly, and serious disease, with more than 2/3 of US 
adults considered to be overweight or obese (Flegal et al., 2012). This growing epidemic makes 
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the study of potential regulators of metabolic signaling both timely and necessary. Given that 
increased RGS2 expression may be involved in obesity and metabolic disease in humans, and 
our findings that a lack of RGS2 leads to decreased body weight and improved metabolic 
profiles, RGS2 may be an important target for the future development of anti-obesity strategies.  
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 Summary and Discussion 
6.1.1 Chapter 3 – Cardiomyocyte specific overexpression of a 37 
amino acid domain of RGS2 inhibits cardiac hypertrophy and 
improves function in response to pressure overload in mice 
Cardiac hypertrophy is a known risk factor for cardiovascular diseases such as heart failure, 
and involves de novo protein synthesis in the post-mitotic cardiomyocyte population of the 
heart (Anversa et al. 2007; Carvalho 2010). RGS2 has been well established as an inhibitor of 
cardiomyocyte hypertrophy via its inhibitory effects on Gq and Gs-mediated signalling (Roy et 
al. 2006; Zou et al. 2006; Nunn et al. 2010; Zhang et al. 2011). We have previously reported 
that RGS2 can also inhibit protein synthesis through a 37 amino acid domain within its RGS 
domain (Nguyen et al. 2009), which we have termed RGS2eb. We observed these effects in 
both cell lines and cultured neonatal cardiomyocytes (Chidiac et al. 2014; Nguyen et al. 2009), 
and thus hypothesized that the cardiomyocyte-specific overexpression of RGS2eb could result 
in the in vivo inhibition of protein synthesis, and potentially offer protection against the 
development of hypertrophy in an experimental model of pressure overload. The aim of the 
studies described in Chapter 3 of this thesis was to determine the extent of cardiac hypertrophy 
in transgenic RGS2eb (RGS2eb TG) mice compared to WT sham and transverse aortic 
constriction (TAC) animals, and whether there were associated benefits to cardiovascular 
function.  
Following 28 days of TAC, mice with cardiomyocyte specific overexpression of RGS2eb were 
resistant to the development of significant cardiac hypertrophy compared to WT TAC mice. 
At the cellular level, measurements of cardiomyocyte cross-sectional area showed a 
corresponding increase in cell size for WT but not RGS2eb TG mice after TAC. In addition, 
systolic and diastolic indices of cardiac function via pressure-volume loop analyses suggested 
that RGS2eb TG animals were able to maintain significantly improved cardiac function 
following TAC compared to WT animals. Furthermore, the expression of the “fetal” genes β-
MHC and ANP, which are often upregulated during conditions of hypertrophy and heart 
failure, was completely abrogated in RGS2eb TG compared to WT TAC mice. These results 
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are consistent with our overall hypothesis that expression of the eIF2B-interacting domain of 
RGS2, RGS2eb, can protect against pathological cardiac hypertrophy and dysfunction in vivo, 
and that this may be via the direct inhibition of protein synthesis. Along with our previous 
studies, which showed the ability of RGS2eb to inhibit drug-induced cardiomyocyte 
hypertrophy, our current findings suggest that the RGS2eb region is an important contributor to 
the reported beneficial cardiac effects of RGS2.  
6.1.2 Chapter 4 – Effects of transverse aortic constriction and drug 
induced experimental pressure overload hypertrophy on Rgs2-/- 
mice with cardiomyocyte specific overexpression of RGS2eb 
The aim of Chapter 4 was to explore whether the cardioprotective effects of RGS2eb that we 
observed in Chapter 3 could be extended to an Rgs2-/- model of experimentally-induced cardiac 
hypertrophy. Rgs2-/- mice are highly sensitive to TAC-induced cardiac hypertrophy and heart 
failure (Takimoto et al. 2009), and have been shown to have mild to moderate levels of 
hypertension (Oliveira-Dos-Santos et al. 2000; Heximer et al. 2003). The use of Rgs2-/- mice 
could provide further clarity into the cardioprotective role of the RGS2eb region, endogenous 
RGS2 was still present in the Rgs2+/+(eb) mice from our earlier studies (Lee et al. 2017). Based 
on our observations in Chapter 3, we hypothesized that the cardiomyocyte specific expression 
of RGS2eb in Rgs2-/- mice (Rgs2-/-(eb)) could potentially decrease the severity of cardiac 
hypertrophy and heart failure resulting from experimentally induced pressure overload, thereby 
compensating for the absence of full-length RGS2.  
For our Chapter 4 studies, we generated novel transgenic Rgs2-/- mice with cardiomyocyte 
specific overexpression of RGS2eb (Rgs2-/-(eb)). However, when we initially began our TAC 
studies with Rgs2-/- and WT mice, we found that the mortality rate for Rgs2-/- animals 
significantly exceeded that of WT controls following TAC surgery, suggesting an impaired 
ability to recover from cardiovascular insult. Due to the unexpectedly high mortality rate of 
Rgs2-/ - mice, the TAC model was determined to be unsuitable for the evaluation of cardiac 
hypertrophy, and was discontinued before the addition of Rgs2-/-(eb)mice to the study. We thus 
proceeded to examine the effects of drug-induced models of hypertension on Rgs2-/- mice. 
Starting with an angiotensin II model of chronic agonist infusion via osmotic pumps 
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(1.44mg/kg/day), we observed that although there was hypertension in our angiotensin II 
treated animals, significantly detectable cardiac hypertrophy did not develop in any 
experimental angiotensin II groups (WT, Rgs2+/+(eb), Rgs2-/-, and Rgs2-/-(eb)) compared to saline 
control mice. Further studies with angiotensin II infusion at higher concentrations (3.0 
mg/kg/day for 14 days) using WT and Rgs2-/- mice also failed to induce clearly detectable 
cardiac hypertrophy. Thus, we went on to perform pilot studies with twice daily injections of 
isoproterenol (ISO) for 14 days; our preliminary results suggest that a full study with prolonged 
injections beyond 14 days may result in cardiac hypertrophy. Such a reproducible model of 
cardiac hypertrophy would then allow for the effective examination of whether the inhibitory 
effects of RGS2eb on protein translation is sufficient to provide cardioprotection in a null RGS2 
background. 
6.1.3 Chapter 5 – Loss of RGS2 alters the effects of acute and chronic 
diet restriction on metabolic outcomes in C57 BL.6 mice 
Cardiovascular dysfunction, including pathological cardiac hypertrophy, is known to be 
directly influenced by obesity and weight gain, which are major risk factors for cardiovascular 
diseases such as coronary heart disease, atrial fibrillation, hypertension, venous 
thromboembolisms, and congestive heart failure (Klein et al. 2004; Poirier et al. 2006; Tedrow 
et al. 2010; Wattanakit et al. 2012). Adiposity is determined by energy expenditure versus 
energy intake, and possible sources of energy imbalance in cases of obesity or weight loss 
could come from the dysregulation of food intake/nutrient absorption, lipid storage, metabolic 
rate, physical activity, or CNS-related changes. 
Multiple GPCRs have been shown to be involved in energy metabolism, and alterations in G 
protein signalling (which is regulated by RGS proteins) can lead to both lean and obese 
phenotypes (Colombo et al. 1998; Nambu et al. 2011; Grillet et al. 2005; Cho et al. 2008). We 
have previously reported that Rgs2-/- mice exhibit a lean phenotype, are hyperphagic, have 
smaller adipose tissue deposits and adipocytes, and are ultimately resistant to age-related 
weight gain (Nunn et al. 2011). In addition, comparable nutrient absorption suggested that 
increased physical activity and/or metabolism could be underlying factors to the observed lean 
phenotype. However, although the lean phenotype was present throughout the Rgs2-/- mouse 
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lifespan on an ad libitum standard rodent diet, these animals nonetheless became obese and 
insulin-resistant under high-fat diet conditions (Nunn et al. 2011), suggesting that Rgs2-/- mice 
do not have a major impairment with respect to their ability to accumulate adipose. Thus, we 
hypothesized that the observed lean phenotype may reflect underlying changes in energy 
utilization. The aim of our studies in Chapter 4 was to understand the role of RGS2 in 
metabolism and body weight regulation using CLAMS metabolic cages to simultaneously 
assess indirect calorimetry parameters and ambulatory activity in freely moving age-matched 
control and Rgs2-/- mice under normal and diet-restricted conditions. Analysis of ad libitum 
data showed Rgs2-/- mice had significantly increased metabolism compared to WT controls, 
and that these differences were exacerbated both by chronic and acute caloric restriction. Since 
no changes in ambulatory activity were observed, these observations suggest that internal 
metabolism, rather than overt physical activity, is the major contributor to the lean Rgs2-/- 
phenotype. Furthermore, since skeletal muscle is a major site of metabolism (Salvatore et al. 
2013) qPCR for metabolically-related genes in the gastrocnemius tissue of WT and Rgs2-
/-- mice suggest that both glucose metabolism and resting metabolic rate may be altered in Rgs2-
/- mice compared to WT animals. Altogether, our current findings in combination with our 
previous reports demonstrate an important role for RGS2 in the regulation of weight and body 
metabolism. 
 
 Future directions 
In Chapter 3, we demonstrated the cardioprotective potential of RGS2eb in an in vivo model of 
cardiac hypertrophy. Currently, the majority of drugs for cardiovascular diseases target GPCRs 
(Rask-Andersen, Almén, and Schiöth 2011). Although these medications can offer significant 
benefits to patients, heart failure continues to be a global leading cause of morbidity and 
mortality. In addition, inhibiting GPCR signalling often results in “off-target” effects due to 
the broad cascade of signalling pathways that they control (Allen and Roth 2011). The 
specificity of RGS2eb for the inhibition of protein synthesis at the level of translation initiation 
could potentially mitigate such issues and lead to improved therapeutics. Indeed, interest in 
RGS2 and other RGS proteins as possible drug targets is on the rise (Sjogren et al. 2012; 
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Sjögren and Neubig 2010; Sjögren, Blazer, and Neubig 2010; Le and Coffman 2003; Go et al. 
2013; Turner et al. 2012; Sjögren et al. 2016). Future steps in characterizing the potential of 
RGS2eb as a cardioprotective factor could involve its direct delivery to the heart after 
experimentally-induced cardiac injury in lieu of our current cardiac-specific overexpression 
model, where activation of the RGS2eb transgene in the heart occurs soon after birth. 
Recombinant adeno-associated viruses (rAAVs) could be a potential avenue for RGS2eb 
delivery to the heart, as they are currently the most widely used vectors for safe, long-term 
gene delivery and expression in the heart due to their ability to transduce post-mitotic cells 
such as cardiomyocytes (Zsebo et al. 2014). rAAVs are unique among viruses used for gene 
therapy in that the wild-type (AAV) virus has not been shown to cause human disease (Thomas, 
Ehrhardt, and Kay 2003). In addition to their low immunogenicity, rAAVs demonstrate 
efficient long-term transgene expression and low rates of insertional mutagenesis; previous 
experiments using various combinations of AAV capsids (which control receptor-mediated 
cellular entry) and rAAV pseudotypes have established rAAV2/1, rAAV2/6, rAAV2/8, 
rAAV2/9, and rAAV2/10 as the most cardiotropic (Pacak and Byrne 2011). Multiple in vivo 
studies and clinical trials lend credence to the use of rAAVs as a delivery system for RGS2eb 
to the heart (Zsebo et al. 2014; Li et al. 2003; Hoshijima et al. 2002; Asfour et al. 2002; Kawase 
et al. 2008; McTiernan et al. 2007), which could be explored in future studies.  
In Chapter 4, the substantially lower survival rates of Rgs2-/- mice compared to WT 
counterparts following TAC surgery support studies in the literature that suggest that impaired 
cardiovascular function in Rgs2-/- mice may be due to enhanced susceptibility to atrial 
fibrillation (Jones, Tuomi, and Chidiac 2012). Although our specific aims and hypotheses for 
this chapter focused on cardiac hypertrophy and related functional effects, the observed Rgs2-
/- mortality rates suggest that further exploration of this reaction to TAC surgery could prove 
interesting. In terms of understanding any potential roles of RGS2eb in Rgs2-/- mice, protocol 
optimization is certainly required for our studies. Although cardiac hypertrophy was not 
induced in our experimental angiotensin II animals, the presence of hypertension reflected 
successful infusion of the drug into agonist-treated mice. Since hypertension-induced 
hypertrophy via angiotensin II is a less severe model of hypertrophy compared to TAC 
surgeries, prolonged angiotensin II infusion beyond our current 28 day study design may 
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clarify the timeline for cardiac hypertrophy development in our mouse strains; similar studies 
would extend to our pilot isoproterenol models.  
The Chapter 5 studies expand on our previous work, in which we found Rgs2-/- mice to be 
resistant to normal, age-related weight gain (Nunn et al. 2011). We were previously unable to 
reconcile obvious changes in lipid metabolism and body weight with measured lower 
metabolic rates; using the more sensitive CLAMS cages, we demonstrate in this study that 
metabolic rates as measured by indirect calorimetry are in actuality increased in Rgs2-/- mice. 
These effects are further enhanced by both chronic and acute diet restrictions, and also suggest 
that Rgs2-/- mice may have enhanced carbohydrate metabolism. To our knowledge, we are the 
first group to report a metabolic phenotype in Rgs2-/- mice. Future studies to fully characterize 
this phenotype could examine the effects of various physical activity modalities; since skeletal 
muscle is one of the most metabolically active tissues, and we observed the upregulation of 
several genes which regulate glucose and basal metabolism, studies using physical activity as 
a variable (e.g. treadmill running) could prove interesting. Furthermore, a detailed assessment 
of additional metabolic genes (perhaps via RNA-seq analysis) is warranted given the currently 
observed effects of Dio2, Glut-4, Ryr1, and Pygm gene expression, and could ultimately lead 
to a clearer understanding of the specific mechanisms and key GPCRs which drive the Rgs2-/- 
lean phenotype. 
 
 Conclusions 
Cardiovascular diseases and metabolic dysregulation affect millions around the world, and the 
study of their underlying factors and mechanisms could lead to the identification of novel drug 
targets for improved treatment. The first part of this thesis examined the cardioprotective 
potential of RGS2eb, and we determined that cardiac hypertrophy could indeed be inhibited 
following TAC by the targeted expression of this truncated protein, with accompanying 
improvements in cardiac function. Although we were limited in our characterization of the 
Rgs2-/-(eb) mouse line in the second part of our thesis, the poor survival rates that we observed 
in Rgs2-/- animals following TAC surgery may lead to additional studies examining RGS2 
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activity in the context of cardiac electrophysiology. The metabolic role of RGS2 is explored in 
the third part of this thesis, and reveals that loss of RGS2 leads to significant upregulation in 
metabolic genes and basal metabolism. Altogether, these studies provide new insights into the 
role of RGS2 in cardiovascular health and metabolism. 
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Appendix C: Supplementary information 
 
 
Measurement definitions:
Label Description Units
LVAW;d Left ventricular anterior wall (diastole) mm
LVAW;s Left ventricular anterior wall (systole) mm
LVPW;d Left ventricular posterior wall (diastole) mm
LVPW;s Left ventricular posterior wall (systole) mm
LVID;d Left ventricular internal diameter (diastole) mm
LVID;s Left ventricular internal diameter (systole) mm
Calculation definitions:
Name Description Units Formula
LV Vol;d (M-Mode) Left ventricle volume diastole µL ((7.0 / (2.4 + LVID;d)) * LVID;d3 )
LV Vol;s (M-Mode) Left ventricle volume systole µL ((7.0 / (2.4 + LVID;s)) * LVID;s3)
%EF (M-Mode) LV ejection fraction % 100 * ((LV Vol;d – LV Vol;s) / LV Vol;d)
%FS (M-Mode) LV fractional shortening % 100 * ((LVID;d – LVID;s) / LVID;d)
LV Mass (M-Mode) LV mass uncorrected mg 1.053 * ((LVID;d + LVPW;d + IVS;d)3– LVID;d3)
LV Mass Cor (M-Mode) LV mass corrected mg LV Mass (M-Mode) * 0.8
 
 
 
 
 
 
 
 
 
 
Table C1. Measurement and calculation definitions for VisualSonics analysis of 
cardiac function 
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A        B  
 
 
 
 
 
C        D 
 
 
 
 
 
 
 
 
14 day (A) Saline and (B) ISO-treated mice were weighed daily, with (C)(D) survival recorded 
for each treatment and genotype. Data represent means ± SEM, n=3-8 per group using two 
way ANOVA with Bonferroni’s post hoc test for body weight data and Log rank test for 
survival curves. 
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Figure C1. Body weights and survival, 14 days of twice daily saline or 50 mg/kg ISO  
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Table C2. Selected microarray genes, fold change, and significance 
Of the genes below, only Dio2 expression and significance were validated by qPCR. 
Gastrocnemius tissue, n=2 per group (WT and KO). 
Gene p-value fold change fold change description 
Adcy2 0.380 3.428 KO up vs WT
Adcy5 0.001 -1.478 KO down vs WT
Adrb1 0.011 1.239 KO up vs WT
Adrb2 0.507 1.785 KO up vs WT
Atp2a1 0.414 17.464 KO up vs WT
Atp5g1 0.074 1.434 KO up vs WT
Cs 0.287 1.930 KO up vs WT
Dio2 0.036 1.343 KO up vs WT
Hk2 0.355 5.699 KO up vs WT
Pygm 0.419 20.016 KO up vs WT
Ryr1 0.430 11.336 KO up vs WT
Slc16a2 0.440 -3.300 KO down vs WT
Slc2a4 0.378 7.765 KO up vs WT
Thra 0.477 1.402 KO up vs WT
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cellular process (GO:0009987) (19; 24.4%)
metabolic process (GO:0008152) (14; 17.9%)
developmental process (GO:0032502) (9; 11.5%)
multicellular organismal process (GO:0032501)(8; 10.3%)
localization (GO:0051179) (6; 7.7%)
response to stimulus (GO:0050896) (6; 7.7%)
biological regulation (GO:0065007) (5; 6.4%)
immune system process (GO:0002376) (4; 5.1%)
cellular component organization or biogenesis (GO:0071840) (3; 3.8%)
biological adhesion (GO:0022610) (2; 2.6%)
reproduction (GO:0000003) (1; 1.3%)
locomotion (GO:0040011) (1; 1.3%)
A       B 
 
 
 
 
 
 
 
 
 
 
Figure C2. Biological processes, Rgs2-/- down vs. WT  
(A) Microarray genes with a higher expression in Rgs2-/- mice vs. WT (1.4 fold or higher and 
P<0.05) were analyzed by the PANTHER gene list program for functional classifications. (B) 
The metabolic process section was further expanded for secondary level process details. Chart 
legends are read as: category name (accession) (# genes; percent of gene hit against total # 
process hits). 
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 A       B    
 
 
 
 
 
 
 
 
 
 
(A) Microarray genes with a lower expression in Rgs2-/- mice vs. WT (1.4 fold or higher and 
P<0.05) were analyzed by the PANTHER gene list program for functional classifications. (B) 
The metabolic process section was further expanded for secondary level process details. Chart 
legends are read as: category name (accession) (# genes; percent of gene hit against total # 
process hits). 
 
 
 
 
 
Figure C3. Biological processes, Rgs2-/- up vs. WT  
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Figure C4. Cellular components and molecular function for microarray genes, Rgs2-
/- genes up or down vs. WT 
A 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
(A) Microarray genes with a higher expression in Rgs2-/- mice vs. WT (1.4 fold or higher and 
P<0.05) were analyzed by the PANTHER gene list program for cellular components and 
molecular function, as were (B) genes with lower expression. Chart legends are read as: 
category name (accession) (# genes; percent of gene hit against total # process hits). 
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